University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

April 2019

Understanding the adoption process of an HPV vaccine schoolentry requirement in Puerto Rico
Coralia Vázquez-Otero
University of South Florida, coralia9981@yahoo.com

Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the Public Health Commons

Scholar Commons Citation
Vázquez-Otero, Coralia, "Understanding the adoption process of an HPV vaccine school-entry requirement
in Puerto Rico" (2019). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/8420

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has
been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar
Commons. For more information, please contact scholarcommons@usf.edu.

Understanding the adoption process of an HPV vaccine school-entry requirement
in Puerto Rico

by

Coralia Vázquez-Otero

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Community and Family Health
College of Public Health
University of South Florida

Co-Major Advisor: Ellen M. Daley, Ph.D., MPH
Co-Major Advisor: Dinorah Martinez Tyson, Ph.D., MPH
Cheryl A. Vamos, Ph.D., MPH
Nancy Romero-Daza, Ph.D., MA
Jason Beckstead, Ph.D.

Date of Approval:
April 5, 2019

Keywords: HPV vaccine, vaccine mandates, HPV vaccine school-entry requirement, cancer
prevention, Puerto Rico.
Copyright © 2019, Coralia Vázquez-Otero

Dedication

To my daughter Ariana. Te amo, mami.

Acknowledgements

I want to thank Drs. Daley and Martinez Tyson for their unconditional support during this
journey. I want to acknowledge the members of my Committee Drs. Vamos, Romero-Daza, and
Beckstead for their continuous help and feedback. Thank you to all my family for their patience.
Juan Pablo, gracias.
Mami and Papi, gracias.
Isis, Viviana, and Lili, gracias.
Evi and Jerry, gracias.
Gerardo, gracias.
Thanks to my friends who walked this long path with me. DeAnne thank you for always
being there for me no matter what time of the day…or night. Stacey, we did it! Rachel, thanks
for letting me use the office computer whenever I pleased. Melissa, you are the best TA ever.
Thanks to my students for being such good sports and for hanging in there when my sleep
deprivation and caffeine addiction were too noticeable.
Finally, this study would not have been possible without the funding provided by the
College of Public Health and the Office of Graduate Studies.

Table of Contents
List of Tables ................................................................................................................................. iv
List of Figures ................................................................................................................................. v
Abstract .......................................................................................................................................... vi
Chapter 1: Introduction ................................................................................................................... 1
Background ......................................................................................................................... 1
Public Health Significance .................................................................................................. 5
Statement of Need ............................................................................................................... 7
Key Terms ........................................................................................................................... 9
Chapter 2: Literature Review ........................................................................................................ 10
The Human Papillomavirus .............................................................................................. 10
The HPV Vaccine ............................................................................................................. 13
HPV vaccine uptake and completion rates in the US. .......................................... 15
Health implications of increasing HPV vaccination rates. ................................... 16
Economic implications of increasing HPV vaccination rates. .............................. 19
Factors that impact HPV vaccine rates. ................................................................ 20
Individual level. ........................................................................................ 20
Interpersonal level..................................................................................... 25
Community level....................................................................................... 26
Organizational level. ................................................................................. 27
Societal level. ............................................................................................ 27
Vaccine Interventions ....................................................................................................... 29
States’ police powers, vaccine mandates, and public health. ............................... 31
School-entry requirements. ....................................................................... 32
HPV vaccine mandates. ........................................................................................ 33
Arguments in favor of and against the HPV vaccine school-entry
requirement. .................................................................................................... 35
Overall studies’ characteristics. ................................................................ 35
Stakeholders/participants. ......................................................................... 36
Reasons and Factors in Support of or Against an HPV vaccine
school-entry requirement among Parents/Guardians, Physicians, and
Policymakers. .................................................................................................. 37
Parents/guardians. ..................................................................................... 37
Physicians. ................................................................................................ 42
Policymakers. ............................................................................................ 43
The case of Puerto Rico .................................................................................................... 43
Background. .......................................................................................................... 43
Current immunization policy. ............................................................................... 43
i

Summary ........................................................................................................................... 44
Chapter 3: Theoretical Framework ............................................................................................... 46
Introduction ....................................................................................................................... 46
Theoretical Framework: Multiple Streams Theory........................................................... 46
Overview of the Theoretical Framework. ............................................................. 46
Key Structural Elements of MSA. ........................................................................ 48
Critiques. ............................................................................................................... 50
Other research applications of MSA. .................................................................... 51
Current related research. ....................................................................................... 52
Summary ........................................................................................................................... 53
Chapter 4: Methods ....................................................................................................................... 54
Introduction ....................................................................................................................... 54
Purpose and Research Questions. ......................................................................... 54
Research Setting: Puerto Rico .......................................................................................... 54
Aftermath of hurricane Maria. .............................................................................. 56
Overview of study design ................................................................................................. 56
Phase 1: In-depth Interviews ............................................................................................. 57
Recruitment. .......................................................................................................... 57
Inclusion Criteria. ................................................................................................. 58
Data collection. ..................................................................................................... 58
Sample size. .............................................................................................. 58
Instrumentation. .................................................................................................... 59
Data analysis. ........................................................................................................ 60
Protection of Human Subjects. ............................................................................. 61
Phase 2: Content Analysis of PR’s newspaper articles ..................................................... 62
Protocol. ................................................................................................................ 63
Newspapers and unit of analysis. .......................................................................... 63
Key terms. ............................................................................................................. 63
Inclusion and Exclusion criteria. .......................................................................... 64
Instrumentation. .................................................................................................... 64
Data collection. ..................................................................................................... 66
Scanning steps........................................................................................... 66
Data abstraction. ....................................................................................... 66
Data analysis. ........................................................................................................ 66
Trustworthiness ................................................................................................................. 67
Reflexivity. ........................................................................................................... 69
Triangulation ..................................................................................................................... 71
Summary ........................................................................................................................... 71
Chapter 5: Results ......................................................................................................................... 72
Introduction ....................................................................................................................... 72
Phase 1: Interviews ........................................................................................................... 72
Sample Description. .............................................................................................. 72
Themes. ................................................................................................................. 73
Problem Stream. ........................................................................................ 73
ii

Policy Stream. ........................................................................................... 81
Politics Stream. ......................................................................................... 87
Policy Windows. ....................................................................................... 91
Policy entrepreneurs.................................................................................. 92
Aftermath of hurricane Maria ................................................................... 98
Phase 2: Content analysis of newspaper articles............................................................... 99
Reliability.............................................................................................................. 99
Overall sample description. .................................................................................. 99
Further investigation of the news articles that mentioned the
HPV vaccine school-entry requirement in PR. ................................. 102
Arguments against the HPV vaccine school-entry requirement articles. ........... 103
Data triangulation............................................................................................................ 106
Summary ......................................................................................................................... 109
Chapter 6: Discussion ................................................................................................................. 110
Introduction ..................................................................................................................... 110
Intersection of Problems, Policy, and Politics ................................................................ 110
Policy Entrepreneurs ....................................................................................................... 116
Comparison of PR’s HPV vaccine school-entry requirement to Virginia,
Washington DC and Rhode Island’s HPV vaccine school-entry
requirements. ................................................................................................. 117
Arguments in favor of and against the HPV vaccine school-entry requirement
in PR.......................................................................................................................... 118
Strengths and Limitations ............................................................................................... 121
Research, Practice, and Policy Implications ................................................................... 124
Summary ......................................................................................................................... 126
Tables and Figures ...................................................................................................................... 127
References ................................................................................................................................... 147
Appendix A: IRB Approval ........................................................................................................ 179
Appendix B: Informed Consent Form ........................................................................................ 181

iii

List of Tables
Table 1: Information regarding available HPV vaccines ............................................................ 127
Table 2: Studies about stakeholders’ reasons and factors associated with HPV vaccine.
school-entry requirement in the US: Studies’ characteristics (N=25) ...................... 128
Table 3: Studies about stakeholders’ reasons and factors associated with an HPV
vaccine school-entry requirement in the US: Main findings (N=25) ....................... 133
Table 4: Additional exemplary quotes by theme ........................................................................ 139
Table 5: Timeline of policies and strategies leading to the HPV vaccine school-entry
requirement in PR ..................................................................................................... 143
Table 6: Number of news articles published by year .................................................................. 144
Table 7: Overall distribution of newspaper articles by primary focus........................................ 144
Table 8: Articles published for each primary focus category by year ........................................ 145
Table 9: Number of articles that mentioned the HPV vaccine school-entry
requirement published by year and newspaper source ............................................. 145
Table 10: Type of argument included in the articles that mentioned the HPV
vaccine school-entry requirement by year of publication ......................................... 146

iv

List of Figures
Figure 1. Overview study design ................................................................................................... 57
Figure 2. Article selection process for content analysis (based on PRISMA guidelines
by Moher, Liberati, Tetzlaff, & Altman, 2009) ........................................................... 65
Figure 3. Average number of articles per month ........................................................................ 100
Figure 4. Average number of articles per month by the top eight primary
focus categories ........................................................................................................ 101
Figure 5. Number of articles by argument category by year of publication ............................... 103
Figure 6. Application of MSA to study findings .......................................................................... 111

v

Abstract
Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI)
in the US. Infection with low-risk HPV (i.e., 6 and 11) can cause genital warts, and persistent
infection with high-risk HPV types (i.e., HPV 16 and 18) can progress to cancer. Currently, there
is an HPV vaccine that is recommended for boys and girls, aged 11 to 12. Healthy People 2020
established a national objective of 80% completion of HPV vaccination among children aged 13
to 15 years old. Although the HPV vaccine is proven to be a safe and effective primary
prevention strategy, uptake and completion rates remain low in the US.
Vaccination mandates for school entrance are an effective strategy to improve
vaccination coverage. In the US, HPV vaccine policies vary; some legislate in favor of
educational campaigns, while others require health insurance to cover the HPV vaccine or
require it for middle-school entry. Currently, only Virginia, Rhode Island, and Washington DC
require the HPV vaccine for school entrance. In Puerto Rico (PR) the Department of Health
recently approved the HPV vaccine school-entry requirement for children 11 to 12 years old,
starting in fall 2018.
Despite HPV vaccination’s cancer-preventive properties and vaccine mandates’
effectiveness, HPV vaccine school-entry requirements have not been widely adopted in the US.
Guided by the Multiple Streams Approach, the purpose of this study was to understand the
adoption process of PR’s HPV vaccine school-entry requirement. Phase 1 consisted of a
qualitative study in PR using in-depth interviews. Participants included stakeholders in the PR
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HPV vaccine school-entry approval process (in favor/against). Purposive sampling was used to
recruit stakeholders identified from online sources, by consulting local experts, and utilizing
snowball sampling. Interviews were audio-recorded and transcribed. Data were analyzed using
applied thematic analysis. Phase 2 consisted of a content analysis of PR’s newspapers from
January 1st, 2015 to July 31st, 2018. Data were described quantitatively and qualitatively.
From 21 stakeholders that were interviewed, only one person expressed views against the
HPV vaccine school-entry requirement. The stakeholders highlighted problems such as, the high
incidence of HPV and HPV-related cancers in PR (e.g., cervical/oropharyngeal) that needed to
be resolved. Social factors such as the case of Rhaiza López Plumey, a young mother, who died
of cervical cancer in 2015, and the VOCES HPV Advisory Panel Report served as focusing
events that motivated the adoption process. Stakeholders also discussed other policy initiatives,
such as changes to the current immunization law. The political turn-over in key government
positions facilitated the adoption process. During the summer of 2017, a policy window opened,
and the HPV vaccine school-entry requirement was adopted in the summer of 2018. The policy
entrepreneurs worked on what was needed for the HPV vaccine school-entry requirement to be
adopted through collaborations among different sectors.
A total of 286 news articles included the key terms “HPV” or “human papillomavirus” in
Spanish. Thirty-four articles mentioned the HPV vaccine school-entry requirement. The highest
number of publications that mentioned the HPV vaccine school-entry requirement in PR
occurred in 2017, and during the first seven months of 2018. The arguments listed in the articles
included concerns related to the side effects of the HPV vaccine, the sexual nature of the
transmission of the virus, and that it should be the parents’ right to choose to vaccinate their
children. Other areas such as the HPV clears by itself and that there is no consensus regarding
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the HPV vaccine, were mentioned less frequently. Findings from this study can inform other
states and public health practitioners interested in adopting HPV vaccine policy initiatives to
improve HPV vaccination rates across the US and target the prevention of HPV-related cancers.
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Chapter 1: Introduction
Background
The Human Papillomavirus (HPV) is the most common sexually transmitted infection
(STI) in the United States (Centers for Disease Control and Prevention, 2015; Satterwhite et al.,
2013), with around 18 million adolescents between the ages of 15 and 24 currently infected
(Satterwhite et al., 2013). New cases of HPV are estimated to be around 14 million a year, half of
which occur among this age group (Satterwhite et al., 2013). Common risk factors for HPV
infection include a higher number of sexual partners (concurrently or sequentially), early sexual
initiation, lacking or inconsistent condom use, young age, partner’s sexual behavior, immune
system status, and biological susceptibility (Burchell, Winer, de Sanjose, & Franco, 2006;
Centers for Disease Control Prevention, 2015; Markowitz et al., 2014; Ratanasiripong, 2012;
Trottier & Franco, 2006). Infection with low-risk HPV types, HPV 6 and 11, causes anogenital
warts (Garland et al., 2009), and persistent infection with high-risk types 16 and 18 can cause
cancers such as cervical, vulvar, vaginal, penile, anal, and oropharyngeal (Forman et al., 2012;
Markowitz et al., 2014; zur Hausen, 2002).

Currently, there is an HPV vaccine that is mainly targeted for boys and girls 11 to 12
years old (Centers for Disease and Control Prevention, 2016c), due to a better immune response
before children become sexually active (Block et al., 2006). This segment of the population only
requires two doses of the HPV vaccine (Centers for Disease and Control Prevention, 2016c).
Catch-up vaccination is recommended for females between the ages of 13 and 26 years and for
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males between the ages of 13 and 21 years, who will need three doses of the HPV vaccine
(Markowitz et al., 2014; Petrosky et al., 2015). Furthermore, the nine-valent and the quadrivalent versions are also recommended up to age 26 years of age for men who have sex with men
(Markowitz et al., 2014; Petrosky et al., 2015), transgender young adults and people with
immunocompromised conditions (Centers for Disease and Control Prevention, 2016c).

During 2015, coverage with at least one dose of the HPV vaccine was 56.1%, and three
doses were 34.9% among 13 to 17-year-old adolescents (Reagan-Steiner et al., 2016). Thus,
uptake and completion rates of the HPV vaccine remain low in the US. Furthermore, there is
state variation in the initiation and completion rates of the HPV vaccine among this age group.
For example, Florida had a 62.5% initiation rate among females and 45.3% among males.
Completion rates were 36.8% and 19.8%, for females and males respectively (Reagan-Steiner et
al., 2016). Puerto Rico had overall initiation and completion rates estimated to be 75.8% and
52.8% respectively. Among females, the initiation rate was 80.8% and among males was 71.1%.
Completion rates were 61.9% and 44.1%, for females and males respectively (Walker et al.,
2017).
This low uptake and completion rates are due to a combination of multi-level factors.
Factors such as young age, gender, low parental awareness of the HPV vaccine, parental
concerns about their children’s sexual behavior, vaccine side effects and safety have been noted
at the individual level (Berenson, 2015; Holman et al., 2014). At the interpersonal level factors
such as lack of physician recommendation (Dorell, Yankey, Kennedy, & Stokley, 2013) and
communication between mother and child (Gross, Laz, Rahman, & Berenson, 2015) have been
found to impact HPV vaccine initiation and completion. Ethnicity is a factor at the community
level, with Hispanic minorities usually having higher rates of HPV vaccine initiation (Henry,
2

Warner, Ding, & Kepka, 2015). At the organizational level, the HPV vaccine has received an
endorsement from many important professional organizations such as the American Academy of
Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians
and Gynecologists, among others (Byington et al., 2016). Lastly at the societal level, issues such
as the social perception of HPV as a female only issue (Daley et al., 2016), news media messages
(Gollust, LoRusso, Nagler, & Fowler, 2016), and the variation of state-level policies regarding
the HPV vaccine (Laugesen et al., 2014), also impact HPV vaccine uptake and completion.
Vaccines interventions have contributed to the improvement of the overall health of our
society. Consequently, the reduction of vaccine-preventable diseases through vaccination is
celebrated as one of the ten greatest public health achievements (Centers for Disease and Control
Prevention, 1999; Centers for Disease Control and Prevention, 2011; Dube et al., 2013; Larson,
Jarrett, Eckersberger, Smith, & Paterson, 2014). Vaccines were instrumental in the eradication of
diseases such as polio and smallpox (Centers for Disease and Control Prevention, 1999; Dube et
al., 2013), and have aided in lowering the incidence of pneumococcal infections and rotavirus
hospitalizations in the US during the last decade (Centers for Disease Control and Prevention,
2011).
Vaccine interventions, mainly vaccination mandates, are an effective strategy to improve
vaccination coverage. Based on the Community Preventive Services Task Force (GCPS, 2016)
definitions, ‘school-entry requirements’ refer to laws that require vaccination and documentation
as a condition to school attendance. The states create these laws; thus, there is variation across
jurisdictions in the vaccinations included, the evidence required as documentation, the opt-out
options (reasons parents can choose not to vaccinate their children), and how they are
implemented (GCPS, 2016). ‘Vaccine mandates’ can be defined as a broad term that refers to
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any law requiring vaccination. These can include school-entry requirements, or laws requiring
hospital employees to be vaccinated (Cole & Swendiman, 2014). On the other hand, ‘schoolbased programs’ are defined as vaccination programs where immunization is delivered at the
schools. These programs usually include education and promotion, tracking of vaccination status,
and referral components (GCPS, 2016).
School-entry requirements are a highly effective strategy commonly used in the US to
increase adolescent uptake of vaccines (Averhoff et al., 2004; Field & Caplan, 2008; Hinman,
Orenstein, Williamson, & Darrington, 2002). Unfortunately, HPV vaccine policies have
encountered a lot of resistance due to the intersection of vaccine safety and adolescent sexuality
(Colgrove, Abiola, & Mello, 2010). Overall, arguments in favor and against of the HPV vaccine
mandates have been previously debated. In 2006, when the HPV vaccine was approved by the
FDA, arguments in support for HPV vaccine mandates was influenced by framing the issue
under the umbrella of women’s health and children’s welfare (Colgrove, 2006). Additional
arguments in favor of a school vaccine mandate note the vaccine cost-effectiveness, the
appropriate age range for inoculation, the importance of preventing and reducing cervical cancer,
and parental involvement in health decisions (Vamos, McDermott, & Daley, 2008). Arguments
against the HPV vaccine mandates included concerns related to the lack of transmission of the
virus through casual contact, interfering with parental autonomy, public distrust due to
pharmaceutical lobbying during policy development, and the potential economic burden on the
government, health departments, and private physicians (Gostin & DeAngelis, 2007; Javitt,
Berkowitz, & Gostin, 2008; Mello, Abiola, & Colgrove, 2012).
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Public Health Significance
In 1988, the Institute of Medicine (IOM) established in its seminal report ‘The Future of
Public Health’ the core functions of public health as assessment, policy development, and
assurance. These functions apply to all levels of the government (i.e., local, state, and federal),
each level with its unique responsibilities (Institute of Medicine, 1988). The assessment core
function includes the recommendation for public health agencies to “collect, assemble, analyze,
and make available information on the on the health of the community, including statistics on
health status, community health needs, and epidemiologic and other studies of health problems.”
(Institute of Medicine, 1988, p. 7). Governmental and agencies cooperation was recommended to
accomplish this function.
Policy development refers to “the development of comprehensive public health policies
by promoting the use of the scientific knowledge base in decision-making about public health
and by leading in developing public health policy” within the context of the democratic political
process (Institute of Medicine, 1988, p. 8). Finally, assurance is a recommendation for public
health agencies to guarantee their citizens the services that are needed “to achieve agreed upon
goals are provided, either by encouraging actions by other entities (private or public sector), by
requiring such action through regulation, or by providing services directly” (Institute of
Medicine, 1988, p.8). Additionally, public health agencies should “involve key policymakers and
the general public in determining a set of high-priority personal and communitywide health
services that governments will guarantee” (Institute of Medicine, 1988, p. 8).
In 1994, the US Public Health Service operationalized the core functions; and the Ten
Essential Public Health Services were created (Novick & Morrow, 2008). In the IOM’s 2003
follow-up report ‘The Future of the Public’s Health in the 21st Century’, the emphasis was on
strengthening the public health infrastructures, and the importance of partnerships to enhance the
5

system (Novick & Morrow, 2008). Thus, six areas were identified to assure the conditions for
population health. These include community, healthcare delivery system, employers and
business, the media, academia, and government public health infrastructure (Institute of
Medicine, 2003, as cited in Novick & Morrow, 2008).
In addition to the core functions and the essential services, public health is based on
overarching tenets. These include an understanding that protecting the health of entire
communities may sometimes be in conflict with the individuals’ autonomy, the idea that health
depends on social, behavioral, and biological factors that affect all the population, and that
prevention (i.e., primary, secondary and tertiary) is the desirable approach (Novick & Morrow,
2008; Schneider, 2016). Thus, the core functions, the ten essential services, and public health
overarching tenets have contributed to the formation of the discipline and its current
achievements.
The Centers for Disease Control and Prevention (2011) has identified ten areas in which
public health has achieved significant accomplishments in lives and money saved during the first
decade of the 21st century. These endeavors are in the areas of 1) vaccine-preventable diseases,
2) prevention and control of infectious diseases, 3) tobacco control, 4) maternal and infant
health, 5) motor vehicle safety, 6) cardiovascular disease prevention, 7) occupational safety, 8)
cancer prevention, 9) childhood lead poisoning prevention, and 10) public health preparedness
and response (Centers for Disease Control and Prevention, 2011).
The present study falls under the policy development core function of public health by
contributing to the overall science and creation of evidence. The study addresses issues related to
the promotion of public health policy, the HPV vaccine school-entry requirement. The study’s
research focus overlaps with two areas, vaccine-preventable diseases, and cancer prevention. The
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research, practice, and policy implications that result from the study have been considered under
this framework and will be discussed in Chapter 5.
Statement of Need
Healthy People 2020 established a national objective of 80% completion of the HPV
vaccination among females and males aged 13 to 15 years old (U.S. Department of Health and
Human Services & Office of Disease Prevention and Health Promotion, 2015). Despite research
demonstrating the safety and effectiveness of the HPV vaccine as a primary prevention strategy
(Petrosky et al., 2015; Stokley et al., 2014), HPV vaccination rates among adolescents remain far
below the Healthy People 2020 goal.
HPV is the cause of most cervical, vulvar, vaginal, anal, and penile cancers, and is also
associated with anogenital warts and recurrent respiratory papillomatosis (Markowitz et al.,
2014). The HPV vaccine affords the opportunity to successfully prevent these types of cancers
and HPV-related diseases (Markowitz et al., 2014; Petrosky et al., 2015). Moreover, the annual
medical direct cost of the prevention and treatment of HPV-associated diseases in the US has
been estimated to be around $8 billion (2010 US dollars) (Chesson et al., 2012). Thus, an overall
reduction of the infection of HPV would significantly reduce the morbidity and mortality of
these diseases and their associated economic costs.
In the US, provider recommendation and parental education have been widely used the
strategies to promote HPV vaccination; thus, a call has been made to consider HPV vaccine
school-entry requirements as part of the approaches to increase HPV vaccination rates (Daley,
Thompson, & Zimet, 2019). Recommendations are based on the available evidence of the
effectiveness and previous experience in the US with vaccination mandates for school entrance
(Averhoff et al., 2004).
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Currently, the policies related to the HPV vaccine vary in content; some legislate in favor
of educational campaigns while others require health insurances to cover the HPV vaccine or
require the HPV vaccine for middle school entrance (Abiola, Colgrove, & Mello, 2013; Colgrove
et al., 2010; Laugesen et al., 2014). Virginia, Rhode Island, Washington DC (Barraza,
Weidenaar, Campos-Outcalt, & Yang, 2016), and Puerto Rico (PR) are the only states/territories
currently requiring the HPV vaccine for school-entry.
Despite cancer-preventive properties of HPV vaccination and the effectiveness of prior
vaccine mandates, there is a need to understand why HPV vaccine school-entry requirements
have not been widely adopted in the US. Thus, guided by the Multiple Streams Approach, the
purpose of this study is to understand the macro level factors that influenced the adoption of the
HPV vaccine school-entry requirement in PR. This purpose will be achieved via the following
research questions:

1. How did the problems, politics, and policy streams intersect to inform the HPV vaccine
school-entry requirement in Puerto Rico?
2. Who were the policy entrepreneurs involved in the adoption process and what were their
roles?
3. What were the arguments in favor of and against the HPV vaccine school-entry
requirement?

8

Key Terms
HPV – human papillomavirus
STI – sexually transmitted infection
US – United States
PR – Puerto Rico
MSA – Multiple Streams Approach/Theory/Framework
DOH – Puerto Rico’s Department of Health
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Chapter 2: Literature Review
The Human Papillomavirus
The Human Papillomavirus (HPV) is the most common sexually transmitted infection
(STI) in the United States (Centers for Disease Control and Prevention, 2015; Satterwhite et al.,
2013). Around 79 million people aged 15 to 59 are currently infected with the HPV, 18 million
of them between the ages of 15 and 24 (Satterwhite et al., 2013). New cases of HPV are
estimated to be around 14 million a year, half of those among youth 15 to 24 years old
(Satterwhite et al., 2013). Most of all sexually active individuals will contract the virus at least
once during their lifetime. For instance, it was estimated that among heterosexual individuals
with at least one sexual partner, 84.6% of women and 91.3% of men, will contract HPV by age
45 (Chesson, Dunne, Hariri, & Markowitz, 2014).
The HPV belongs to the Papillomaviridae family a group of non-enveloped DNA viruses
that can cause tumors in the epithelium tissue (Morshed, Polz-Gruszka, Szymanski, & PolzDacewicz, 2014). In particular, HPV has an 8,000 base-pair long circular DNA wrapped in a
protein shell composed of two molecules (L1 and L2) (Gattoc, Nair, & Ault, 2013; Munoz,
Castellsague, de Gonzalez, & Gissmann, 2006). These two proteins (L1 and L2) and six early
proteins (E1, E2, E4-E7) are necessary for the viral DNA replication within the infected cells
(Morshed et al., 2014; Munoz et al., 2006). Currently, 170 types of HPV have been identified, 40
of which infect the genital tract (de Villiers, 2013).
An HPV infection is mostly asymptomatic and localized and can occur via various routes
of transmission. HPV’s infections primarily occur via genital contact during sexual intercourse,
10

but other means of sexual contagion include oral-genital and anal-genital contact (Moscicki et
al., 2012). Evidence also indicates other routes of transmission, such as skin-to-skin contact,
vertical transmission from mother to infant during vaginal delivery, hands to genitals or genitals
to hands, and/or by contaminated fomites – objects that could carry the virus (e.g., sonography
probes, speculum) (Liu, Rashid, & Nyitray, 2015; Tay, 1995).
Common risk factors for HPV infection include higher number of sexual partners
(concurrently or sequentially), early sexual initiation, lack or inconsistent condom use, young
age, partner’s sexual behavior, immune status, and biological susceptibility (Burchell et al.,
2006; Centers for Disease Control Prevention, 2015; Markowitz et al., 2014; Ratanasiripong,
2012; Trottier & Franco, 2006). Most HPV infections are transient and will clear within one to
two years without clinical repercussions (Burchell et al., 2006; Trottier & Franco, 2006).
Nevertheless, persistent infection can lead to diseases such as respiratory papillomatosis, genital
warts, and some types of cancers (Centers for Disease Control Prevention, 2015; Jemal et al.,
2013; Markowitz et al., 2014; Molano et al., 2003; Moscicki, 1998; zur Hausen, 2002). Among
women, HPV infection can be tested during a routine Papanicolaou test; however, there are no
HPV tests approved for men (Markowitz et al., 2014).
Low-risk HPV types 6 and 11 cause more than 90% of anogenital warts (Garland et al.,
2009). It has been reported that anogenital warts or condylomata acuminate, can develop clinical
symptoms as early as two to three months after infection with HPV (Garland et al., 2009; Winer
et al., 2005). It is difficult to estimate the incidence of anogenital warts because in the US this is
not required to be reported (Park, Introcaso, & Dunne, 2015). Based on data from the US
National Health and Nutrition Examination survey from 1999 to 2004, among 18 to 56-year-old
adults, 5.6% of reported having a prior genital warts diagnosis (Dinh, Sternberg, Dunne, &
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Markowitz, 2008). Additionally, this study found that diagnosis of anogenital warts was higher
among 25 to 34-year-old women and 35 to 44-year-old men, 10.4% and 6.0% respectively.
Factors associated with having genital warts include sex, age, race/ethnicity, the number of
lifetime sexual partners, and illegal drug use (Dinh et al., 2008).
Another less prevalent condition caused by HPV types 6 and 11 is recurrent respiratory
papillomatosis (Lacey, Lowndes, & Shah, 2006; Markowitz et al., 2014). Infection with the HPV
virus typically during childbirth, causes the growth of benign tumors in the respiratory tract (i.e.,
nose, mouth, larynx, lungs) (National Institute on Deafness and Other Communication Disorders,
2010). These tumors can be removed through surgery but often grow back causing respiratory
obstruction (Lacey et al., 2006). Due to its rare occurrence, incidence and prevalence rates are
difficult to evaluate, but some estimates indicate 80 to 1,500 incident cases and 700 to 3,000
prevalent cases among individuals younger than 18 years old in the US (Armstrong et al., 2000).
HPV-related cancers include cervical, vulvar, vaginal, penile, anal, and oropharyngeal
(Forman et al., 2012; Markowitz et al., 2014; zur Hausen, 2002). From 2008 to 2012,
approximately 30,700 HPV-associated cancers were diagnosed annually in the US (Viens et al.,
2016). Specifically, 91% of cervical and anal cancers, 72% of oropharyngeal cancers, 63% of
penile cancers, 75% of vaginal cancers, and 69% of vulvar cancers were attributable to HPV
(Markowitz et al., 2014). Moreover, approximately 64% of these cancers are caused by HPV
types 16 and 18 (Centers for Disease Control Prevention, 2015; Markowitz et al., 2014). This is
because persistent biological infections with high-risk HPV types (i.e., HPV 16 and 18) are more
likely to progress to cancer (Jemal et al., 2013; Markowitz et al., 2014; Schiffman, Castle,
Jeronimo, Rodriguez, & Wacholder, 2007). Additionally, about 10% of the HPV-associated
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cancers are attributed to HPV types 31, 33, 45, 52, and 58 (Centers for Disease Control and
Prevention, 2015; Markowitz et al., 2014; Petrosky et al., 2015).
The HPV Vaccine
Currently, there are three approved HPV vaccines. The first two vaccines developed and
later approved by the Food and Drug Administration (FDA) were the bivalent (Cervarix®) –
only recommended for females – and the quadri-valent (Gardasil®) – recommended for both
males and females. The Advisory Committee on Immunization Practices (ACIP) first
recommended the HPV vaccine for routine vaccination for females in 2006 and males in 2011
(Markowitz et al., 2014). The third vaccine that was approved by the FDA in 2014 was the ninevalent version (Gardasil 9®). ACIP made it part of its recommended vaccines for both sexes in
2015 (Petrosky et al., 2015). Table 1 contains a detailed description of the HPV vaccines
available.
The current ACIP recommendations indicate vaccinating children at 11 to 12 years of
age, due to a better immune response before children become sexually active (Block et al.,
2006). Additionally, the HPV vaccine is recommended for females between the ages of 13 and
26 years, and for males between the ages of 13 and 21 years, also as the known catch-up group,
(Markowitz et al., 2014; Petrosky et al., 2015). Other populations to which the nine-valent and
the quadri-valent versions of the HPV vaccine are also recommended include men who have sex
with men (Markowitz et al., 2014; Petrosky et al., 2015), transgender individuals and people with
immunocompromised conditions, all groups through age 26 (Centers for Disease and Control
Prevention, 2016c).
Until recently, all approved vaccines required three intramuscular shots over a six-month
period (scheduled at zero, two, and six months after the first shot) (Petrosky et al., 2015). The
HPV vaccine series costs between $390 and $450, and additional fees may be charged by the
13

clinics and providers for administration costs (Association of Reproductive Health Professionals,
n.d.). Research pointed to non-inferiority of two doses of the HPV vaccine (Dobson et al., 2013;
Kreimer et al., 2015); thus in 2016, there was change to a two-dose/shots regime in the
recommended number of dosages in the US. All 11 to 12 years old children should get two shots
of the HPV vaccine six to 12 months apart. A third dose is required if the children received the
two shots less than five months apart or if adolescents are older than 14 years or for 9 to 26-yearold individuals with immunocompromised conditions (Centers for Disease and Control
Prevention, 2016c). Currently, the World Health Organization (WHO) recommends a two-dose
schedule for females younger than 15, and a three-dose schedule for females older than 15, and
immunocompromised or HIV-infected individuals (World Health Organization, 2014).
The vaccines are made of HPV L1 protein, which produces virus-like particles by using
recombinant DNA technology; thus, making the vaccines not infectious (Markowitz et al., 2014).
Common mild side effects associated with the HPV vaccine include pain and swelling at the
injection site, headache, nausea, and muscle or joint pain (Centers for Disease and Control
Prevention, 2015). Nonetheless, a recent review of nine years (up to the year 2015) of
worldwide data from active and passive post-licensure safety surveillance of the 4valent HPV
vaccine, found that only syncope (i.e., fainting) and possible skin infection were associated with
vaccination. Furthermore, the review found that there was no higher incidence of serious adverse
events, such as anaphylaxis, stroke, and autoimmune diseases, compared to background rates
(Vichnin et al., 2015).
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HPV vaccine uptake and completion rates in the US.
For 2016, it was estimated that only 56.0% of males between the ages of 13 and 17 years
had received at least one dose of the HPV vaccine, in contrast to 65.1% of females in the same
age group (Walker et al., 2017). For that same year, only 49.5% of females and 37.5% of males
13 to 17 years old had three doses of the HPV vaccine. Among both male and female
adolescents, coverage with at least one dose of the HPV vaccine was 60.4%, and three doses
coverage was 43.4% (Walker et al., 2017). These coverage rates are 28% points lower than at
least one dose of the Tdap and 22% lower than at least one dose of the meningococcal vaccine
(Walker et al., 2017). Lower rates are observed among the catch-up population. In 2012, the
HPV vaccine uptake among females between the ages of 18 and 26 (considered catch-up group)
was around 34.1% (Schmidt & Parsons, 2014). During the 2011 to 2012 period, the uptake rate
among males 18 to 26 years old was 5.5% (Pierre-Victor, Mukherjee, Bahelah, & Madhivanan,
2014).
There is state variation in the initiation and completion rates of the HPV vaccine among
adolescents 13 to 17 years old. During 2016, Rhode Island had the highest rate of initiation
among females (90.1%) and males (87.8%). Mississippi had the lowest initiation rates for
females (47.8%), while Indiana and Wyoming had the lowest initiation rates for males (36.9%).
HPV vaccine three dose completion among females ranged from 30.8% in South Carolina to
73.0% in Rhode Island. Among males, completion rates ranged from 19.3% in Wyoming to
68.7% in Rhode Island. Overall initiation and completion rates in Puerto Rico were estimated to
be 75.8% and 52.8% respectively. Among females, the initiation rate was 80.8% and among
males was 71.1%. Completion rates were 61.9% and 44.1%, for females and males, respectively
(Walker et al., 2017).
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There are also racial/ethnic differences in HPV vaccination, as well as differences based
on poverty level. In 2014, HPV vaccination initiation and completion were higher among
Hispanic adolescents compared to non-Hispanic White adolescents (Reagan-Steiner et al., 2016).
Non-Hispanic Black adolescents and American Indian/Alaska Native males had a higher HPV
vaccine initiation rates compared to non-Hispanic Whites. Additionally, compared with
adolescents living at or above the poverty level, HPV vaccination initiation was higher among
adolescents living below the poverty level (Reagan-Steiner et al., 2016).
Healthy People 2020 established a national objective of 80% completion of the HPV
vaccination among females and males aged 13 to 15 years old (Reagan-Steiner et al., 2016; U.S.
Department of Health and Human Services & Office of Disease Prevention and Health
Promotion, 2015). Despite research demonstrating the safety and effectiveness of the HPV
vaccine as a primary prevention strategy (Petrosky et al., 2015; Stokley et al., 2014), the
initiation and completion rates previously presented show HPV vaccination rates among
adolescents remain far below the Healthy People 2020 goal.
Health implications of increasing HPV vaccination rates.
There are important health implications for increasing HPV vaccination. Research has
reported findings regarding the reduction in the prevalence of HPV in the US population. A
recent study found a 64% reduction in the prevalence of the HPV types covered by the 4valent
vaccine among females between the ages of 14 and 19, within six years of the vaccine
introduction in the US (Markowitz et al., 2016).
As discussed before, HPV is the cause of most cervical, vulvar, vaginal, anal, and penile
cancers, and is also associated with anogenital warts and recurrent respiratory papillomatosis
(Markowitz et al., 2014). Thus, an overall reduction of the infection of HPV would significantly
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reduce the morbidity and mortality of these diseases. Moreover, HPV is also the cause of 72% of
all oropharyngeal cancers; however, the HPV vaccine is not currently recommended for the
prevention of this type of cancer because of lack of clinical trial data (Chaturvedi et al., 2011;
Markowitz et al., 2014). Nonetheless, the vaccine includes HPV types 16 and 18, associated with
62% of the HPV-related oropharyngeal cancers (Gillison, Chaturvedi, & Lowy, 2008; Markowitz
et al., 2014; Steinau et al., 2014). Therefore, increasing HPV vaccination rates could also have an
impact on the reduction of oropharyngeal cancer rates.
It is important to note that, there are some disparities in the distribution of HPVassociated cancer incidence and mortality among race/ethnicities in the US (Jemal et al., 2013).
For instance, data from 2008 to 2012 showed that cervical cancer rates were higher among
Blacks compared to their White counterparts (9.2% and 7.1% respectively) (Viens et al., 2016).
This same study found that cervical cancer rates were higher among Hispanics (9.7%) compared
to non-Hispanics (7.1%) (Viens et al., 2016). Recent simulation models have been conducted to
project changes in HPV-associated cancer burden. Findings suggest that HPV vaccination could
not only decrease the morbidity and mortality of HPV-related cancers among all
races/ethnicities, but it could also reduce the absolute degree of disparities (Burger et al., 2016).
Nonetheless, some relative differences could worsen. For example, among males, the lifetime
risk of dying of HPV-associated cancer lowered by 60%, but relative disparities increased when
high uptake of the second generation of the HPV vaccine was assumed (Burger et al., 2016).
Thus, the authors conclude that if the fundamental causes of disparities are not addressed (e.g.,
limited access to health care and cancer treatments) the relative disparities will likely continue
and may even broaden (Burger et al., 2016).
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Globally there is evidence in the reduction of HPV-related disease. A recent metaanalysis of female HPV vaccination programs in nine high-income countries (Australia, Canada,
Denmark, England, Germany, New Zealand, Scotland, Sweden, and the US), was conducted to
assess the population-level effects of these programs on the rates of genital warts (Drolet et al.,
2015). Findings demonstrated significant reductions of HPV 16 and 18 infections, and of
anogenital warts among 13 to 19-year-old girls when female vaccination coverage was at least
50% (Drolet et al., 2015). Among this age group, a significant reduction of HPV types 31, 33 and
45 was seen; thus, indicating some level of cross-protection. Among males under 20 years and
women between 20 and 39 years old, a significant decrease of anogenital warts was also found
indicating herd immunity effects (Drolet et al., 2015). In places with female vaccination
coverage less than 50%, there were still significant decreases in HPV 16 and 18 infections and
anogenital warts; however, no signs of cross-protection or herd immunity effects were found
(Drolet et al., 2015).
Reductions in the rates of genital warts in the US has also been reported. For example,
among female members of private health insurance 15 to 19 years old, the prevalence of genital
warts significantly decreased during the years of 2007 to 2010 compared to 2003 to 2006,
indicating some effect of the HPV vaccine after its introduction (Flagg, Schwartz, & Weinstock,
2013). Furthermore, Bauer, Wright, and Chow (2012) found a 35% and 19% significant
reduction in genital warts diagnoses among females and males younger than 21 years,
respectively, using a claims data from a California public family planning clinic. More recently,
in a group of low-income and minority adolescents, rates of genital warts significantly decreased
from pre- to post-vaccination periods from 3.5% to 1.5% in females and from 3.6% to 2.9% in
males (Perkins, Legler, & Hanchate, 2015).
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Economic implications of increasing HPV vaccination rates.
Besides the health implications, there are economic consequences of improving HPV
vaccination. The annual medical direct cost of the prevention and treatment of HPV-associated
diseases in the US has been estimated to be around $8 billion (2010 US dollars) (Chesson et al.,
2012). Routine cervical cancer screening and follow-up accounted for about $6.6 billion, cervical
and oropharyngeal cancers cost were around $1 billion, anogenital warts accounted for $288
million, and recurrent respiratory papillomatosis accounted for 171 million dollars (Chesson et
al., 2012). Furthermore, women bear about two-thirds of the annual costs of HPV-associated
diseases (Chesson et al., 2012). Therefore, increasing the HPV vaccination rates could save
billions of dollars to the US health care system, and could result in a decrease in the burden of
HPV-related diseases among women. Additionally, routine HPV vaccination of 12-year-old
females, “in the context of current screening and assuming lifelong vaccine-induced immunity,
had an incremental cost-effectiveness ratio of $43,600 per QALY gained, as compared with
screening alone” (Kim & Goldie, 2008, p. 825).
In the US, recent data showed a 64% and a 34% decrease in the prevalence of HPV 6, 11,
16, and 18 after the HPV vaccine introduction among 14 to 19-year-olds and 20 to 24 years old
females, respectively (Markowitz et al., 2016). Thus, in addition to the reduction of the
prevalence of anogenital warts (i.e., HPV 6 and 11) by the uptake of the HPV vaccine, this could
also mean the savings of around 167.4 million dollars; which was the estimated direct costs
associated with genital warts among 15 to 24 year old young adults (Chesson, Blandford, Gift,
Tao, & Irwin, 2004).
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Factors that impact HPV vaccine rates.
Many barriers and facilitators influence HPV vaccine acceptance among stakeholders,
which affect HPV vaccination rates in the US. 1 In this section, common barriers and facilitators
to HPV vaccine uptake and completion will be presented following the levels of the SocioEcological Model (SEM). The SEM is a framework commonly used in public health to identify,
organize, and analyze factors that can impact/influence a public health issue or/in a population.
This framework consists of the following levels of influence: intrapersonal, interpersonal,
organizational, community, and societal (Coreil, 2010). Because of this multilevel perspective,
the SEM is useful for understanding health problems, identifying needs or areas for public health
intervention, and for developing interventions.
Individual level.
Factors such as age, sex, beliefs, attitudes, and knowledge are usually considered at the
individual level. In the case of the HPV vaccine, the adolescent’s sex is a factor that influences
vaccination rates. A study using data from the National Immunization Survey-Teen 2013 (NISTeen 2013), showed that girls were more likely to be vaccinated and had completed the three
doses compared to boys between the ages of 13 and 17 years (Lindley et al., 2016). This is also
the case among the college student population. A recent study noted that, although the difference
between males and females decreased in comparison to rates of fall 2009 to 2011, HPV

1

There are two systematic reviews that summarize barriers to HPV vaccination among adolescents aged
11 to 17 living in the US Holman et al. (2014) included studies from 2009 to 2012. Berenson (2015)
followed-up Holman’s review by looking at studies from 2013 to 2015. Therefore, some of the factors
presented in the following sections are based on the studies included in these reviews.
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vaccination rates in years 2012 and 2013 were still higher among females than males college
students (Thompson et al., 2016).
Age is another factor that influences HPV vaccination. In most studies identified by
Holman et al. (2014), younger age was a reason for not vaccinating or for delaying vaccination
(Baldwin, Bruce, & Tiro, 2013; Bastani et al., 2011a; Control & Prevention, 2012; Dorell,
Yankey, Santibanez, & Markowitz, 2011; Gilkey, Moss, McRee, & Brewer, 2012; Hoffman et
al., 2012; Laz, Rahman, & Berenson, 2012; Reynolds & O'connell, 2012). However, among
males, this age difference was not observed in either HPV vaccine initiation or completion
(Control & Prevention, 2012; Curtis et al., 2013).
Parents, including caregivers, also report individual-level barriers to HPV vaccination.
Holman et al. (2014) and Berenson (2015) noted in their reviews of studies that parents report
the need for more information about the HPV vaccine. Additionally, in a recent study, parents of
children 11 to 17 years old who decide to delay the HPV vaccine, have also reported the need for
more information about the vaccine (Gilkey, Calo, Marciniak, & Brewer, 2017). Parents have
also mentioned the cost of the HPV vaccine as a barrier to uptake in most studies summarized by
Holman et al. (2014). Moreover, Berenson (2015) highlighted the cost of the HPV vaccine is a
barrier to adolescent vaccination. This perception of the cost of the HPV vaccine is a barrier to
HPV vaccination among parents even when they could get the vaccine through the Vaccines for
Children program (Vadaparampil, Staras, et al., 2013).
As reported by Holman et al. (2014) and Berenson (2015), research has found that some
parents also think that the HPV vaccine will cause their children to initiate sexual activity and/or
engage in risky sexual behavior. For instance, in a qualitative study with Puerto Rican mothers
one of the themes related to HPV vaccination uptake was the idea that the vaccine would indicate
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to their daughters that it would be fine to engage in sexual activity (Fernandez et al., 2014). This
phenomenon is known as sexual risk compensation or sexual disinhibition (Zimet, Rosberger,
Fisher, Perez, & Stupiansky, 2013). Nonetheless, two systematic reviews have concluded that
there is no evidence for these concerns (Kasting, Shapiro, Rosberger, Kahn, & Zimet, 2016;
Madhivanan et al., 2016). Furthermore, among college students no association between
inconsistent condom use and HPV vaccination was found (Vazquez-Otero et al., 2016), further
providing evidence that the HPV vaccine does not promote risky sexual behaviors.
Holman et al. 2014 noted that studies’ findings of parental worries related to side effects
and safety, and concerns about the newness of the vaccine did not clearly indicate if HPV
vaccine uptake was affected (Laz et al., 2012; Litton, Desmond, Gilliland, Huh, & Franklin,
2011; Sanders-Thompson, Arnold, & Notaro, 2011). Berenson (2015) also identified studies in
which parents expressed concerns about the possibility of long-term health effects associated
with the vaccine as a reason for not vaccinating their children (Blackman et al., 2013; Dorell et
al., 2014). For example, in a sample of African American and Bahamian parents, most agreed
needing more assurance on the HPV vaccine safety (Blackman et al. 2013). Concerns about
adverse events were also found to be among the most common factors against HPV vaccination
among parents from Georgia (Gargano et al., 2013).
Parental religiosity or religious beliefs influence HPV vaccination uptake is a contested
factor. Holman et al. (2014) found two studies in which religious affiliation was associated with
disapproval in getting the vaccine (Pierre-Joseph et al., 2012; Thomas, Strickland, DiClemente,
Higgins, & Haber, 2012), whereas in two other studies there was no association to HPV vaccine
acceptance (Litton et al., 2011; Sanders-Thompson et al., 2011). For example, Litton et al.,
(2011), conducted a survey among female caregivers of 10 and 14-year-old girls, and found that

22

religious attendance as well as factors such as perceived susceptibility and severity of the
infection were not associated with intention to vaccinate their children. On the other hand,
among African American parents of young children, religious affiliation was correlated with
planning and getting the HPV vaccine (Thompson et al., 2011).
Furthermore, Berenson (2015) found studies that reported that among parents there is a
lack of awareness and knowledge of the HPV likelihood of infection, of the risks or
understanding that transmission of the virus can be prevented with the vaccine; resulting in some
parents choosing not to vaccinate their children. For example, in a recent qualitative study guided
by the HBM, most of the participants of a sample of African American parents perceived that
their adolescent daughters were not susceptible to the virus. These parents believed their
daughters were not sexually active (Galbraith‐Gyan et al., 2019). Similarly, Berenson (2015)
reported on studies that found that among adolescents there is lack of knowledge about the virus,
cervical cancer, and the HPV vaccine.
Overall these barriers and concerns contribute to HPV vaccine hesitancy among
parents/caregivers (Patel & Berenson, 2013). Additionally, health care providers may not
recommend the HPV vaccine if they perceive parental vaccine hesitancy (Allison et al., 2016).
Vaccine hesitancy (VH) has emerged as a concept to describe the phenomena of individuals
deciding to delay or refuse vaccination. VH was defined by the SAGE Working Group as “delay
in acceptance or refusal of vaccination despite the availability of vaccination services. Vaccine
hesitancy is complex and context specific, varying across time, place and vaccines. It is
influenced by factors such as complacency, convenience, and confidence” (MacDonald, 2015, p.
3). This definition integrates the concepts ‘complacency’, ‘convenience’ and ‘confidence’ all
part of the “3 C’s” model previously developed by the WHO EURO Vaccine Communications
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Working Group in 2011 (MacDonald, 2015). The first C, ‘complacency,’ occurs when there is a
perception of low risk of vaccine-preventable diseases and people think vaccines are not needed
(MacDonald, 2015, p. 2). The second C, ‘convenience’ covers the accessibility and affordability
factors related to vaccination services (MacDonald, 2015, p. 2). Finally, ‘confidence,’ refers to
the trust people have in vaccine safety, in the health care system and health care providers, and in
the policymakers who create the mandates related to which vaccines are required (MacDonald,
2015, p. 2).
Another critical characteristic of VH is that it is considered along a continuum with
individuals who accept and those who refuse vaccines at the extremes, and the ‘vaccine-hesitant
individuals’ standing as a heterogeneous group in the middle (Benin, Wisler-Scher, Colson,
Shapiro, & Holmboe, 2006; Dube et al., 2013; Kestenbaum & Feemster, 2015; Larson et al.,
2014; MacDonald, 2015). Vaccine-hesitant individuals are heterogeneous because their
indecision varies depending on the type of vaccine; they might refuse some, accept some and/or
delay others (Dube et al., 2013; Larson et al., 2014).
Despite these barriers, there are facilitators to HPV vaccine acceptance and initiation
among parents. In Holman et al. (2014) review of the literature, some facilitators included in the
summarized studies were parents’ interest in protecting their children before the initiation of
sexual activities, perceived risk of diseases associated to HPV, and parental preventive-care
seeking behaviors. Among adolescents, the promotion of health, prevention of STIs, and cancer
prevention were mentioned as common reasons for accepting the HPV vaccine among high
school, college, and graduate health students, respectively (Suryadevara et al., 2016).
Among health care providers Holman et al. (2014) identified studies in their review that
found individual-level barriers. Some of these studies noted barriers such as low knowledge
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about the relationship of HPV with genital warts (Perkins & Clark, 2012a; Saraiya, Rosser, &
Cooper, 2012), providers offering too much or too little information about the vaccine to parents
(Goff, Mazor, Gagne, Corey, & Blake, 2011; Hughes, Jones, Feemster, & Fiks, 2011), assessing
their patients based on perceived risk factors (Goff et al., 2011; Hughes et al., 2011; Perkins &
Clark, 2012a), and concerns about parental attitudes towards vaccination (Perkins & Clark,
2012a, 2012b; Quinn, Murphy, Malo, Christie, & Vadaparampil, 2012).
Additional factors noted by Holman et al. (2014) among this group of stakeholders
included concerns about the cost of the vaccine and issues with insurance coverage and
reimbursement (Luque, Raychowdhury, & Weaver, 2012; Quinn et al., 2012). Berenson (2015)
also reported findings from studies on the cost associated with the storage of the HPV vaccine,
and inadequate reimbursement mentioned as barriers to HPV vaccination by physicians (Allison
et al., 2013; Luque, Tarasenko, Dixon, Vogel, & Tedders, 2014; Malo et al., 2013;
Vadaparampil, Murphy, Rodriguez, Malo, & Quinn, 2013).
Interpersonal level.
At the interpersonal level, factors such as family, peer, and partner and other relationships
are common influences. Relationships with health care providers are essential. Physician
recommendation is the most significant predictor of HPV vaccination among women (Rosenthal
et al., 2011), as well as among adolescents (Dorell et al., 2013; Dorell et al., 2011). However, a
recent systematic review of the literature by Gilkey and colleagues (2016), found that providers
still confront barriers to recommendation such as feeling uncomfortable when talking about sex,
perceiving parental hesitancy to get the vaccine, or believing their patients at are at low risk of
contracting HPV. Additionally, the authors found that if patients were young, male or from a
racial/ethnic minority, providers would be less likely to recommend the HPV vaccine (Gilkey &
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McRee, 2016). For example, data from the NIS-Teen 2013, showed that parents of boys 13 to 17
years old were less likely to report provider recommendation compared to parents of girls in that
age group (Lindley et al., 2016). Lack of physician recommendation has also been cited as a
reason for not receiving the HPV vaccine in a study including high school, college, and graduate
health students (Suryadevara et al., 2016), and among parents as reported in the literature
reviews by Holman et al. (2014) and Berenson (2015).
Another factor that can be listed at this level is the communication between mother and
child. In a survey with mothers of children 9 to 17 years old, communication about STI’s, and
contraception and condom use were positively associated with HPV vaccine initiation (Gross et
al., 2015). This is an important factor because mothers are usually the ones deciding to vaccinate
their children against HPV (Berenson, Laz, Hirth, McGrath, & Rahman, 2014; Gross et al.,
2015).
Community level.
Some factors considered at the community level are geographical and/or cultural
influence. The concept of community can include geographical locations, as well as
cultural/ethnic groups. For instance, among low-income immigrant ethnic minority women
concerns about locating a place for vaccinating their daughters was a barrier to HPV vaccination
(Bastani et al., 2011b). Parents from Latino communities have mentioned the lack of provider
recommendation as the main barrier to HPV vaccination for their sons and daughters (Aragones,
Genoff, Gonzalez, Shuk, & Gany, 2015; Warner et al., 2015). In terms of geographical factors, a
study looking at community-level factors associated with HPV vaccine uptake among female
adolescents found that communities composed of mostly Hispanics and urban residence were
associated with higher vaccine initiation (Henry et al., 2015). Among boys, having public health
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insurance, lower income, education, and being Hispanic are factors associated with HPV
vaccination (Kepka, Ding, Hawkins, Warner, & Boucher, 2016).
Organizational level.
The organization level includes experiences with the health care system, schools, and/or
the workplace. For instance, Holman et al. (2014) found that across studies preventive care
appointments, frequent contact with the medical system, and have received other vaccines were
all associated with receiving at least one dose of the HPV vaccine. Additionally, Berenson
(2015) identified the need to access the health care system at three different occasions as a
barrier for HPV vaccination.
Professional associations can also play a role in promoting the HPV vaccine. The HPV
vaccine has received endorsement and support from multiple influential organizations such as the
ACIP, the American Academy of Pediatrics, the American Academy of Family Physicians, the
American College of Obstetricians and Gynecologists, and the WHO (Byington et al., 2016;
World Health Organization, 2014). Nonetheless, research indicates that vaccine
recommendations alone, by institutions such as ACIP, do not increase immunization rates
(Askelson et al., 2010; Rosenthal, Kottenhahn, Biro, & Succop, 1995).
Societal level.
At this level, factors such as federal and state policies and programs, social norms, and
the media can influence HPV vaccination rates. For example, Holman et al. 2014 found a study
indicating a positive association between HPV vaccine intention with the belief it agreed with
social norms regarding the vaccination of children (Reynolds & O'connell, 2012). This study
used the Health Belief Model and the Theory of Reasoned Action to predict intention to HPV
vaccination in a sample of parents/legal guardians of girls 9 to 18 years old (Reynolds &
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O’Connell, 2012). Additionally, a more recent study looking at social norm’s beliefs among
parents of boys also found that parents who thought other parents were also vaccinating their
children were more likely to have the intention to vaccinate their sons compare to those who did
not agree to vaccinating (Schuler & Coyne-Beasley, 2016).
Another common social perception is that the HPV is a female issue; this notion, known
as the “feminization of HPV”, is largely the result of the intersection between sexism and the
vaccine’s scientific evolution (i.e., the known science) (Daley et al., 2016). Furthermore, on a
review of studies about the US news media coverage of the HPV vaccine since 2006, Gollust and
colleagues (2016) found two common themes: “a rising focus on political controversy and a
consistent emphasis on the vaccine as for girls, even beyond the point when the vaccine was
recommended for boys” (p. 1). These messages influence stakeholders such as parents,
providers, and policymakers. Additionally, network and word cluster analyses of online
presentation of HPV information suggest that compared to boys, HPV vaccine information for
women and girls is usually presented in sexual terms (Ruiz & Barnett, 2015).
At the federal level, the Vaccines for Children program provides the HPV vaccine – and
other required and recommended vaccines – at no cost to providers for use among uninsured or
underinsured, Medicaid-eligible, and to American Indian/Alaska Native children up to 18 years
old (Smith, Hinman, & Pickering, 2014). The Patient Protection and Affordable Care Act of
2010 also requires insurances to cover vaccines recommended by the ACIP with no cost to the
beneficiary (Markowitz et al., 2014). Using data from the National Health Interview Survey, a
recent study estimated that 1.1 million and 854,000 women between the ages of 19 and 25
initiated and completed the HPV vaccine, respectively, based on this ACA provision (Lipton &
Decker, 2015).
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At the state level, the introduced legislation related to the HPV vaccine is varied in
content. Some states, such as Colorado, New Jersey, North Carolina, have legislated in favor of
awareness campaigns, while other states (e.g., Illinois, Maine, Nevada, and New Mexico) require
health insurances to cover the HPV vaccine (Laugesen et al., 2014). The National Conference of
State Legislatures reports that at least 25 states and territories have passed some type of
legislation regarding the HPV vaccine. From those, only the states of Virginia and Rhode Island,
and Washington DC require the HPV vaccine for school entrance (National Conference of State
Legislatures, 2016). Details of the HPV vaccine school-entry policies are described in the
School-entry requirements section (p. 38).
Vaccine Interventions
Vaccines interventions have contributed to the improvement of the overall health of our
society. Consequently, the reduction of vaccine-preventable diseases through vaccination is
celebrated as one of the ten greatest public health achievements (Centers for Disease and Control
Prevention, 1999; Centers for Disease Control and Prevention, 2011; Dube et al., 2013; Larson et
al., 2014). Vaccines were instrumental in the eradication of diseases such as polio and smallpox
(Centers for Disease and Control Prevention, 1999; Dube et al., 2013), and have aided in
lowering the incidence of pneumococcal infections and rotavirus hospitalizations in the US
during the last decade (Centers for Disease Control and Prevention, 2011).
The Community Preventive Services Task Force (CPSTF, 2016) has identified and
organized vaccine interventions into three major categories: 1) enhancing access to vaccination
services, 2) increasing community demand for vaccines, and 3) provider- or system-based
interventions. Reducing out-of-pocket costs, and vaccine programs in schools and organized
childcare centers, are examples of recommended vaccine interventions under the first category
(CPSTF, 2016). Examples under the second category include client reminder and recall systems,
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and vaccination requirements for childcare, school, and college attendance (CPSTF, 2016).
Under the third category, recommended interventions include immunization information systems
and provider reminders (CPSTF, 2016).
It is important to note that school-based programs, school-entry requirements, and
vaccine mandates are different concepts. To differentiate between school-based programs and
school-entry requirements, the definitions provided by the CPSTF (2016) will be used and are
presented below.
School-based programs are defined as:
“Vaccination programs in schools or organized child care centers are multicomponent
interventions delivered on-site to improve immunization rates in children and
adolescents. These programs include two or more of the following components: 1)
Immunization education and promotion, 2) Assessment and tracking of vaccination
status, 3) Referral of under-immunized school or child care center attendees to
vaccination providers, 4) Provision of vaccinations. […] Vaccination programs are often
collaborations between the school or child care center and local health departments,
private healthcare providers, or community healthcare services.” (CPSTF, 2016)
“Potential barriers to implementation of vaccination programs in schools might include
difficulties coordinating between different programs, need for staff training, disruption of
school routines, and concerns regarding confidentiality” (Briss et al., 2000, p. 112).
School-entry requirements are defined as:
“Vaccination requirements are laws or policies requiring vaccinations or other
documentation of immunity as a condition of child care, school, and college attendance.
Their purpose is to reduce the incidence of vaccine-preventable disease and associated
morbidity and mortality by increasing vaccination rates. Laws are created by states, with
the specific vaccines required established by the legislature and embodied in statutes or
adopted as administrative rules by health or education departments. Institutions such as
colleges and private schools may establish additional vaccination policies for attendance
or residence. Vaccination requirements vary across jurisdictions by comprehensiveness,
acceptable documentation of immunity, access to exemptions (especially nonmedical
exemptions), and the type and consistency of enforcement.” (CPSTF, 2016)
“Potential barriers to implementation of vaccination requirements for child care, school,
and college attendance include administrative burden, difficulty coordinating various
programs, and difficulty passing legislation” (Briss et al., 2000, p. 104).
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The last concept, vaccine mandates can be defined as a broad term that refers to any law
requiring vaccination. These can include school-entry requirements, or laws requiring hospital
employees to be vaccinated (Cole & Swendiman, 2014). In a recent systematic review looking at
the economics of vaccine interventions from 1980 to 2012, it was reported that school-based
interventions are considered cost-effective. Population-wide laws had the most reach, but in the
case of school-entry laws, there was no adequate cost and cost-effectiveness data. Additionally,
the authors noted that, from an economic perspective, HPV vaccine strategies were among the
least studied (Jacob et al., 2016).
States’ police powers, vaccine mandates, and public health.
The 10th amendment of the US Constitution prescribes that the powers that are not part of
the federal government nor prohibited by the Constitution are reserved to the states, these are
known as the police powers (Cole & Swendiman, 2014; Gostin, 2008). Due to the police powers,
the states have the authority to enact laws for the protection of the health and general welfare of
their citizens (Cole & Swendiman, 2014; Gostin, 2008). Thus, each state in the US has its power
to decide vaccination policies. From a public health perspective, policy powers “include all laws
and regulations directly or indirectly intended to reduce morbidity and premature mortality in the
population” (Gostin, 2008, p. 135). Examples of these regulations include isolation, quarantine,
and vaccination laws (Gostin, 2008).
The theory of herd immunity has historically been used as a justification to enact vaccine
mandates in the US. This theory poses that a chain of infection is interrupted when large
numbers of individuals in the population are immune to the disease (Javitt et al., 2008). The US
Supreme Court established a legal precedent in the case of Jacobsen v. Massachusetts
(1905.197U.S.11) when it decided to uphold a smallpox vaccine mandate in favor of herd
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immunity over the principle of autonomy (Colgrove & Bayer, 2005; Field & Caplan, 2008).
With this decision, the US Supreme Court acknowledged the state of Massachusetts’ police
powers to create reasonable regulations for the protection of the public’s health (Cole &
Swendiman, 2014). Additionally, public health practitioners tend to favor vaccine mandates
based on a utilitarian perspective, where society’s well-being overrides individual autonomy
(Field & Caplan, 2008). A result of making vaccinations a requirement via vaccine mandates,
access increases for underserved populations; thus, justice is another principle considered by
Field & Caplan (2008) in the ethical framework. Furthermore, other perspectives also justify the
need to enact laws requiring vaccination. Brennan (2016) argues that mandatory vaccination
under a libertarian political framework is achievable because people advocating against vaccines
are imposing unfair harm on others.
School-entry requirements.
Vaccination mandates for school entrance are a highly effective strategy commonly used
in the US to increase adolescent uptake of vaccines (Averhoff et al., 2004; Field & Caplan, 2008;
Hinman et al., 2002). Additionally, vaccine mandates for school entry are recommended by the
CPSTF (2016) to increase vaccination uptake among children and adolescents. Moreover, these
types of mandates have been found to be effective in reducing racial/ethnic disparities in vaccine
uptake; such as in the case of requiring the hepatitis B vaccine for 5th grade in Illinois (Morita,
Ramirez, & Trick, 2008). Currently, all of the US states and Washington DC have some kind of
school-entry laws that require documentation of immunization (Cole & Swendiman, 2014).
However, most of these policies provide opt-out options or exemptions based on medical
reasons, religious objections or philosophical concerns (Bradford & Mandich, 2015; Field &
Caplan, 2008).
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According to Bugenske, Stokley, Kennedy, and Dorell (2012), while education-only
requirements do not increase meningococcal conjugate and HPV vaccine coverage; middleschool requirements are associated with higher coverage of vaccines such as tetanus/diphtheria
(Td) or tetanus/diphtheria/pertussis (TdaP). Thus, one way to increase HPV vaccination rates
would be to make the vaccine mandatory for school entrance. For instance, mandating the polio
vaccine has proven effective in the eradication of the virus in the US (Osazuwa-Peters, 2013).
However, in the case of the HPV vaccine policies, controversy has surrounded the matter due to
“the intersection of two highly charged policy areas: immunization safety and adolescent
sexuality” (Colgrove et al., 2010, p. 785).
HPV vaccine mandates.
As mentioned before, legislation related to the HPV vaccine vary. Some states have
created legislation in favor of educational campaigns, while others require health insurance to
cover the HPV vaccine, or require the HPV vaccine for middle-school entrance (Abiola et al.,
2013; Colgrove et al., 2010; Laugesen et al., 2014). Currently, only Virginia, Rhode Island, and
Washington, DC require the HPV vaccine for school-entry. As of September 2017, eight states
(Georgia, Hawaii, Illinois, Minnesota, New Mexico, New York, Texas, and Rhode Island) have
proposed different bills related to HPV vaccination for the 2017-2018 sessions. From those, only
two from New York proposed for the HPV vaccine to be required for all children born after
January 1, 1996/8 (National Conference of State Legislatures, 2017).
One of the first efforts to require the HPV vaccine occurred in 2007, when the Texas
Governor at the time, Rick Perry, issued an executive order to require the vaccine for sixth-grade
girls (Colgrove et al., 2010). A strong backlash followed when donations from Merck to his
campaign were made public (Mello et al., 2012). The order was overridden by the Legislature,
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which thought the governor was ‘overreaching’ his constitutional powers (Abiola et al., 2013;
Colgrove et al., 2010).
In the US, Virginia’s mandate was the first one to be enacted in 2007 and was put into
effect on 2009 (Pitts & Tufts, 2013). Virginia’s school entry law requires the first dose for
females entering sixth grade. However, it is up to parental/guardian discretion to elect not to get
the vaccine, since broad opt-out options are available (Virginia Department of Health, 2014).
Consequently, such policy has not improved HPV vaccine uptake rates in Virginia five years
after its enactment (Cuff et al., 2016). The Washington DC mandate that was initially passed in
2007 and implemented in 2009 applied only to girls. Later in 2014, it was amended to include
boys (Barraza et al., 2016). It currently requires the three-dose completion for all students
entering sixth to twelve grade and allows for all the types of opt-out options (i.e., medical
reasons, religious objections or philosophical concerns) (Government of the District of Columbia
Department of Health, 2015). Rhode Island’s school-entry HPV vaccine mandate (passed in July
2015 – through public regulation by Rhode Island Department of Health) only allows exceptions
based on medical or religious reasons and requires boys and girls to be vaccinated (State of
Rhode Island Department of Health, 2015; Washburn et al., 2016).
In June 2017, the PR’s Department of Health (DOH) announced the HPV vaccine was
going to be required for children 11-to-12 years old starting on the 2018-2019 academic year.
The Secretary of Health indicated in a press release that the HPV vaccine series should be
initiated at 11 years old along with the Tdap and the meningococcal vaccine. On June 2018, the
official announcement of the DOH was published indicating that the HPV vaccine was going to
be required for children 11-to-12 years old starting in fall 2018.
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Arguments in favor of and against the HPV vaccine school-entry requirement.
Support from different types of stakeholders and the public’s involvement is necessary
for policy creation and adoption (Walt et al., 2008). Thus, exploring and understanding
stakeholders’ reasons and identifying factors in support of or against the HPV vaccine schoolentry requirement is important for these policy processes to be successful. Based on a systematic
search of the literature (last updated on September 12, 2017), 25 studies were identified as
research involving any stakeholder reasons and factors in support or against the HPV vaccine
school-entry requirement (Tables 2 and 3). The purpose of the following sections is to present a
summary of the current state of the literature.
Overall studies’ characteristics.
Although 25 studies were identified, three pairs of studies used the same
dataset/participants (Table 2). Publication years ranged from 2007 to 2016. A total of eight
studies used qualitative methods, 13 studies used quantitative methods, two used mixed methods,
and two studies used an experimental design (Table 2).
Data collection years ranged from 2005 to January 2015 (two studies did not report this
information) (Table 2). Only four studies reported collecting their data after October 2011 when
the HPV vaccine was recommended for routine vaccination for boys by ACIP (Centers for
Disease Control Prevention, 2011). Nan and Madden (2014) did not report year for data
collection, but it was estimated to be during 2012). Furthermore, from these studies, just three
asked if the HPV vaccine school-requirement should be created for boys and girls (Califano,
Calo, Weinberger, Gilkey, & Brewer, 2016; Calo, Gilkey, Shah, Moss, & Brewer, 2016;
Vercruysse et al., 2016). Two studies (although using the same database/participants) were about
an existing mandate (the Virginia school-entry requirement) (Pitts & Tufts, 2013; St John, Pitts,
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& Tufts, 2010), and one study addressed perceptions of school-entry compared to school-based
programs among parents of girls and physicians (Vercruysse et al., 2016).
In terms of theoretical frameworks used; nine studies did not mention any theory, and six
studies used a theoretical approach to guide their study (Table 2). The theories used included
Theory of Planned Behavior, the Awareness-to-adherence Model and the Diffusion Model (Kahn
et al., 2009), the Cultural Cognition/Risk Theory (Kahan, Braman, Cohen, Gastil, & Slovic,
2010), Journalistic Framing (St John et al., 2010), Multiple Streams Theory (Abiola et al., 2013),
the Health Belief Model (HBM) (Perkins et al., 2013) , and the Cultural Theory of Risk with
Message Framing Theory (Nan & Madden, 2014). One study did not mention a theory, but it was
based on the same database/participants from the Abiola et al., 2013 study; thus, it was probably
guided by Multiple Streams Theory (Colgrove et al., 2010).
Finally, seven studies used theories for data collection purposes (e.g., items/scales), such
as the Health Belief Model (HBM) (Pierre-Joseph, Belizaire, et al., 2014; Pierre-Joseph, Clark, et
al., 2014), and Transtheoretical model (Vercruysse et al., 2016). For their data analysis, Tissot et
al. (2007) used framework analysis, Perkins, Pierre-Joseph, Marquez, Iloka, and Clark (2010)
used Grounded Theory and content analysis, and Pitts and Tufts (2013) used thematic analytic
procedures. Sanderson et al. (2009) integrated their findings to the HBM in the discussion
section.
Stakeholders/participants.
In terms of the stakeholders involved in these studies; about half of the studies (n = 12)
included parents/guardians. From those, seven studies were with parents of girls only, four were
with parents of boys and girls, and one study included parents of only boys (Table 2). Three
studies involved physicians; one included pediatricians (Tissot et al., 2007), another one was
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with primary care physicians (Kahn et al., 2009), and one study included both, pediatricians and
family physicians (Califano et al., 2016).
Three studies included multiple types of stakeholders. Abiola et al. (2013) and Colgrove
et al. (2010) (same dataset/participants) had mostly policymakers, but also included
representatives from the industry, medical professional organizations, and advocacy groups.
Vercruysse et al. (2016) recruited both parents of 11 to 17-year-old girls and health care
providers.
Finally, seven studies included other types of stakeholders such as, emergency
department patients (Millen, Ginde, Anderson, Fang, & Camargo, 2009), a national sample of
American adults (mean age 47, study did not indicate if the participants were parents) (Kahan et
al., 2010), minority men 18 to 22 years old (Pierre-Joseph, Belizaire, et al., 2014), minority
women 18 to 22 years old (Pierre-Joseph, Clark, et al., 2014), 18 to 22 years old college students
(Smith, Wilson, Pulczinski, & Ory, 2014), undergraduate students (18 to 29 years old) (Nan &
Madden, 2014), and 18 to 26 year old female college students (Wilson, Smith, Rosen, Pulczinski,
& Ory, 2016).
Reasons and Factors in Support of or Against an HPV vaccine school-entry
requirement among Parents/Guardians, Physicians, and Policymakers.
Parents/guardians. (see Table 3)
Reasons and factors in support of an HPV vaccine school-entry requirement. There are
some characteristics of the parents that make them more likely to support the HPV vaccine
school-entry requirement. These include if the mother - in this case, Latina - has been diagnosed
HPV+ (Sanderson et al., 2009), had a Pap test during the previous year (Yeganeh, Curtis, & Kuo,
2010), and parents having a low socioeconomic status and a history of HPV-related disease
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(Ferris, Horn, & Waller, 2010). Another factor associated with support is the reported ethnicity
of the parent. Ethnic minorities, including immigrants, compared to Caucasians (Perkins et al.,
2010), Latinos compared to another ethnicity (Yeganeh et al., 2010), and Hispanics responding
to a survey in Spanish compared to African Americans and Hispanics answering in English were
more likely to support the HPV vaccine school-entry requirement (Robitz et al., 2011).
When parents discussed reasons to support the HPV vaccine school-entry requirement,
characteristics specific to the HPV vaccine were mentioned. An overall positive attitude towards
the benefits of the vaccine (St John et al., 2010), its function in the prevention of cervical cancer
(Perkins et al., 2010) and STIs (Vercruysse et al., 2016) were some of the reasons mentioned.
Moreover, factors associated with support included thinking that the vaccine works well (Robitz
et al., 2011), the benefits of the vaccine (Carlos et al., 2011), vaccine safety (Yeganeh et al.,
2010), being interested in the vaccine (Ferris et al., 2010), knowledge about the reduction of the
risk and effectiveness of the vaccine against cervical cancer (Ferris et al., 2010; Smith et al.,
2011), and genital warts (Ferris et al., 2010). Furthermore, the perceived severity of the virus was
also a reason to support the HPV vaccine school-entry requirement among parents of adolescent
boys (Perkins et al., 2013).
There were also factors related to the child that parents associated with the support of an
HPV vaccine school-entry requirement. For instance, parents of children between the ages of 12
and 14 compared to parents of younger (9-11) and older children (15-17) were more likely to
support it (Ferris et al., 2010). Similarly, Smith et al. (2011) found parents were more likely to
agree if they thought there were more benefits of providing the vaccine at a younger age. Other
factors associated with supporting the requirement was if their daughters were already vaccinated
(Yeganeh et al., 2010) or if the parents intended to get the HPV vaccine for their daughters
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(Robitz et al., 2011; Smith et al., 2011). Some factors were about their children’s’ sexual
behavior. Parents thinking that their children are susceptible to contract the HPV (Ferris et al.,
2010) were more likely to support the requirement. Similarly, parents considering protecting
sexually active adolescents expressed their support (Perkins et al., 2010).
Another reason mentioned among parents that support the HPV vaccine school-entry
requirement was the idea that it is a public health intervention that would be beneficial for all
(Perkins et al., 2010; Perkins et al., 2013; Vercruysse et al., 2016). Moreover, one study found
that irrespective of parents supporting or not the mandate; they all thought it should be required
for both, boys and girls (Perkins et al., 2013). In the Smith et al. (2011) study, parents who
thought all children should get the vaccine were also more likely to support the requirement.
Lastly, there were factors related to the characteristics of the HPV vaccine school-entry
requirement. Back in 2008, parents thought the opt-out option of the Virginia HPV vaccine
school-entry requirement was a ‘ploy’ to get parents to agree to it (St John et al., 2010), and once
the vaccine is normalized the government would remove the option to opt -out. However,
subsequent studies have found that parental agreement increases when opt-out options are
provided in the requirement. For example, agreement to the HPV vaccine school-entry
requirement increased from 59% to 92% (Robitz et al., 2011), from 47% to 84%, and from 21%
to 57% (Calo et al., 2016) when opt-out options were included as part of the mandate. Moreover,
in a recent study by Calo et al., 2016, factors associated with supporting an HPV vaccine schoolentry requirement were evaluated by looking at the HPV vaccine school-entry requirement with
and without the opt-out option. Without the opt-out option, Hispanic parents compared to nonHispanic Whites were more likely to support the HPV vaccine school-entry requirement; as well
as parents who thought the HPV vaccine was as important as other vaccines and was effective at
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preventing cervical cancer. Similarly, parents who thought it would be difficult to find a clinic or
provider to get the vaccine were more likely to support the HPV vaccine school-entry
requirement without any opt-out option provided (Calo et al., 2016). When the opt-out option
was considered, parents who thought that the HPV vaccine is effective at preventing cervical
cancer, and is as or more important than other vaccines, were more likely to support the
requirement (Calo et al., 2016).
Reasons and factors against the HPV vaccine school-entry requirement. The
infringement on parental rights and autonomy was the most common reason cited and associated
with being against the HPV vaccine school-entry requirement (Ferris et al., 2010; Horn, Howard,
Waller, & Ferris, 2010; Pitts & Tufts, 2013). Moreover, they expressed it is the parents’ rights or
personal choice to decide to vaccinate their children, thus; a mandate would be a limitation to
parental autonomy (Perkins et al., 2013; Pitts & Tufts, 2013; Smith et al., 2011; St John et al.,
2010; Vercruysse et al., 2016).
There were characteristics of the parents or parental factors associated with not
supporting an HPV vaccine school-entry requirement presented in the literature. These factors
included ethnicity, such as African American (Robitz et al., 2011), and Caucasian (Perkins et al.,
2010), their beliefs that the vaccine will not work, and not having vaccinated or not having the
intention to vaccinate their daughters (Robitz et al., 2011). Lastly, parents residing in the
Midwest states compared to the Northeast states were less likely to support the HPV vaccine
school-entry requirement when on opt-out option was provided (Calo et al., 2016).
There were also reasons related to the HPV vaccine and the HPV. Parents who thought
that the vaccine was new and who had safety concerns about it and its side effects were more
likely to be against the HPV vaccine school-entry requirement (Carlos et al., 2011; Horn et al.,
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2010; Perkins et al., 2010; Robitz et al., 2011; Smith et al., 2011). The newness of the vaccine
was also mentioned as a reason not to support the HPV vaccine school-entry requirement, even
though the data for this study were collected during 2012 to 2013, almost a decade after the HPV
vaccine approval by the FDA (Vercruysse et al., 2016). Also, parents discussed that there is not
enough research on the vaccine and that its long-term efficacy it’s not known (Pitts & Tufts,
2013). The mode of HPV transmission was also discussed as a reason to be against the HPV
vaccine school-entry requirement among parents. Some noted the lack of casual transmission
(Perkins et al., 2013; Vercruysse et al., 2016), while others emphasized the sexual transmission
of the virus (Pitts & Tufts, 2013).
Related to sexual activity/behavior of their children, parents who thought that their
daughters would initiate sexual activity were less likely to support the HPV vaccine school-entry
requirement (Smith et al., 2011). Additionally, parents also discussed that adolescents were not
sexually active; thus, there was no need for the requirement (Vercruysse et al., 2016).
Additionally, mothers who thought their daughters were too young for vaccination were less
likely to support the HPV vaccine requirement for school entrance (Carlos et al., 2011).
Parents who thought that drug companies or ‘pharma’ were behind the push for the HPV
vaccine school-entry requirement were less likely to support it (Calo et al., 2016; Smith et al.,
2011). This was also a concern among parents when discussing their thoughts about the existing
mandate in Virginia (Pitts & Tufts, 2013). These parents also mentioned a lack of information
about the mandate and the safety and efficacy of the vaccine as concerns for them (Pitts & Tufts,
2013; St John et al., 2010), which were also commented among parents of boys (Perkins et al.,
2013).
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Physicians. (see Table 3)
Among physicians reasons mentioned in support of the HPV school-entry requirement
included the effectiveness of this strategy to increase immunization and its public health impact
(Kahn et al., 2007; Tissot et al., 2007; Vercruysse et al., 2016). Similar to parents, agreement to
an HPV school-entry requirement increased when opt-out provisions were provided (Califano et
al., 2016). In this study 74% of physicians supported an HPV vaccine school-entry requirement
with or without opt-out options; but when opt-out options were not specified only 47% agreed.
Moreover, being in practice longer than 20 years, providing a good quality HPV vaccine
recommendation (which was a self-reported measure the authors based on the following
characteristics: as being gender and age appropriate, consistent, urgent and with a strong
endorsement), and considering the HPV vaccine as important as Tdap and meningococcal
vaccines were physicians’ characteristics associated with support when no opt-out options were
included (Califano et al., 2016).
The most common reason mentioned against the HPV vaccine school-entry requirement
among physicians was the lack of HPV transmission through casual contact (Kahn et al., 2009;
Tissot et al., 2007; Vercruysse et al., 2016). Physicians also expressed concerns about the longterm efficacy and safety (Kahn et al., 2009; Tissot et al., 2007) and newness of the HPV vaccine
(Vercruysse et al., 2016). Other reasons such as limitations to parental autonomy (Kahn et al.,
2009), costs, and challenges of the implementation (Vercruysse et al., 2016), worries that some
patients not covered by Medicaid or VFC may not be able to get vaccine, society’s poor
understanding of HPV and the vaccine, and the limited clinicians’ experience with the HPV
vaccine (Kahn et al., 2009) were also discussed.
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Policymakers.
Colgrove, Abiola, and Mello (2010) found policymakers have indicated factors such as
newness of the vaccine, the sexually transmitted nature of the HPV, cost of the vaccine,
governmental coercion, and the policy process as reasons against the adoption of school
mandates. Policy entrepreneurship was reported as in important factor in support of this type of
vaccine mandates (Colgrove et al., 2010).
The case of Puerto Rico
Background.
For July 2016, the US Census Bureau estimated a population of 3,411,307 in the Commonwealth
of Puerto Rico. Moreover, 20.4% of the estimated population was under 18 years of age, and
52.4% of the population was estimated to be female (United States Census Bureau, n.d.). PR is
among the states/territories with the highest rates of estimated HPV-associated cancer (including
anal, cervical, oropharyngeal, and rectal cancers), with a rate of 13.10 cases per 100,000 people
who develop cancer (Centers for Disease and Control Prevention, 2016a). Furthermore, PR has
the highest rate of HPV-associated cervical cancer in the nation with rates of 11.70 cases per
100,000 women; followed by West Virginia with a rate of 9.9 per 100,000 women (Viens et al.,
2016). Overall initiation and completion rates in Puerto Rico were estimated to be 75.8% and
52.8% respectively. Among females, the initiation rate was 80.8% and among males was 71.1%.
Completion rates were 61.9% and 44.1%, for females and males respectively (Walker et al.,
2017).
Current immunization policy.
PR’s current immunization law is Act 25 of 1983, which repealed Act 235 from 1974.
Act 25 of 1983 was enacted to cover mandatory immunization for private and public schools at
all levels, day care centers and social treatment centers ("Ley de Inmunizacion," 1983). As part
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of the instructions of the law, students need to provide the completed DOH’s certificate of
immunization at the beginning of the academic year, to be accepted at school. It is the duty of the
school’s director and staff to ask for this certificate and notify the parents/caregivers if any of the
required vaccinations is missing and where to get them (“Ley de Inmunizacion,” 1983). The optout option mechanisms provided by this law include either a sworn declaration indicating
religious reasons or a certification indicating medical reasons. School administrators must also
prepare a report to the DOH indicating the number of students accepted, those accepted
provisionally, and those who submitted any type of exception (“Ley de Inmunizacion,” 1983).
The immunization record should be revised every 60 days until all immunizations have been
completed. Those who do not comply after the determined timeframe will be excluded from
school (“Ley de Inmunizacion,” 1983).
By the law guidelines, the Secretary of Health must announce the required vaccinations
every year three months before the beginning of classes (“Ley de Inmunizacion,” 1983). The
only vaccines listed in the law are the ones against polio, diphtheria, tetanus, measles, and
mumps (“Ley de Inmunizacion,” 1983). Additionally, under Act 25 of 1983, PR’s government
authorized the Secretary of Health to decide which vaccines will be required for school entrance.
Under this regulatory authority, the Secretary of Health officially announced in the summer of
2018 that the HPV vaccine was going to be required for children 11-to-12 years old starting in
the fall of 2018.
Summary
Persistent infections with Human Papillomavirus (HPV), the most common STI in the
US, can lead to genital warts and cancers such as cervical, vaginal, penile, anal, and
oropharyngeal. The HPV vaccine provides the opportunity to prevent cancer; yet, vaccination
rates in the US remain low. Vaccine mandates such as school-entry requirements are
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recommended evidence-based population strategies use to increase vaccination. In the case of the
HPV vaccine, only Virginia, Rhode Island, Washington DC, and more recently Puerto Rico,
have adopted an HPV vaccine for school entrance. PR adopted the HPV vaccine school-entry
requirement in the summer of 2018 providing a timely scenario to explore the limited use of this
type of policy. Thus, the purpose of this study is to understand the macro-level factors that
influenced the adoption of the HPV vaccine school-entry requirement in PR.
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Chapter 3: Theoretical Framework
Introduction
Theories are useful in research to explain and predict phenomena, such as human
behaviors. According to Glanz, Rimer, and Viswanath (2008), a theory is “a set of interrelated
concepts, definitions, and propositions that present a systematic view of events or situations by
specifying relations among variables, in order to explain and predict the events or situations”
(p.26). Theories can help investigators frame their research questions, the study design, the
process for data analysis, and the writing/reporting of their findings. Also, theories are useful in
the development and evaluation of public health interventions (Glanz et al., 2008). The purpose
of this study is to understand the macro level factors that influenced the adoption of the HPV
vaccine school-entry requirement in PR. Multiple Streams Approach/Framework (MSA)
considers macro-level factors, as well as the process by which a policy is adopted. In the
literature, Multiple Streams has been labeled as a theory, a framework and as an approach. The
following sections describe the theoretical framework used for this study.
Theoretical Framework: Multiple Streams Theory
Overview of the Theoretical Framework.
In 1984 John W. Kingdon published his seminal work Agendas, Alternatives, and Public
Policies in which he led the underpinnings for MSA (Kingdon, 1995; Zahariadis, 2007, 2014).
His primary goal was to understand “why some subjects become prominent on the policy
agenda, and others do not, and why some alternatives for choice are seriously considered while
other are neglected” (Kingdon, 1995, p. 3). Kingdon was curious about the agenda-setting
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process in the US, rather than about the implementation of policies. Therefore, MSA explains
how the coupling of the three streams – problems, politics, and policy – by the policy
entrepreneurs during policy windows increases the chance of policy adoption (Kingdon, 1995;
Zahariadis, 2007, 2014).
MSA considers choice as a collective output of the system in which policymaking occurs
under ambiguity (Zahariadis, 2014). More recently, Zahariadis has defined MSA as “a lens or
framework […] that explains how policies are made by the government under conditions of
ambiguity” (Zahariadis, 2014, p. 25). Additionally, he argues that manipulation is an important
aspect of the dynamics of the policy process since it is a way to deal with ambiguity (Zahariadis,
2003, 2014). Ambiguity is manipulated by the policy entrepreneurs to serve different aims in the
policy process (Zahariadis, 2014).
Zahariadis (2014) describes the following assumptions in which MSA is based. First;
“Individual attention or processing is serial, systematic attention or processing is parallel” (p.
28). MSA operates under the assumption that, in political systems, many issues can be seen at
the same time – parallel processing – and that MSA includes the broader social aspects and the
individual level, thus; goes from the macro to the micro level. Second; “Policymakers operate
under significant time constraints” (p. 29), which refers to the lack of time policymakers have to
attend the different problems and potential solutions. Third, “The streams flowing through the
system are independent” (p. 29), which describes how the three streams – problems, policy, and
politics – run separate and in parallel one to another. These assumptions of MSA are useful in the
understanding of how the system works, and for setting the context for the policy decision
making process.
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Key Structural Elements of MSA.
The problem stream, policy stream, politics stream, policy window, and the policy
entrepreneurs are the five key structural elements part of the MSA (Zahariadis, 2007, 2014). For
a diagram that shows the relationship of these key elements see Zahariadis, 2007.
The problem stream is composed of the concerns and conditions that people, such as
policymakers and citizens, believe need to be resolved. For example, increasing HPV vaccine
uptake and completion or reducing cervical cancer disparities. Policymakers become aware of
these concerns through the following factors: indicators or the data that describe the problem
(e.g., HPV vaccine uptake data from the National Immunization Survey-Teen), the focusing
events – which are events that call attention to the problems these are usually pointed out by the
media or the policy entrepreneurs (e.g., Merck “One Less” campaign), feedback from previous
experiences that worked or did not work, and the load or the amount of problems the
policymaker needs to attend to (Zahariadis, 2007, 2014).
The policy stream includes the “primeval soup” of ideas or all the options for solutions
coming from the experts. It is important to note that not all ideas will receive consideration by
the policymakers (Kingdon, 1995; Zahariadis, 2014). Thus, MSA posits that there are criteria
that guide and are part of the policymakers’ selection process (Zahariadis, 2007, 2014). These
criteria include; technical feasibility, value acceptability, and level of integration. If a solution
seems challenging to implement, does not align with the values of the policymaker, or seems too
costly, it has a lesser chance of approval (Zahariadis, 2007, 2014).
The politics stream refers to the broader political context and is composed of three
features: “the national mood, pressure-group campaigns, and the administrative or legislative
turnover” (Zahariadis, 2007, p. 73). The way groups of people think, the changes in members,

48

positions and political parties in power, and the influence some groups have over policymakers,
all impact the chance that an idea is set on the agenda (Zahariadis, 2007, 2014). Moreover, when
the national mood and changes in the government combine, these have powerful effects on the
agenda (Zahariadis, 2014).
The policy windows are particular moments in time when the three streams align,
intersect or couple. These moments tend to be short in duration, and MSA assumes that the
policy windows open one at a time (Zahariadis, 2007, 2014). As Kingdon (1995) defines it, a
policy window “is an opportunity for advocates of proposals to push their pet solutions, or to
push attention to their special problems” (p. 165). These windows are critical because they
provide context to the policy-making process. For example, this alignment (policy window)
occurred in 2009 when the state of Virginia was able to pass the first HPV vaccine school-entry
requirement in the US (Pitts & Tufts, 2013).
Finally, the policy entrepreneurs are the people or institutions who work on the coupling
or joining the three streams together when the policy window opens (Kingdon, 1995). This group
includes individuals and organizations, such as think tanks. They are, as Zahariadis (2007, 2014)
describes, the manipulators of the policymakers, and those with the strategies, time, and
resources to invest in their problem of interest.
MSA includes three processes in order for these elements to combine and produce a
choice. These processes are 1) attention, 2) search, and 3) selection (Zahariadis, 2014).
Attention, the first of these processes, tends to be limited or scarce among policymakers. MSA
posits that this is resolved by “institutional structure, the type of policy window that opens, and
the symbols used to attract attention” (p. 36). The search process of solutions in governments is
constant and influenced by the policy communities. Both public and private sectors can generate
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ideas, and depending on the integration of these communities, different approaches will be
conceived (Zahariadis, 2014). Lastly, the selection process is directed by the policy
entrepreneurs using their skills and manipulation tactics. These strategies include framing or how
the options are presented; affect priming or using emotions to drive social processes; salami
tactics (slicing solutions into distinct phases presented to the policymakers who perceive them in
this way as less risky); and the use of symbols which provide messages and evoke emotions
(Zahariadis, 2014).
Critiques.
Several critiques have been raised regarding MSA. One critique questions if the
conclusions of MSA are either empirical or assumption driven. To this, Zahariadis (2014)
explains, that although MSA is based on the garbage can model in which decisions are the result
of unplanned energy fluctuations, and in MSA the policy entrepreneurs couple the streams on
purpose. These fluctuations are based on, what MSA assumes is the ambiguity of the decisionmaking process by the policymakers. Zahariadis (2016) notes this “does not reject but rather
supplements rational choice” (p. 4)
Furthermore, a meta-review concluded that, even though MSA has been very prolific, has
been used in many studies to analyze public policy, and has also been used in a variety of
political contexts; most studies only use the five main or core elements but lack consistency in
using all the subcomponents of the theory (Jones et al., 2016). This presents a problem since all
the components were proposed to work together when the theory was developed (Jones et al.,
2016; Kingdon, 1995). Others point to MSA’s easy usability or low ‘barrier to entry’, due to its
flexibility and apparent lack of need for a thorough codebook or hypotheses testing; and call for
further empirical theoretical development (Cairney & Jones, 2016).
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Other research applications of MSA.
MSA has been used as an approach to evaluate different areas of health policy. This
approach has been commonly used in tobacco policy research. For instance, a systematic review
of qualitative studies looked at the application of frameworks used in tobacco policy studies and
found that most of the studies used MSA (Arabloo, Tourani, & Ravaghi, 2018). One study
included in the systematic review, used MSA to assess the enactment of a smoke-free law in
Kentucky despite strong opposition from the hospitality industry. Findings noted the importance
of collaborations between health care providers and a legal group with knowledge in tobacco
control (Greathouse, Hahn, Okoli, Warnick, & Riker, 2005). MSA also guided another study that
used interviews and archival documents to evaluate a non-smoker protection act brought to the
agenda by the Governor of Tennessee (Mamudu et al., 2014). The authors noted the convergence
of the streams occurred, but the contextual factors did not support the policy change; thus,
resulting in the use of a weaker bill (Mamudu et al., 2014).
Blackman (2005) utilized MSA to describe the literature regarding tobacco control policy
process in the state of California and highlights a couple of limitations of the theory. These
limitations relate to the power differential between the stakeholders (i.e., the tobacco industry
and public health advocates), and the lack of focus on implementation (Blackman, 2005). In a
case study included in the systemic review, MSA was used to understand the factors of tobacco
control in Turkey and included data from interviews, documents, and surveys (Hoe, Rodriguez,
Uzumcuoglu, & Hyder, 2016). Based on the findings, these researchers added the global stream
to include the influence that had global prioritization of the issue of tobacco control (Hoe et al.,
2016). Lastly, in a recent case study, MSA was also used to appraise the adoption of Bill C-32
banning flavored tobacco products in Canada (Lencucha, Ruckert, Labonte, & Drope, 2018).
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Other studies have used MSA to guide the analysis of interview data on health care
administration practices in Canada (Smith et al., 2015), to explore, via interviews with
policymakers and researchers, the agenda-setting process of HIV/AIDS control in Iran
(Khodayari-Zarnaq, Ravaghi, Mohammad Mosaddeghrad, Sedaghat, & Mohraz, 2016), and to
look at non-communicable diseases policy development in Barbados and identify policy
entrepreneurs (Unwin, Samuels, Hassell, Brownson, & Guell, 2016). Also, a recent study by
Kumar, Gleeson, and Barraclough (2018), used MSA to analyze interviews with consumer
advocates, and food industry and government employees on the development of nutrition
labeling standards in Australia.
Current related research.
Research using MSA includes a literature review of the issues of redefining HPV-related
anal neoplasia as a problem of all sexually active individuals and not only an issue of people
living with HIV (Walhart, 2013). In this review, policy solutions to increase anal cancer
screening are examined via a theoretical application of MSA (Walhart, 2013). The author uses
the elements of problem, policy and political streams, policy window, and policy options in her
application of MSA. There are also two publications using qualitative methods, one explored the
factors that influenced states’ action regarding the HPV vaccine mandates (Colgrove et al.,
2010), and another one explored the HPV vaccine policy formation process in the US (Abiola et
al., 2013). These studies used the same dataset consisting of 73 key informant interviews
collected from six states (i.e., California, Indiana, New Hampshire, New York, Texas, and
Virginia). These interviews were conducted following an interview guide based on the elements
of MSA. Abiola et al. (2013), provides a comprehensive description and discussion of MSA in
its application to understanding the political dimensions of HPV vaccine policy formation in
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those six states. The authors found the importance of effective policy entrepreneurs in the
influencing of the policy process. For Colgrove et al. (2010) it is important to note that there is
no mention of MSA in their publication, but the study is included here because the data used
were collected using MSA as the guiding framework.
Lastly, a recent study by Shapiro, Guichon, Prue, Perez, and Rosberger (2017) utilized
MSA to explore the reasons why some Canadian jurisdictions decided to fund the HPV vaccine
school-based program for boys by reviewing the literature. The authors conclude that MSA was
useful to identify factors that influenced the decision under each of the streams, particularly how
cost-effectiveness and stakeholder advocacy guided the policy-making process (Shapiro et al.,
2017).
Summary
This chapter presented the theoretical framework used for this study selected based on the
purpose of this study, which is to understand the macro-level factors that influenced the adoption
of the HPV vaccine school-entry requirement in PR. The key elements of Multiple Streams
Theory were discussed, as well as critiques, other research applications of MSA, and current
research related to the topic at hand.
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Chapter 4: Methods
Introduction
The methodology used to conduct this study is presented in this chapter. The purpose and
research questions guiding this study are provided to guide the reader. Also, an overall
description of the setting is presented to contextualize the study. An overview of the study design
is followed by the details of the methodology used for each Phase. The chapter ends with a
description of the strategies used to maximize data trustworthiness.
Purpose and Research Questions.
Guided by the Multiple Streams Theory, the purpose of this study is to understand the macro
level factors that influenced the adoption of the HPV vaccine school-entry requirement in PR
during the summer of 2018. This was achieved via the following research questions:
1. How did the problems, politics, and policy streams intersect to inform the HPV vaccine
school-entry requirement in Puerto Rico?
2. Who were the policy entrepreneurs involved in the adoption process and what were their
roles?
3. What were the arguments in favor of and against the HPV vaccine school-entry
requirement?
Research Setting: Puerto Rico
Puerto Rico is an island on the Caribbean with an estimated population of around
3,411,307 million residents (United States Census Bureau, n.d.). In 2015, the Puerto Rican
median house income was $18,626 with 58% of children living in poverty (Krogstad, Starr, &
Sandstrom, 2017), and the unemployment rate was estimated to be at 13% (Government
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Development Bank for Puerto Rico, 2016). In a 2014 Pew Research Center survey describing
religion in Latin America found that 56% of Puerto Ricans identified as Catholic, 33% as
Protestant, 8% as unaffiliated, and 2% as other. Spanish is the main language spoken on the
island.
A Spanish colony since 1493, PR became a US territory in 1898, after Spain lost the
Spanish-American war and conceded the island. In 1900, the Foraker Act established a civil
government, after two years of military rule (Trías Monge, 1997). The Jones Act awarded Puerto
Ricans US citizenship in 1917 (Trías Monge, 1997). The Commonwealth of PR was established
in 1952 when the US government approved the island’s constitution, and a three-branch
government (i.e., executive, legislative and judiciary) was created (Government Development
Bank for Puerto Rico, n.d.).
Every four years, local elections take place, and Puerto Ricans elect their Governor and
the members of the Legislative Assembly (Senate and House of Representatives). Puerto Ricans
living on the island have representation in the US Congress via a Resident Commissioner, but
cannot vote for members on the Congress or the President (Government Development Bank for
Puerto Rico, n.d.). The current Governor, elected in 2017, is from the PNP party (Partido Nuevo
Progresista). This political party advocates for statehood status for the island.
As a territory of the US, PR has a Medicaid Program that receives funds from the federal
government since January 1st, 1966 under the Social Security Act (Departamento de Salud, n.d.b). This program is managed directly by the PR’s DOH and provides healthcare services access
to the medically indigent population. The Administration of Health Insurances of Puerto Rico or
ASES (Administración de Seguros de Salud de Puerto Rico – in Spanish) plays the role of
administrating the PR’s government health plan or “Plan de Salud Vital del Gobierno” which is
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responsible for providing coverage for physical and mental health services through networks of
preferred providers (Administracion de Servicios de Salud [ASES], n.d.).
In terms of preventative health services, a division in the DOH administer the
immunization funds available from the VFC to vaccinate low-income population from 0 thru 18
years old (Departamento de Salud, n.d.-a). Also, the ‘Centros de Salud Primaria 330’ provide
immunization services to uninsured or underinsured groups. Funds for these primary care clinics
come from the Bureau of Primary Health Care part of HRSA (VOCES, 2015). In the private
sector, there are health insurance carriers available on the market. For immunization coverage,
there are available vaccination centers in private hospitals that accept private health insurances
with the corresponding copayments. Also, but less common, there are some providers, such as
pediatricians, who provide these services (VOCES, 2015).
Aftermath of hurricane Maria.
This section is described here to provide contextual information about the period during
which this study took place. On September 20th, 2017 Maria hit PR as a category four hurricane
with winds of 155 mph spreading all over the island and rain producing catastrophic flooding
(National Weather Service, 2017). Due to this atmospheric event, the island lost
power/electricity causing significant damages to the healthcare system, including the private and
the public sectors.
Overview of study design
This study employed an exploratory sequential mixed-methods research design (Clark &
Creswell, 2011). The study consisted of two phases (Figure 1). First, a qualitative phase
consisting of in-depth interviews, followed by a content analysis of newspaper articles. This
second phase of the study was conceptualized to address the need for information on the
arguments against the HPV vaccine school-entry requirement.
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Figure 1. Overview study design
Phase 1 consisted of in-depth interviews. Participants included stakeholders in the PR’s
HPV vaccine school-entry approval process. Purposive sampling was used to recruit stakeholders
identified from online sources, by consulting local experts, and utilizing snowball sampling.
Interviews were audio-recorded and transcribed. Data were analyzed using applied thematic
analysis (Guest, MacQueen, & Namey, 2012a). Phase 2 consisted of a content analysis guided
by Bernard and Ryan (2010) steps and Neuendorf (2016) recommendations, that looked at
articles published about the HPV vaccine school-entry requirement in two PR’s newspapers from
January 1st, 2015 to July 31st, 2018. Data were described quantitatively and qualitatively. More
details describing each of these phases are provided below. All study materials and procedures
were approved by the University of South Florida Institutional Review Board (Appendix A).
Phase 1: In-depth Interviews
Recruitment.
Participants were recruited using a non-random sampling strategy or purposive
recruitment which is appropriate for qualitative studies (Hennink, Hutter, & Bailey, 2011).
Purposive sampling techniques were used to recruit stakeholders identified from online sources
with publicly available contact information (e.g., PR’s Department of Health website), by
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consulting local experts, and utilizing the snowballing technique (Hennink et al., 2011). If
participants were identified through an online source, they were contacted via email using the
information available online. Email recruitment scripts provided information about the study.
Key informants shared study information with potential participants and provided them with the
researcher’s information (i.e., phone and email) if they were interested in further details about
the study.
Inclusion Criteria.
Inclusion criteria included being 21 years old and older and involved in the PR’s HPV
vaccine school-entry adoption process (in favor or against), such as staff from the department of
health, physicians and organizations that played a role in the policy process. Participants
categories included members from non-profit organizations, leaders from professional medical
organizations, government employees, professors, researchers, and physicians, among others
(See Phase 1: Interviews, Sample Description in the Results section). Exclusion criterion
included being younger than 21 years old.
Data collection.
All interested participants meeting the inclusion criteria were scheduled for an in-depth
interview. In-depth interviews were conducted either by phone or in-person depending on the
participant’s preference and were audio-recorded.
Sample size.
In qualitative research, there is no mathematical formula to determine the sample size.
Guest, Bunce, and Johnson (2006) call to “operationalize the concept as the point in data
collection and analysis when new information produces little or no change to the codebook” (p.
65). In other words, when the “information you collect begins to repeat itself” (Hennick et al.
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2011, p. 88). For in-depth interviews, Guest et al. (2006) have suggested that data saturation can
be achieved with 12 interviews. Thus, interviews were conducted until saturation was reached,
measured by following guidelines provided by Guest et al., 2006 and the when during the
snowballing process participants recommended stakeholders who had already been interviewed
or were scheduled for an interview. A total of 21 interviews were conducted. Twenty participants
described themselves as in favor of, and one was against the HPV vaccine school-entry
requirement. From the 21 interviews, eight were conducted in person, and 13 were conducted
over the phone. Interviews lasted an average of 45 minutes (ranging in minutes from 20:30 to
72:30) and were completed between May and August 2018.
Instrumentation.
The interview guide consisted of open-ended questions adapted from an instrument used
by Abiola et al. (2013). This guide was composed of open-ended questions to evoke
conversations with the participants (Hennink et al., 2011). The format followed Hennick et al.,
2011 recommendations. Thus, a funnel design with an introduction, opening, introductory,
transition, key, and closing questions was considered in the adaption of the interview guide. The
main topic areas of the interview guide included background information about the participant,
previous work (e.g., strategies or policies) related to the HPV vaccine, motivation, barriers and
facilitators for the adoption, and arguments in favor of and against the adoption of the HPV
vaccine school-entry requirement.
This interview guide was translated into Spanish by the researcher and shared with two
local experts for feedback. Additionally, the interview guide was pilot tested with two key
informants, and suggested changes were made. The suggested changes mainly consisted in the
variation of some words to reflect everyday language, and the flow/order of the questions. A
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journal was kept to collect notes and thoughts during and after the interview was conducted.
Probing was another technique used to gather information during discussions (Hennick et al.,
2011).
Data analysis.
Data were analyzed using applied thematic analysis (Guest et al., 2012a) and techniques
recommended by Hennink et al. (2011). The following analytic steps were followed and are
expanded below: the creation of a codebook, training of a second coder, assessment of intercoder
agreement, application of data reduction and summarization techniques, and the selection of
exemplary quotes. All the data were analyzed in Spanish.
First, the audio-recorded material for all interviews was transcribed. A codebook with a
priori codes, based on the interview guide was prepared. Additionally, the researcher was
cognizant of emerging themes that arose from the data; thus, inductive codes were included in
the codebook as suggested by Hennink et al. (2011). The codebook included the name and short
name of the code, a description of the code, and an example of a quote from the data as
recommended by Hennink et al. (2011). The notes taken during the interviews (noted in the
journal) helped during the codebook development process by providing the ID number of the
participant who provided a good quote or was eloquent in their narration when answering the
questions.
A second coder who is proficient (reading and speaking) in Spanish was trained using the
codebook. Before all the data were coded, the researcher and the second coder independently
coded one interview. Then they met to clarify issues about the codebook, and discuss the coding
of the interview to achieve agreement (Morrison-Beedy, Côté-Arsenault, & Feinstein, 2001).
After the meeting, the researcher made the agreed changes to the codebook and listed the set of
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coding rules that were also agreed with the second coder. The journal also helped to keep track
of the agreements and discussions that occurred during the training process.
All interview data were imported to MaxQDA (VERBI Software, 2017). After the
training process discussed above, the second coder and the primary investigator independently
and consecutively coded three interviews (n = 3). An inter-coder agreement score of Kappa equal
to 0.80 or more is a standard recommended to establish the reliability of the coded data (Guest,
MacQueen, & Namey, 2012b). Using MaxQDA a Kappa score was calculated using those three
interviews. After meeting and clarification of the coding, a final Kappa score of 0.89 was
achieved. The remainder of the interview data were coded by the researcher (n = 18). During the
process of coding, the researcher created memos that were later used for the creation of the data
summaries.
During the data reduction phase, qualitative matrixes were created by code. This step
enabled the researcher to use a cross-case comparison technique to identify patterns by
comparing a code across all interviews (Hennink et al., 2011). Additionally, categorization of the
data was done to create summaries. These summaries or themes were linked back to the
theoretical framework, by conceptualizing the data at an abstract level (Hennink et al., 2011).
Exemplary quotes were chosen by the researcher to represent the themes. In Chapter 5: Results,
the themes are presented following the key elements of MSA.
Protection of Human Subjects.
As part of the steps set in place to ensure the protection of human subjects, this study was
submitted to the University of South Florida Institutional Review Board (USF IRB) for review
and approval. All recruitment materials (i.e., emails) were prepared following the USF IRB
guidelines.
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All participants in Phase 1 were asked to sign an informed consent form (Appendix B)
approved by the USF IRB and were given adequate time to read and ask questions about the
study. A copy of the consent form was provided to each participant, which contained the contact
information for the USF IRB and the researcher. Participants who took part in the phone
interviews were asked to provide verbal consent. The researcher explained the purpose of the
study to all participants. Participants were informed that they could stop participation at their
discretion. Interviews were audio recorded after obtaining informed consent from the
participants. Participants received a $20 gift card in appreciation for their time. Participants who
preferred to complete the interview over the phone received the gift cards via email.
All data collected were stored on a password-protected computer. Data were only shared
with members of the research team (doctoral candidate, Committee Members, and second coder).
Data analyses were conducted with de-identified data. Lastly, exemplary quotes taken from the
participant's interview data were de-identified for the dissemination activities (i.e., posters,
dissertation, and oral presentations).
Phase 2: Content Analysis of PR’s newspaper articles
During Phase 1 of this study only one person who identified as been against the HPV
vaccine school-entry requirement was interviewed. Thus, this second phase of the study was
conceptualized to address the need to include more information on the arguments against the
HPV vaccine school-entry requirement. Overall, the methodology of this phase was guided by
the seven steps of content analysis as summarized and recommended by Bernard and Ryan
(2010, p. 289) and listed here:
“1. Formulate research question or a hypothesis, based on existing theory or prior
research.
2. Select a set of texts to test the question or hypothesis.
3. Create a set of codes (variables, themes) based on the research questions or hypothesis.
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4. Pretest the variables on a few of the selected texts. Fix any problems that turn up with
regards to the codes and the coding so that the coders become consistent with the coding.
5. Apply the codes to the rest of the texts. Keep checking for coder reliability.
6. Create a case-by-variable matrix from the texts and codes.
7. Analyze the matrix using whatever level of analysis is appropriate.” (Bernard and
Ryan, 2010, p. 289)
Additionally, guidelines from Neuendorf (2016) on the design of descriptive quantitative
content analysis as well as previously published content analysis guided the development of
Phase 2. Guidelines by Neuendorf (2016) used in this study included the addition of a second
coder, the recommendation for coder training, and the calculation of Kappa for the assessment of
inter-rater reliability. Previously published content analyses related to the HPV vaccine (Dodd,
Marlow, Forster, & Waller, 2016; Penţa & Băban, 2014; Quintero Johnson, Sionean, & Scott,
2011) and the HPV vaccine school-entry requirement newspapers’ coverage (Casciotti et al.,
2014), were used to guide the selection and development of potential variables to abstract.
Protocol.
A protocol delineating the steps for this phase was developed. This document was shared
with members of the committee for their feedback. The information included in the protocol that
guided the content analysis is described below.
Newspapers and unit of analysis.
Two of the most circulated Puerto Rican newspapers and their respective websites were
reviewed (El Nuevo Dia, n.d.; elVocero.com, 2013). These are El Nuevo Día and El Vocero.
Both newspapers are available online. Each article was considered the unit of analysis.
Key terms.
The words ‘VPH’ and ‘virus del papilloma humano’ (Spanish), (‘HPV’ and ‘Human
Papillomavirus’), were the key terms used to search the articles on each of the newspapers search
engine.
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Inclusion and Exclusion criteria.
Articles published from January 1st, 2015 to July 31st, 2018 were included. The year
2015 was chosen as the starting date because on May 2015 the VOCES HPV Panel Report was
published by VOCES (PR’s vaccine coalition). This report summarizes HPV and HPV-related
cancers epidemiological data, HPV vaccination uptake and completion rates, and population
sexual behaviors all in the context of PR. It also included the HPV vaccine school-entry
requirement as one of the strategies to help achieve the Healthy People 2020 goal (80% of males
and females with the recommended doses of the HPV vaccine). Additionally, the report was
mentioned by the stakeholders who participated in the interviews as an important document that
guided the process of adoption of the HPV vaccine school-entry requirement. The unrelated
advertisement was excluded from the content analysis. The process of selection is described in
Figure 2.
Instrumentation.
A set of variables was created based on the previous studies listed, and from the findings
of Phase 1. A data collection sheet (i.e., a codebook) was prepared and tested with a sample of
10% of the articles by two coders. This step allowed for latent themes, if any, to be captured, and
for revisions to the data collection sheet. The final version of the data collection sheet was
transformed into a case-by-variable matrix in Excel. Each article was listed in the first column by
their identification number. The other variables were listed in a column each.
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Figure 2. Article selection process for content analysis (based on PRISMA guidelines by Moher,
Liberati, Tetzlaff, & Altman, 2009)
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Data collection.
Scanning steps.
The researcher searched for the keywords on each of the newspapers’ online database
search engines. The titles of articles were reviewed to eliminate articles that were not relevant or
could be excluded based on the date. Repeated articles were also excluded. The remaining
articles were accessed in full and were reviewed using the inclusion and exclusion criteria
described above (Figure 2).
Data abstraction.
Data were abstracted from the articles and entered into the case-by-variable matrix. The
researcher and a second coder independently coded a random sample of 10% of the articles and
an inter-coder agreement was calculated. Kappa of ≥ 0.80 was used as a reference to establish
reliability (Bernard & Ryan, 2010). Coding of the rest of the articles was completed by the
researcher on the main variables that summarized the articles. As additional assurance of
reliability, intra-coder reliability or stability reliability (Neuendorf, 2016) was assessed when the
researcher reached the coding of the first 100 articles. A randomly selected sample of 10% of the
articles was coded a second time by the researcher and intra-coder Kappa was calculated. SPSS
version 24 was used to calculate Kappa scores.
Data analysis.
Data were summarized using descriptive statistics (i.e., frequencies and percentages) in
Excel and SPSS version 25. The articles were also analyzed qualitatively to identify the
arguments against the HPV vaccine school-entry requirement. This analysis was also conducted
following techniques of applied thematic analysis (Guest et al., 2012a), such as coding,
categorization, summarization, and the selection of exemplary quotes. These steps were
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conducted using Excel and a word document, due to the small simple size of the articles
analyzed qualitatively.
Trustworthiness
The concept of trustworthiness was introduced in the 1980s in order to address the
criteria needed to evaluate the quality of qualitative research (Morse, 2015; Ulin, Robinson, &
Tolley, 2005). These criteria or standards include credibility, transferability, dependability, and
confirmability (Guba, 1981; Lincoln & Guba, 1985), and are equivalent to what in quantitative
research is called internal validity, external validity, reliability, and objectivity (Guba, 1981;
Morse, 2015). Not without criticism, these criteria have been used with little change over time
(Morse, 2015). The following descriptions of trustworthiness apply to both phases of the study.
Credibility (i.e., validity), refers to “the confidence in the truth of the findings, including
an accurate understanding of the context” (Ulin et al., 2005, p. 25). To maximize credibility for
the findings of this study, the researcher engaged in prolonged engagement with the data, had
debriefing meetings with the co-major advisors, and triangulated the findings from the phases
when writing the Results and Discussion Chapters (more details in the Triangulation section), as
recommended by Guba (1981). Moreover, interviews were conducted until saturation was
reached, measured by following guidelines provided by Guest et al., 2006 and the moment
during the snowballing process when participants recommended stakeholders who
had already been interviewed or were scheduled for an interview. Additionally, the findings are
based on the narrative data, as exemplified by the included quotes, to show credibility (Ulin et
al., 2005).
Transferability (external validity, generalizability), refers to the ability to be able to apply
findings to other contexts, however, in qualitative research “data are conceptually, not
statistically, representative of people in a specific context” (Ulin et al., 2005, p. 27). To be able
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to achieve this, it was important to select a sample representative of the experiences crucial for
answering the research questions noted for the study (Ulin et al., 2005). As recommended by
Guba (1981), purposive sampling was utilized for both phases of this study. Additionally, the use
of a theoretical framework and an interview guide adapted from a previous study, help with the
transferability when comparing and contrasting the findings to other contexts.
Dependability (reliability), refers to “whether the results are dependable, whether the
research process is consistent and carried out with careful attention to the rules and conventions
of qualitative methodology” (Ulin et al., 2005, p. 26). For this study, a journal that includes all
the decisions made regarding data collection and analysis during the investigation was kept as a
way to address dependability by creating an audit trail (Guba, 1981). Having a second coder for
both of the phases to discuss coding also helped with this criterion (Morrison-Beedy et al., 2001).
Additionally, for Phase 1 inter-coder agreement, i.e., Kappa statistic, and for Phase 2 inter-coder
and intra-coder agreement were calculated and considered. These steps contributed to creating a
methodically sound study that can be replicated, even though its findings will be context specific
due to the nature of qualitative research (Ulin et al., 2005).
Confirmability (objectivity) means that the researcher makes an effort to separate her
personal values from those of the participants (Ulin et al., 2005, p. 26). For the current study, the
researcher kept a journal in which she wrote her thoughts, assumptions, and biases during the
data collection and analysis steps of both phases of the study (see Reflexivity section) (Guba,
1981). Additionally, during the data analysis process memos were written to track any thoughts
that might bias the interpretation and/or the findings, and were considered during the data
summarization (Guest et al., 2012a). The limitations of the study are also recognized as
suggested by Shenton (2004) (see Chapter 6: Discussion).
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Reflexivity.
As the researcher of this study, my perspectives may have influenced the data collection
and analysis processes (Hennink et al., 2011). Reflexivity requires the researcher to keep track of
his/her thoughts, biases and assumptions along the research process to be able to identify
situations in which those could influence the data collection and analysis (Ulin et al., 2005).
Thus, in my reflection described below, I tried to put forward my background, position, and
biases, as a way to acknowledge their potential effect during the overall research process of this
study.
I am from Puerto Rico. I was born and raised in San Juan, the capital of Puerto Rico.
Both of my parents are physicians. Although in mainland US, I am categorized as
“Latina/Hispanic,” in the sociocultural context of PR I am a white woman from a highly
educated family. Before entering the world of public health research, I studied law and became
an attorney. I worked in PR as an attorney in a non-profit corporation that provided legal aid for
underserved populations. This job exposed me to the detrimental effects of social inequality,
poverty, addiction, violence, and abuse daily. As a mother, witnessing other mothers lose
custody of their children was almost unbearable. I could not prevent myself from empathizing.
The difficult situations experienced by my clients under extremely aggravating circumstances
produced a profound feeling of sadness and a sense of powerlessness. I was able to momentarily
aid my clients, but I knew that once they got out of the door, they would again face the same
social circumstances that in the first place got them in trouble. This made me realize that social
problems require a change at the collective level, and not at the individual level. Larger societal
changes take place through policy change.
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During and after my MPH program, I had the opportunity of working with cancer
survivors. Interviewing cancer survivors and talking about personal experiences was saddening
and draining. Following that, I did research with various USF faculty on oropharyngeal cancer
prevention, Hispanic cancer survivors, and barriers to HPV vaccine uptake in Hispanic
populations. After identifying and understanding some of the barriers for cancer prevention at the
individual and societal levels, my interest continued to be on policy. I was interested in
documenting, analyzing, and understanding the process of adoption of the HPV vaccine schoolentry requirement. This was taking place in Puerto Rico and was perfect timing for my
dissertation research.
As a native Puerto Rican with well-developed interpersonal-professional skills, it was
easy to navigate the institutional culture in Puerto Rico. I have a good understanding of unwritten
rules, social expectations, and subtleties during social interactions that can only be learned by
living many years as a Puerto Rican in the island. This allowed me to gain access to informants
and promote openness during interviews, by being assertive.
This project involved studying a population of Puerto Ricans, not as the other, but as a
member of it; with the capacity to “zoom out” and observe as an outsider. This has provided me
with multiple angles and varied ranges of magnification for analysis. My perspectives have one
foot on the emic side and one foot on the etic side. On the emic side, I share some of the
experiences, views, and identities of the Puerto Rican participants. On the etic side, I bring the
outsider’s perspective of a researcher who has been academically trained in the mainland US.
Making sense of what lies behind the events that led to the process of adoption, requires an
understanding of the historical and cultural particularities of Puerto Rico. This is where being
Puerto Rican is an asset.
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Triangulation
By using different sources of data and methods, or triangulation, a better understanding
of phenomena can be achieved (Carter, Bryant-Lukosius, DiCenso, Blythe, & Neville, 2014;
Patton, 1999). In qualitative research, triangulation can also be used to “test validity through the
convergence of the information from different sources” (Carter et al., 2014, p. 545). Four types
of triangulation have been described: 1) method, 2) investigator, 3) theory, and 4) data source
triangulation (Denzin, 1978; Patton, 1999). This study used method and data source triangulation
to better understand the process of adoption of the HPV vaccine school-entry requirement. The
details of the data triangulation for this study are provided in Chapter 5: Results.
Summary
This chapter presented the design of the current study as well as the detailed information
about the methodology conducted for both phases. Phase 1 consisted of a qualitative study in PR
using in-depth interviews. Participants included stakeholders in the PR HPV vaccine schoolentry approval process (in favor/against). Purposive sampling was used to recruit stakeholders
identified from online sources, by consulting local experts, and utilizing snowball sampling.
Interviews were audio-recorded and transcribed. Data were analyzed using applied thematic
analysis. Phase 2 consisted of a content analysis of PR’s newspapers from 2015 to July 2018 to
further explore the arguments against the HPV vaccine school-entry requirement. Data were
summarized and described quantitatively and qualitatively. The findings from both phases are
presented in the next chapter.
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Chapter 5: Results
Introduction
The following chapter presents the findings from this study. For each phase, an overall
description of the sample is provided, followed by a summary of the results. For Phase 1 of the
study, findings are framed following the key elements of the theoretical framework. Phase 2
results are presented following the stages of the content analysis. A final section includes
triangulation of the results obtained from each phase.
Phase 1: Interviews
Sample Description.
A total of 21 stakeholders were interviewed. These participants spoke about their current
or past experience with the adoption process of the HPV vaccine school-entry requirement. In
the sample, there was only one person who expressed views against the HPV vaccine schoolentry requirement. For the purpose of an overall description participants were categorized into
five groups: 1) “Non-profit” included leaders and members of non-profit organizations or from a
public corporation (n = 5), 2) “Professional Organization” included leaders of professional
medical organizations (n = 3), 3) members of the “Government” (e.g., DOH employees and
policymakers) (n = 5), 4) “Researchers” included members of the academia such as professors
and researchers (n = 4), and 5) “Other” category (i.e., physicians, attorney, pharma
representative) (n = 3). Note that participants could fit under two of the previous categories based
on their different roles. For this sample description, participants were grouped under the category
they identified their role was during the interview. For example, two OBGYN physicians
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expressed their thoughts from their experiences as researchers, thus, were grouped under the
Researchers group.
Themes.
Based on the interview data, and presented guided by the MSA elements, the following
themes were found to be salient in the process of adoption of the HPV vaccine school-entry
requirement in PR. The stakeholders highlighted indicators such as the high incidence of HPV
and HPV-related cancers in PR (e.g., cervical/oropharyngeal) indicators of problems to be
resolved. Also, social factors such as the case of Rhaiza López Plumey, a young mother, who
died of cervical cancer in 2015, and the VOCES HPV Advisory Panel Report served as focusing
events during the process. Stakeholders discussed other policy initiatives, such as changes to the
current immunization law as concurrently being worked on.
Additionally, the political turn-over in key government positions influenced the adoption
process. During the summer of 2017, a policy window opened, and the HPV vaccine school-entry
requirement was adopted in the summer of 2018. All the work needed for the HPV vaccine
school-entry requirement to be adopted was conducted through collaborations among different
sectors composed of the policy entrepreneurs. Below is a summary of each of the themes
including exemplary quotes to illustrate the findings. Additional exemplary quotes are listed in
Table 4.
Problem Stream.
Stakeholders talked about problems or factors they perceived served as catalysts to the
process of adoption of the HPV vaccine school-entry requirement. These conditions can be
organized into two categories, either health-related (indicators) or social conditions (focusing
events).
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Indicators.
Among the health-related problems, one of the most frequently mentioned condition by
the participants was the high HPV-related cancers incidence and prevalence in the island’s
population. Particularly, stakeholders mentioned the current high rates of cervical cancer and the
increasing rates of oropharyngeal cancer. Another health-related problem that served to initiate
the process of adoption was the concern of how common HPV is in PR, as evidenced by studies
conducted in the island. For example, stakeholders from a medical professional organization and
from the government noted about HPV and cervical cancer;
“Bueno, yo creo que el hecho de que los
cánceres cervicales hayan estado
aumentando dramáticamente y se presentaron
de hecho en la conferencia de prensa que se
hizo las estadísticas del aumento en cáncer de
cervicales y de que no hemos podido bajar el
cáncer de boca y de las áreas asociadas, no
porque no estemos bajando la incidencia de
fumar sino porque nos está aumentando los
asociados a VPH.” –003

“Well, I think that the fact that cervical
cancers have been increasing dramatically,
and as a matter of fact the statistics of the
increase in cervical cancer were shown in the
press conference that was done, and that we
have not been able to decrease oral cancer
and related areas, not because we are not
decreasing smoking incidence, but because
we have an increase of HPV related
[cancers]”—3, Professional Organization

“Con VPH por la consecuencia tan terrible
que es el desarrollo de cáncer y por las tasas
elevadas de prevalencia de la infección, no
del cáncer sino de la infección, sobre todo en
las mujeres jóvenes de Puerto Rico, ciertos
grupos entienden que esto se debe hacer.”—
007

“With HPV, due to the terrible consequences
of developing cancer and the high incidence
of infection rates, not cancer but the infection,
especially in young women in Puerto Rico,
some groups understand that this needs to be
done.” –007, Government

Participants noted that PR already had a relatively high HPV vaccine uptake (first dose).
However, participants mentioned the need to increase HPV vaccine completion rates. This need
to increase HPV vaccination completion rates was another health-related problem that needed to
be solved. The following quotes from a researcher and a member of a medical professional
organization convey these notions;
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“El hecho de que muchos teníamos una
primera dosis bien alta en los 60 y pico
porciento, pero entonces no se ponían la
segunda ni la tercera.”—006

“The fact that we had a high percentage, 60
something, of first dose [of the vaccine], but
then they would not get the second or
third.”—006, Researcher

“Puerto Rico siempre ha tenido una buena
cobertura de la primera dosis, se habla de un
85%. Ahora, donde ha decaído es la segunda
y la tercera dosis que está por debajo del 50 y
ahora al hacerse requisito supongo que ese
porcentaje estimamos que suba también.”
—013

“Puerto Rico has always had good coverage
of the first dose; it is said to be 85%. Now,
where it has declined it is for the second and
third doses which fall under the 50, and now
with it becoming a requirement I suppose that
percentage...we estimate it will go up too.”—
013, Professional Organization

Focusing events.
Among the social conditions affecting the adoption of the HPV school entry requirement
policy, stakeholders mentioned two main factors 1) VOCES HPV Advisory Panel Report
(Report), and 2) the case of Rhaiza López Plumey, a young Puerto Rican mother, who died of
cervical cancer in 2015.
VOCES HPV Advisory Panel Report (Report): Participants highlighted the importance of
the Report made possible by VOCES and publicly available in 2015. VOCES took the initiative
to make this report by creating a panel of experts. This report documented the need for
increasing HPV vaccination on the island due to the high prevalence of HPV and HPV-related
cancers and provided recommendations for action. One of the main recommendations suggested
by the Report’s panel was to make the HPV vaccine a requirement for school entrance.
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The following quote illustrates how stakeholders described the Report;
“No es algo que se logró de hoy para
mañana, o que fue un capricho, sino esto fue
un plan de trabajo establecido que yo te
puedo compartir el documento, este es un
documento de casi 70 y pico de páginas. De
hecho, lo puedes encontrar en el Internet,
puedes poner "Informe del panel asesor", de
hecho, se llama "Informe y recomendaciones
del Panel Asesor de VPH al Departamento de
Salud.” –002

“It [HPV vaccine school-entry requirement]
is not something that was accomplished
overnight, or that it was a whim, instead this
was an established work plan for which I can
share with you the document, this is an almost
70-something page document. In fact, you can
find it on the Internet, you can enter “Informe
del panel asesor” [Advising Panel’s Report],
in fact, it is called “Informe y
recomendaciones del Panel Asesor de VPH al
Departamento de Salud” [HPV Advising
Panel’s report and recommendations for the
Department of Health].” –002, Non-profit

Among other recommendations, the Report noted the need for comprehensive HPVrelated education not only for the parents but also for providers, religious leaders, and the press.
The following quote from a stakeholder part of the government shows how education was an
important area for improvement;
“Una de las cosas que se ha identificó es que,
“One of the things that was identified was
en ese momento, tanto la comunidad, como
that, at that moment, the community, and even
hasta los mismos profesionales de la salud,
the healthcare professionals, had not received
no habían recibido suficiente educación sobre
adequate education regarding the vaccine,
la vacuna, indicaciones, sus efectos, el
indications, its effects, purpose, side effects,
propósito, efectos secundarios, que la gente, that the people, in particular, the community,
particularmente la comunidad, pero también but there was also a lack of knowledge in the
había desconocimiento en las profesionales
healthcare professionals.” –015, Government
de la salud.” – 015
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Here is a quote from a member of the ‘Other’ category that illustrates how the Report
promoted the HPV vaccine school-entry requirement as a recommendation from the expert
panel;
“Hubo un consenso, uniforme de todos los
participantes, de que en Puerto Rico se debía
promover el uso de la vacuna y que,
eventualmente, si queríamos bajar nuestras
tasas de incidencia del virus, debíamos
promocionar también que fuese uno de los
requisitos de admisión escolar […]”—005

“There was a unanimous consensus of all
participants, that in Puerto Rico the use of the
vaccine should be promoted and that,
eventually, if we wanted to lower our virus
incidence rates, we should also promote that
it be one of the requirements for school
admission […]” –005, Other

The case of Rhaiza López Plumey: Another social condition mentioned was the case of
Rhaiza López Plumey. Stakeholders described the case of Rhaiza as the story of a young Puerto
Rican mother of three boys who died of cervical cancer in 2015. Rhaiza took part in an interview
that narrated her cancer journey/story and made a call to all women to get screened for cervical
cancer. This interview was part of a video that was posted and shared on social media. From the
participants’ perspectives, Rhaiza’s story, and later her death, impacted the PR population and
seemed to have brought awareness to the issue of cervical cancer. The following quotes illustrate
Rhaiza’s case as a significant factor in the adoption;
“Una de las cosas que surtió un efecto, que “One of the things that had an effect, that was
fue como bien emotivo fue un video que
like very moving was a video prepared by
preparó Rhaiza Vélez Plumey, una joven
Rhaiza Vélez Plumey, a 32-year-old young
madre de 32 años que murió a consecuencia
mother that died as consequence of cervical
de un cáncer de cérvix, donde ella hacía un cancer, in which she made a plea to women to
llamado a las mujeres a hacerse los exámenes
get their routine tests of cervical cancer
de rutina, de prevención de cáncer de cérvix y
prevention and a plea to get vaccinated to
un llamado a vacunar a los jóvenes para
young people to avoid cervical cancer.” –
evitar el cáncer de cérvix.”— 015
015, Government

“A nosotros nos ayudó mucho también, por
último, la historia de Rhaíza. La historia de
Rhaíza para mí fue
un turning point total […]”—002

“Rhaíza’s story helped us a lot too. For me,
Rhaíza’s story was a complete
turning point [...]” –002, Non-profit
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Feedback.
Stakeholders described the work that was accomplished before the HPV vaccine schoolentry requirement could be adopted in 2018. These efforts to increase HPV vaccination rates date
back to the years when the vaccine was first recommended by ACIP. The PR’s DOH listed the
HPV vaccine as a recommend vaccination for girls and women, and then for boys and men
following the ACIP guidelines and approvals for each group. For example, this quote illustrates
DOH’s actions to stay on par with ACIP guidelines changes on age recommendations for girls;
“Aquella vez, para el año 2006, el ACIP
decía, "Vamos a vacunar a las niñas a los 11
años, ese es el mejor momento" te dan toda la
data científica y se estableció esa política
pública. después entendimos, un año más
tarde, entendimos que no había que limitarlo
solamente a los 11 años, sino que aquella que
no se hubiese vacunado a los 11 y ahora
tuviera 13 o 15 podía beneficiarse porque
calificaba para el programa, así que
emitíamos (DOH) la recomendación.” –007

“That time, for 2006, the ACIP was saying,
“We are going to vaccinate girls at age 11,
that is the best moment” they give you all the
scientific data and it was established as a
public policy. Afterwards we understood, a
year later, we understood that it should not be
only limited to 11-year-olds, but that for those
[talking about girls] that had not been
vaccinated at 11 and now had 13 or 15 could
benefit because [she/they] still qualified for
the program, hence we (DOH) issued the
recommendation.” –007, Government

Following the changes in the ACIP guidelines related to the inclusion of boys, the DOH
also recommended the HPV vaccine for boys. As illustrated by this quote, a pediatrician noted;
“Sí, la vacuna del VPH una vez salió se
integró como parte de las recomendaciones
del Departamento de Salud y se dieron
charlas […] luego salió que se aprobó para
los niños y cuando se aprobó hubo una
campaña para que se vacunara a los varones
también.” –001

“Yes, once the HPV vaccine came out it was
integrated as part of the Department of
Health’s recommendations and talks were
given [...] after, it came out that it was
approved for boys and when it was approved
there was a campaign for the vaccination of
boys too.” –001, Other

Having limited access to the HPV vaccine in terms of availability and cost was also
commonly mentioned as a barrier to the adoption. The HPV vaccine is expensive, and the
stakeholders considered that it needed to be covered by the health insurances. Therefore,
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previous work described also included the support of policies that made it mandatory for private
insurance companies to cover the HPV vaccine for girls (2010) and then for boys (2012). As
indicated by the stakeholders, Vaccines for Children and Salud Vital (insurance provided by the
PR’s government) cover the vaccines for the public sector. Thus, access to the public and the
private sectors was ensured. As noted by the following participants;
“Antes de eso, también apoyamos lo que fue
la primera legislación, que tenía que ver con
lograr que todos los planes médicos que hay
en Puerto Rico ofrecieran la vacuna de
manera gratuita, que la tuvieran en su
cubierta para las niñas primero, y después en
la política pública se incluyó varones.
Nosotros tuvimos la oportunidad de revisar
esos proyectos de ley, y apoyar que se
dieran.” – 014

“Before that [HPV vaccine school-entry
requirement], we also supported what was the
first legislation, that had to do with
accomplishing that all health insurance plans
in Puerto Rico offered the vaccine free of
charge, that they would have in their
coverage for girls first, and then in the public
policy boys were included. We had the
opportunity to revise those bills, and
supported they were achieved.” –014,
Researcher

“En Puerto Rico la legislatura de los años
“In Puerto Rico the legislature of the years
2009 y posteriormente en el 2014 se legisló
2009 and later in 2014 legislated that for all
para que todos los seguros-- O sea, además insurance [plans]-- that is, in addition to the-de las-- Del código de seguros que te
insurance code that I mentioned and the
mencioné y la ley federal, hay unas leyes
federal law, there are some HPV specific
locales específicas sobre el VPH sobre de que
local laws on how insurance companies
las aseguradoras deben cubrir el costo de la
should cover the cost of the vaccine.”—007,
vacuna.” – 007
Government

Also, stakeholders noted the importance of different strategies to increase education and
awareness about cervical cancer (2016) and the HPV vaccine. As it is illustrated in the following
quote, a member of a non-profit organization provided an example of a bill to increase HPVrelated cancer awareness;
“El otro proyecto de ley que se trabajó, … fue
crear un mes de awareness para los cánceres
asociados a VPH y crear un mes de
awareness para lo que es el mes del cáncer
cervical que es el por ciento mayor de
canceres asociados que estamos viendo, así

“The other proposed bill that was worked on,
was to create an HPV-related cancers
awareness month, and to create a cervical
cancer awareness month which is the highest
percentage of related cancers that we are
seeing, so a proposed bill was created in PR
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que se creó un proyecto de ley en Puerto Rico
that was approved [enacted] in 2016, in
que fue aprobado en el 2016 donde se declara which January is declared as cervical cancer
enero como el mes del cáncer cervical y todos month and all gynecological cancers related
los cáncer ginecológicos asociados a VPH y
to HPV and this by law and the TEAL month
eso está por ley y se creó lo que es el mes
was created which means, it is an acronym
TEAL que significa, es un acrónimo que dice
that says Take Early Action and Live, so we
Take Early Action and Live, así que
started this campaign that we have been
empezamos esta campaña, llevamos
doing for three years, in which men and
tres años haciéndola donde los hombres y
women wear a TEAL accessory and education
mujeres se ponen un accesorio TEAL y se
is given on which are the HPV-related
educa sobre cuáles son los cánceres
cancers.” –002, Non-profit
asociados a VPH.” – 002
Table 5 shows a timeline of the specific policies and strategies that were mentioned by
the participants and identified by the researcher.
Stakeholders noted these previous efforts that happened before the HPV vaccine schoolentry requirement, seemed to have helped increase HPV vaccine rates in PR. The following
quote illustrates this remark by a member of the government;
“En los últimos años, a pesar de que todavía
no era efectivo el que fuera mandatorio la
vacuna, sí la campaña promoviendo la
vacuna, educando a la gente y a todos los
profesionales lograron aumentar
significativamente el nivel de vacunación
contra VPH en PR.” – 015

“In recent years, despite that the vaccine
mandate was still not realized, yes the
campaign promoting the vaccine, educating
people and all professionals achieved
significant increases in the vaccination rates
against HPV in PR.” –015, Government

In fact, stakeholders indicated that the CDC awarded recognition to the PR’s DOH in the
summer of 2018 due to high adolescent overall and HPV specific vaccination rates. For example,
a member from a non-profit organization noted;
“Para que tengas una idea, Puerto Rico en el
2016 ganó el territorio de mayor a nivel de
vacunación de HPV en toda la nación. Lleva
dos años consecutivos ganando este premio a
nivel del Departamento de Salud, y realmente
“nosotros si tú miras dentro de esta nacional
del Gobierno Federal, pues la primera dosis
ya nosotros estamos al 80%, la segunda dosis

“So you can have an idea, Puerto Rico in
2016 won the territory in all of the nation
with the highest rates of HPV vaccination. It
has won this award consecutively for two
years at the Department of Health level, and
“we really if you look inside of that national
from the Federal Government, well we
already have the first dosage at 80%, for the
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estamos como un 60 y pico. Ahora, como
ellos se enfocan entre las edades de la
encuesta de 11 a 14 años, pues no hablamos
de la tercera dosis sino que se mantiene en
esa población, y los varones tienen un
incremento de un 13% a un 44%,
en dos años.” – 002

second one we are at a 60%-something. Now,
as they focus between the ages of the
poll/survey from 11 to 14 years, well we do
not really talk about the third shot in that
population, and the boys had an increment
from 13% to a 44%, in two years.” –002,
Non-profit

The DOH Secretary announced during the summer of 2017 that the HPV vaccine schoolentry requirement was going to start during the 2018 academic year. The purpose of this
announcement was to have an entire year for additional education and promotion of the HPV
vaccine, and for parents to begin the HPV vaccine series for their children. This notion is
illustrated by the following quote by a member of the government;
“En ese año el Departamento de Salud y
otros grupos han hecho campañas de
educación, de divulgación, se han hecho
actividades educativas para enfermeras, para
médicos, para personal escolar, inclusive
hasta para periodistas, comunicaciones en
periódicos y otros medios, para educar al
pueblo sobre este mandato.” –015

“During that year the DOH and other groups
have done educational campaigns, promotion,
educational activities for nurses, for
physicians, for school personnel, even for
journalists, and other media, to educate the
country about the requirement” –015,
Government

Policy Stream.
After the 2017 DOH’s announcement during the summer, other policies started to be
considered by policymakers. Some stakeholders mentioned the House of Representatives (HR)
Bill 537 and HR Resolution 537, HR Bill 1303, and HR Bill 1576 (Table 4).
Stakeholders described the purpose of the HR Bill 537 to investigate the safety and
efficacy of the HPV vaccine as a reaction by policymakers after anti-vaccination groups raised
concerns. Public hearings were conducted in early 2018, and HR Resolution 537 was published
in June 2018. The investigation concluded that the DOH’s determination to include the HPV
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vaccine to the school required vaccine schedule aligns with the medical community position, as
it is illustrated in the following quote;
“Un proyecto de ley [Proyecto 537] donde
supuestamente la cámara de representantes,
la Comisión de Salud de la Cámara de
Representantes investiga cuán segura es la
vacuna de HPV. […] Pero por lo menos se
vio. Se vio y se habló ahí, todo mundo tuvo
tiempo de exponer cuán segura era la vacuna,
fueron todos los expertos, etcétera.” –009

“A bill [referring to HR 537] where
supposedly the chamber of representatives,
the HR representatives’ Health committee,
researches how safe the HPV vaccine is. […]
But at least it was looked upon. It was looked
upon and talked about there; everybody had
time to state how safe the vaccine was, all the
experts were there [attended] etcetera.”
–009, Non-profit

Some stakeholders also talked about HR Bill 1303 as a project that was petitioned by
VOCES and supported by the DOH. This bill had the goal of changing the current immunization
law (Act 25 of 1983). The bill included making the use of the PR Immunization Registry (PRIR)
as mandatory and continue to require health insurance companies to pay for vaccinations.
The following quote by a member of a medical professional organization describes some
of the changes proposed to the current immunization law by Bill 1303;
“El cambio que se está haciendo ahora es
poniendo en ley, es que aquí nosotros
tenemos en Puerto Rico el Puerto Rico
Inmunization Registry [PRIR], se está
incluyendo ahí, como para que todo,
cualquier proveedor y cualquier escuela que
acepte niños, tenga necesidad y la obligación
de entrar toda la data al sistema. […]
Lo otro era obligar a las aseguradoras a
crear conciencia en cuanto a la prevención,
para que cubrieran sus vacunas y todas las
vacunas, que salen no solo en el esquema de
vacunación, si no las que están requisitos,
las paguen.” –013

“The change that has been done right now is
including in the law, is that here in Puerto
Rico we have the Puerto Rico Immunization
Registry [PRIR], it is being included there, so
that everything, any provider and school that
takes in children, have the necessity and
obligation to enter all the data into the system
[...] The other change was to make the health
insurers to raise awareness regarding
prevention, for them to cover the vaccines and
all the vaccines, that are not only on the
scheduled vaccines but the ones that a
requirements, to be covered [paid for].” –
013, Professional Organization
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During the summer of 2018, again as a reaction to the HPV vaccine school-entry
requirement announcement by the DOH Secretary, the anti-vaccination groups promoted the
presentation of Bill 1576. A few participants mentioned Bill 1576 which proposed an
amendment to Law 25 of 1983. The amendment consisted in the addition of the philosophical
vaccination exception that would allow parents to not vaccinate their children due to their
beliefs. The amendment proposed on Bill 1576 was described by a Researcher as follows;
“La 1576 [Proyecto] todavía no ha entrado a
floor no ha sido discutida, pero para mí el
elemento más importante que tiene esa ley, es
que se abre otra oportunidad para que el
padre puede decir que no quiere vacunar a su
hijo por conciencia, por conceptos
filosóficos.” –019

“The 1576 [Bill] has not yet been brought to
floor, it has not been discussed, but for me the
most important element that this law has, is
that it opens another opportunity for the
parent to say that he/she does not want to
vaccinate his/her child due to beliefs, due to
philosophical beliefs.”—019, Researcher

Technical feasibility.
The fact that the current PR immunization law authorizes the DOH Secretary, not the
Legislature, to decide the addition of the HPV vaccine to the list required vaccinations for school
entrance was also mentioned by the stakeholders as a facilitator. As the following participant
described;
“Por ejemplo, en los 50 estados de los
“For example, in the 50 states of the United
Estados Unidos quien decide si se pone una
States the ones that decide if a vaccine
vacuna mandatoria o no, son los legisladores becomes mandatory or not, are the legislators
y los senadores, en Puerto Rico no. En Puerto and senators, not in Puerto Rico. Law 25 in
Rico la Ley 25, que es la ley de Inmunización
Puerto Rico, which is the Immunization law
que si quieres también te la puedo compartir,
that if you want, I can share it with you too,
establece que quien tiene la responsabilidad
established the secretary of health is the one
de velar por la salud pública en términos de
that has the responsibility to look out for
enfermedades prevenibles es el secretario de
public health in terms of preventable
salud. La ley 25 le da esa potestad al
diseases. Law 25 gives that authority to the
secretario, obviamente, el secretario tiene que secretary. Obviously, the secretary has to do
hacerlo todo con evidencia, no es porque a él
everything with evidence, not because it is
le dio la gana, poner la vacuna, entiendes.
his/her caprice to include the vaccine, you
Así ha sido históricamente, y él tiene un
understand. That is historically the way it has
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equipo de expertos que es el que sienta con él
a hacerle las recomendaciones.” —002

been, and he has a team of experts that give
him the recommendations.” –002, Non-profit

Additionally, stakeholders considered that announcing the requirement during the
summer of 2017 eased the adoption process of the HPV vaccine school-entry requirement. The
stakeholders described that the DOH Secretary made this announcement a year early in order to
provide education and orientation for parents before making it officially mandatory for 2018.
The following quotes illustrate this decision;
“El año pasado para mayo del 2017 ya el
“Last year around May 2017, the secretary of
secretario de salud anunció que durante el
health had already announced that for the
año escolar 2018-2019 la vacuna del VPH
2018-2019 school year the HPV vaccine will
comenzaba como un requisito en ese grupo de
be a requirement for that group [between]
edad de 11 y 12 años. Eso es un paso muy
ages 11 and 12. That is a very wise step from
sabio de parte del departamento de salud que
the department of health that gave the
dio a la población un año completo para
population a whole year for them to educate
educarse en el tema, para buscar información
themselves, to seek information from their
con sus proveedores de salud, fuese médico,
health providers, be it medical,
farmacéutico, enfermeras, centro de
pharmaceutical, nurses, vaccination centers.
vacunación. Y tienes un año completo de esa
And you have a whole year of that
preparación y esa educación.” –005
preparation and that education.” –005, Other

“El secretario firmó el comunicado que él
hace todos los años promulgando la política
pública de salud dando un año para que
hubiese un proceso de educación, de
divulgación, esto lo firman el 17, para que
entonces en vez de ser efectivo en el 17, fuera
efectivo en el curso escolar que comienza en
agosto de 2018.” –015

“The secretary signed the announcement that
he does every year promoting the public
health policy giving a year so that there was
an education, dissemination process, this was
signed the 17, so that instead of being official
in the 17, it would be official during the
school year that starts in August 2018.” –015,
Government

Another aspect that participants mentioned made the HPV vaccine school-entry
requirement feasible, was that it targeted 11 and 12-year-old adolescents. This was an important
factor for the stakeholders due to two reasons 1) the economic savings of only having to provide
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two doses, and 2) the better immune response to the HPV vaccine at these ages. These two
reasons are illustrated in the following quotes;
“11, 12 años es la edad que se ha escogido
por el Departamento de Salud actualmente
para que sea el requisito preadmisión
escolar. Sabemos que el CDC extiende la
edad hasta los 26 años, pero mientras más
joven la persona, científicamente se ha
descubierto que más resistencia o mejor
apego a su sistema inmunológico va a
tener esa persona.”—005

“The current chosen age requirement for
school entry by the Department of Health is
11, 12 years of age. We know that the CDC
extends it until 26 years, but it has been
proven scientifically that the younger the
person is the higher the response or the better
the adherence to his/her immunological
system that person will have.”—005, Other

“En este caso lo que va a decir la orden
“In this case what the administrative order is
administrativa es el corte, se le llama el corte,
going to say is the cohort, it is called the
de 11 a 12, y cada año se va a ir añadiendo
cohort, from 11 to 12, and an additional
un grupo adicional. Pues nosotros vamos
group will be added each year. Well, we are
asegurando que esas niñas y esos niños
going to ensure that those girls and boys
reciban solamente dos dosis, lo que va a
receive just the two dosages, which will
representar una economía inmediata en dosis
represent an immediate economization in
de vacuna, porque si esperas a los 14,
vaccine doses, because if you wait till 14, then
entonces le tocan tres.”—002
[he/she] will need three.”—002, Non-profit

Value acceptability.
The HPV vaccine school-entry requirement also aligned with the stakeholders’ idea of
providing protection and overall public health wellness to the population of the island. From
their perspective the creation of this requirement would address HPV-related cancer health
disparities in the population. A researcher noted;
“Sigue siendo un problema de salud pública,
porque si tú miras históricamente tú miras la
data, el cáncer cervical y muchos de los
cánceres asociados al virus del VPH tienden
a ocurrir en las pacientes que son
socioeconómicamente nivel más bajo.”—017

“It is still a public health issue because if you
look historically if you look at the data,
cervical cancer and many of the HPV-related
cancers tend to occur on low socioeconomic
level patients.”—017, Researcher
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Moreover, stakeholders described the HPV-related cancer prevalence as a public health
issue that needed to be solved. For example, as illustrated with the quotes below;
“Así que dentro de los primeros 10 cánceres,
vamos a poner tanto en hombres como en
mujeres, cánceres asociados a VPH son las
primeras razones de muerte. Por ende, esto es
un asunto de salud pública que hay que
atender.” —002

“So in the first 10 cancers, including in men
as in women, HPV-related cancers are the
first [number one] causes of death. Hence,
this is a public health matter that needs to be
addressed.”—002, Non-profit

In addition to the public health implications of this requirement, some stakeholders
mentioned it was important for them to make sure the HPV vaccine continues to be covered by
the health insurances, and that its cost is reimbursed to medical providers. As conveyed by a
member of a professional organization;
“Importante es el asunto de Salud pública,
“The public health issue is important, that the
que la vacuna sea requisito, cómo se va a
vaccine becomes a requirement, how will it be
cubrir, y estamos bregando con ese asunto en covered, we are dealing with this issue in the
el proyecto de la cobertura y de ese tipo de
coverage project, and that type of things, and
cosas, y de la intención de las aseguradoras
the intention of the insurers to lower what
de bajar lo que pagan por la vacuna del VPH,
they pay for the HPV vaccine, because the
porque va a aumentar la cantidad de gente
people getting vaccinated will increase, which
vacunándose, lo cual es una barbaridad que
what Triple S and MCS did was an atrocity.
hicieron Triple S y MCS. Estamos
We are basically trying to resolve the
básicamente tratando de resolver el asunto
economic issue, but the public health issue is
económico, pero lo más importante es el
the most important, and then now we are
asunto de Salud Pública, y entonces ahora
dealing with the other [thing].” –003,
estamos bregando con lo otro”. –003
Professional Organization

Stakeholders also mentioned the economic savings in the long-term due to the prevention
of HPV-related cancers, as another important factor that was considered for the adoption of the
HPV vaccine school-entry requirement. For instance, a member of a non-profit organization
talked about the data showing the monetary savings;
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“Demostramos con un estudio que hizo el
Centro Comprensivo de Cáncer, de que si
Puerto Rico para el 2020 logra vacunar el
80% de las niñas y el 67% de los niños,
vamos a ahorrar casi $88 millones en
diagnósticos y tratamientos posteriores en
cáncer cervical. Así que se le presentó al
Departamento de Salud una data
contundente, una data basada en evidencia,
una data acumulativa, unas estadísticas.”—
002

“With a study done by the Comprehensive
Cancer Center we showed that if Puerto Rico
achieves to vaccinate 80% of the girls and
67% of the boys by 2020 we will have saved
almost $88 million in diagnosis and
subsequent cervical cancer treatments. So
compelling data were presented to the
Department of Health, a data based on
evidence, cumulative data, statistics.” –002,
Non-profit

Level of integration.
Stakeholders agreed that the adoption process of the HPV vaccine school-entry
requirement was successful because different sectors, such as the government, academia and
non-profit organizations, collaborated to create a consistent message and had a defined purpose.
This aspect is illustrated by the following quote;
“Nosotros teníamos un objetivo claro y ahora
mismo es reducir los cánceres asociados al
VPH a través de inmunización aumentando
un 80% la taza de inmunización en los
adolescentes para la vacuna de VPH, ese es
nuestro objetivo y nuestro norte, y todo lo que
trabajamos, lo trabajamos en esa dirección.
Si tú le preguntas a cualquiera que está
partnership te va decir que ese es su
objetivo.” —008

“We had a clear objective and right now that
is to reduce HPV related cancers through an
80% rate increase of immunization among
adolescents for the HPV vaccine, this is our
objective, our north, and everything we work
on, we work in that direction. If you ask
anyone who is partnership they will tell you
that this is their objective.”—008, Other

Politics Stream.
Pressure-group campaigns.
When the HPV vaccine school-entry requirement was announced by the Secretary of
Health on the summer of 2017, the anti-vaccination groups reacted and created resistance. From
the stakeholders’ perspective, the composition of these groups varied based on their views, but
all shared concerns towards the HPV vaccine and making it mandatory. These views included
87

worries related to the safety and side effects of the vaccine, not wanting to do something against
their will, religious concerns, and lifestyle choices. The following quotes present these
arguments;
“Ellos hablan de la seguridad mayormente, “They mainly spoke about safety problems [of
problemas de seguridad, los cuentos de que
the vaccine], stories that in Spain girls died,
tuvo de que si en España murieron yo no sé
others have neuromuscular problems, or are
qué cuántas niñas que han quedado, que han
paralyzed, etc., and the scientific evidence
tenido problemas neuromusculares, que han
does not support this, this is not what the
quedado paralítico, etcétera, y la evidencia
studies say [about the vaccine]”—009, Noncientífica no prueba eso, no es lo que nos dice
profit
los estudio que se han hecho.”—009
“El hecho de hacerlo obligatorio ha creado
que aquel que no quería vacunarse le estás
reforzando de que alguna razón, que le están
haciendo algo en contra de su voluntad y se
aferra más en no oír las explicaciones.”—001

“The fact of making it mandatory resulted in,
for those that did not want to get vaccinated,
you are reinforcing that for some reason, you
are doing something against his/her will and
they will not pay attention to the
explanation.” –001, Other

“Porque la iglesia aquí en Puerto Rico es
bastante poderosa, y en los estados que la
vacunación es mandatoria, esos son los
grupos que más se han opuesto, porque va un
poco de acuerdo a la filosofía de las iglesias,
que ellos lo que promueven es la abstinencia,
y nosotros lo que estamos promoviendo es
una vacunación.—002

“Because here in Puerto Rico the Church is
quite powerful, in the states where the
vaccination is mandatory these are the groups
that have opposed it the most, because they
promote abstinence in accordance to the
churches’ philosophy, and what we are
promoting is a vaccination.” –002, Non-profit

“Hay un sector bastante amplio de la
sociedad que considera que sus vidas deben
estar guiadas más por lo que dicte la
naturaleza y no por lo que dicte la ciencia,
como con medicamentos, como con químico,
como con producto procesados, como con
productos biológicos, como son las
vacunas.”—005

“There is a quite large sector of society that
considers that their lives should be guided
more by what nature dictates and not by what
science says, like with medicine, like with
chemicals, like with processed products, like
with biological products, what vaccines are.”
–005, Other
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Stakeholders attributed this resistance to the level of misinformation related to the HPV
vaccine and vaccinations in general. A stakeholder noted;
“La dificultad mayor obviamente siempre es
el movimiento antivacunas que reacciona, y
empieza a hacer política pública por ahí por
los pasillos y a hacer ruido en la prensa y en
la televisión, y a dar información errónea a
los padres en cuanto a los supuestos daños.”
–009

“Obviously, the main barrier is always the
anti-vaccine movement which reacts and
starts doing public policy around there by the
hallways and making noise in the press and in
television and provide parents with incorrect
information regarding the supposed harms.”
–009, Non-profit

Also, the misinformation included concerns from parents and religious groups regarding
the (incorrect) relationship of the HPV vaccine with sexual activity in children. For instance, a
pediatrician mentioned;
“Que no querían obligarles a poner, ellos
decían que eso le daba libertad a los niños
para tener relaciones sexuales ya que no van
a tener que pensar, por alguna enfermedad
venérea.” –001

“That they did not want to make them [antivaccination groups (religious)] get it, they
said that it would give kids the freedom to
have sexual relationships since they would
not have to think of some venereal
disease.”—001, Other

A few participants attributed this misinformation to the incorrect information available in
social media. As a researcher noted;
“Porque todo el mundo asume que todo lo
que escriben en el Internet es correcto.
Entonces es como, ¿cómo tú contrarrestas
esto?” –017

“Because everyone assumes that everything
that is available on the Internet is correct.
Then, how do you challenge that?” –017,
Researcher

Stakeholders also mentioned specific anti-vaccination groups representing some of these
views against the HPV vaccine and the requirement. These anti-vaccination groups included a
Catholic priest who was very vocal, an online religious group, a feminist organization, an autism
organization, and parents who said they did not want the vaccine to be mandated.
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Administrative or legislative turnover.
Stakeholders mentioned changes in government positions as a factor that impacted the
adoption process. The current Secretary of Health was named by the current Governor of PR,
and both started in their positions on 2017. For instance, stakeholders noted about the changes in
political parties and in the position of Secretary of Health;
“VOCES hace informe de un panel asesor
que llega a la conclusión de que si la vacuna
no es mandatoria no se hace, porque han
habido proyectos de ley para la vacunación
que se estancan cuando van a crear su
proyecto de ley, por los detractores, porque
viene una vista pública o viene un cambio de
política, un cambio de partido, etcétera. Bajo
la gobernación de Fortuño se firmaron las
leyes de que será cubierta en varones. Viene
luego el mandato de García Padilla, ahí se
presenta un proyecto de ley si
no me equivoco no se hace nada.
Luego cambia el partido y ahí se le presenta
el resultado del panel, el informe del comité
asesor que viene secundario al informe de
vacunación o al panel que hizo Obama, que
hace algo local y ahí se le presenta al
secretario cuando cambia al secretario de
salud. [Previous Secretary of Health] nunca
quiso firmar, no fue una de sus prioridades y
el secretario toma esto como una prioridad y
ahí es que lo firma.” –012

“VOCES creates a report with an expert
panel that concluded that if the vaccine is not
mandatory it [the vaccine] will not be done,
because there have been vaccination bills
previously proposed that get stalled when
they [introduce] the bill, due to detractors,
because there is a public hearing or there is
an upcoming political change, a party
change, etcetera. The laws that covered boys
were signed during Fortuño’s
[governor]administration. Then came Garcia
Padilla’s [governor] administration, in which
a bill is proposed but, if I am not mistaken,
nothing was done. Then the political party
changes and the panel’s results are
presented, the advisory committee’s report is
ancillary to Obama’s vaccination report, [the
VOCES expert panel] does something local
and that is when it is presented to the
secretary, when the secretary of health is
replaced. [The previous Secretary of Health]
never wanted to sign, it was not one of his/her
priorities and the [new] secretary makes this
a priority and then he signs it [HPV schoolentry requirement].” –012, Non-profit

Moreover, this assignment of key government positions facilitating the adoption of the
HPV vaccine school-entry requirement also included the changes in the person occupying the
position of Sub-secretary of Health. A member of a medical professional organization described
this factor noting that;
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“El hecho de que la Subsecretaria de Salud
“The fact that the current subsecretary of
sea ahora pediatra, ella fue subsecretaria
health is a pediatrician, she was subsecretary
cuando Luis Fortuño era gobernador, y
when Luis Fortuño was governor, and now
ahora es de nuevo Subsecretaria de Salud, no
she is health subsecretary again, it was not
se logró cuando Luis Fortuño era
achieved when Luis Fortuño was governor,
gobernador, pero ciertamente se ha
but admittedly it [the HPV vaccine schoolimpulsado grandemente. […] entonces eso
entry requierement] has been pushed very
ayudó que la doctora fuera subsecretaria, de
much [...] hence it helped that the
convencer al secretario de que era importante subsecretary was a physician, to convince the
que esta vacuna fuera requisito.” –003
secretary that it was important for the vaccine
to become a requirement.” –003,
Professional Organization

However, it was also noted that if the current Secretary of Health is changed, the HPV
vaccine does not need to be kept in the list of required vaccination for school entrance by a new
Secretary of Health. For instance, this was expressed by a member of a professional organization
by stating;
“El legislativo es más difícil, obviamente,
“The legislative [process] is the most
porque tienes todos estos grupos religiosos y
difficult, obviously, because you have all
naturistas en contra que cabildean fuerte,
these religious and naturist groups that are
entonces se hacía más lento. Se pudo hacer,
against that lobby strongly, and that made it
que no es tan permanente, no tiene tanta
[the process] slower. It was done, it’s not
sostenibilidad, pero por lo menos nos resolvía
permanent, it does not have a lot of
en el momento el problema y nos ayudaba un
sustainability, but at least it solved us the
poco con el awareness que el Departamento
problem, for now, and it helps a bit that the
de Salud lo adoptara. El problema es que si DOH adopted it with creating awareness. The
cambian el secretario de salud, el otro
problem is that if the secretary of health is
secretario de salud no tiene que honrar eso.
changed, the next secretary does not need to
Nosotros tenemos que convertir eso en un
do it. We have to make this into a bill, and
proyecto de ley, y eso es parte de lo que
that is part of what we have to do.” –004,
tenemos que hacer.” –004
Professional Organization
Policy Windows.
Stakeholders noted that in the summer of 2018 was the moment during which the HPV
vaccine was officially announced by the Secretary of Health to be a requirement for school
entrance, but a previous announcement was done in 2017. This timeframe is described below by
a stakeholder;
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“El año pasado [2017]se tomó la
determinación de hacerla obligatoria para
este año [2018], para dar un año de
orientación para los que no querían
vacunarse. […] al Secretario de Salud se le
presentó […] y el Secretario lo firmó
ahora [2018].” –001

“In the past year [2017] a determination was
made to make it [HPV vaccine] mandatory
for this year [2018], in order to give a year of
orientation to those that did not want to get
vaccinated. […] it was presented to the
Secretary of Health and the Secretary signed
it now [2018].” –001, Other

Stakeholders also noted the disposition and pro-vaccination views of the current
Secretary of Health. These also contributed to the adoption of the HPV vaccine school-entry
requirement during this moment in history. The Secretary of Health was receptive to the
information and committed to decreasing cervical cancer rates in PR. As a stakeholder noted
about the current Secretary of Health;
“Yo entiendo que nos dimos en un momento
histórico donde se ha hecho mucha campaña,
la reacción negativa no ha sido muy severa
como lo ha sido en los Estados Unidos, y nos
vimos con un secretario de salud que es muy
provacuna.”—009

“I think that we had a historical moment
where a lot of campaign was done, the
negative resistance was not as strong as it has
been in the United States, and we have a
secretary of health that is very pro-vaccines.”
–009, Non-profit

Policy entrepreneurs.
Stakeholders listed and described different organizations or sectors of the society that
contributed to the process of adoption of the HPV vaccine school-entry requirement. In general,
stakeholders commented about the composition of these sectors;
“esto es un ejército de organizaciones sin
“This is an army of nonprofit organizations,
fines de lucro, de entidades privadas, de
of private entities, individual people, of health
personas individuales, de científicos
scientists and of course without the
salubristas y por supuesto sin el apoyo del
government's support you cannot do it.
estado no puedes, sin el apoyo del gobierno
Because they are who create and define
no puedes. Porque ellos son los que crean, los public policy, one in the private sector, that is
que definen la política pública, uno en el
to say, nonprofit, or for profit, one can make
sector privado, ya sea sin fines de lucro o con suggestions, and one can have strategies for
fines de lucro, uno puede sugerir y uno puede
making recommendations, but one cannot
tener estrategias para poder hacer unas
create public policy, nor define it, that is up
92

recomendaciones, pero uno no puede crear la
política pública, ni definirla, eso le
corresponde al Gobernador junto a sus
secretarios y directores de agencias.”—005

to the governor alongside his secretaries and
agency directors.” –005, Other

Another stakeholder mentioned a variety of organizations such as;
“Sí, la Coalición para la Prevención del
Cáncer de Puerto Rico que tiene, obviamente
entre tantos sakeholders, está el
Departamento de Salud, está el Centro
Compresivo de Cáncer, está la Coalición de
Vacunación de Puerto Rico, etcétera.” –010

“Yes, the Coalition for Cancer Prevention of
Puerto Rico that has, obviously among many
stakeholders the Department of Health, the
Comprehensive Cancer Center, the
Vaccination Coalition of Puerto Rico,
etcetera.” –010, Government

These groups or organizations mentioned by the stakeholders can be categorized in the
following groups: the non-profit organizations, the academia, the medical professional
organizations, government staff, and the private sector. Each sector had an important and
distinctive role based on each of their expertise and/or area of interest. These sectors as well as
their roles are described below.
Non-profit organizations: VOCES, a pro-vaccinations coalition, is a non-profit
organization that was fundamental in the HPV vaccine school-entry requirement adoption
process. It is important to note the VOCES includes many medical professional organizations,
other cancer prevention coalitions, and members of the private sector. As a researcher noted;
“Lo que pasa es que VOCES reúne todos los
pediatras, la asociación de pediatras, la
obstetra ginecólogo. En realidad, VOCES lo
que hizo fue unir a las distintas instituciones,
que abogan por el departamento de salud,
educación. En un foro hay gente de
farmacéuticas, gente de farmacias,
farmacéuticas como tal de farmacias. No de
farmacéuticas, sino farmacéuticos.”—006

“What happens is that VOCES gathers all the
pediatricians, the pediatrician association,
the OB-GYN. What actually VOCES did was
to unite different institutions, that advocate,
the Department of Health, Education. In a
forum, there are people from pharmacies,
pharmaceuticals such as pharmacies. Not
from pharmaceuticals, but pharmacists.” –
006, Researcher
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VOCES served multiple functions within its role. This coalition created awareness and
provided education about the HPV and HPV-related cancers. They organized the experts that
created the Report and supported its publication.
“El grupo VOCES fue instrumental en
colaboración con ellos, que también diera la
última política pública del secretario de
Salud de lo de la vacuna mandatoria en las
escuelas. Y nosotros como científicos les
proveemos a ellos los datos para justificar
que hace falta ese tipo de política pública en
Puerto Rico, porque los virus asociados a
VPH son un problema en nuestra población.”
–014

“Collaborating with the VOCES group was
instrumental, that the secretary of health gave
the public policy making the vaccine
mandatory for school. And we as scientists
provided them with the data to justify that in
Puerto Rico there is a need for that type of
public policy because the HPV associated
viruses are a problem in our population.”—
014, Researcher

Additionally, they were active actors in undertaking advocacy, by promoting the HPV
vaccine and the HPV vaccine school-entry requirement. As illustrated by this quote;
“Yo tengo que reconocer que en términos de
liderato y de mayor exposición, ha sido
VOCES. Uno por las estrategias que ellos
han delineado y establecido y dos, por los
esfuerzos de Advocacy a nivel de política
pública y a nivel de legislación.” –019

“I have to recognize that in terms of
leadership and major exposition, it has been
VOCES. One because of the strategies they
have delineated and established and two,
because of their advocacy efforts on the
public policy and legislation levels.” –019,
Researcher

Other non-profit organizations mentioned by the stakeholders included the ACS, which
mainly supported education and vaccination, the Head and Neck coalition, and the PR Cancer
coalition.
Academia: Stakeholders listed members of the academia that included researchers from
the University of Puerto Rico (UPR), the UPR Medical School, and UPR Public Health School,
and the Comprehensive Cancer Center. Their role was to provide scientific information to the
overall community including the DOH and Legislature. Their role was important because they
provided evidence from studies conducted in PR. These studies provided relevant evidence about
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the issues affecting the Puerto Rican population, such as the data on the incidence and prevalence
of HPV and related diseases.
“Nosotros hicimos los primeros estudios
donde documentamos, por ejemplo, la
prevalencia del virus del papiloma humano
en mujeres residentes del área metropolitana
de San Juan, infecciones cérvix y en ano.” –
014

“We did the first studies in which we
documented, for example, the prevalence of
the human papillomavirus in women residing
in San Juan’s metropolitan area, cervix and
anal infections.” –014, Researcher

Medical professional organizations: Many medical professional organizations supported
HPV vaccine school-entry requirement adoption process by providing education and advocacy
using their respective expertise. These medical professional organizations included the PR’s
Pediatricians Society, the PR Pediatricians Academy, PR’s ACOG chapter, and PR’s Dentists
Society.
“Como te digo, los diferentes grupos que hoy
vienen nuestro programa de inmunización, la
academia, pero también con los pediatras,
pediatras como que son los pilares aquí para
hacer una recomendación clara y
contundente sobre la importancia de
inmunizar. Los pediatras tienen un rol bien
importante, y también con ellos se ha ido
trabajando a través de los años.” –008

“As I say, the different groups coming here
today, our immunization program, the
academy, but also the pediatricians,
pediatricians are like the pillars here to make
a clear and compelling recommendation on
the importance of immunization. The
pediatricians have a very important role, and
also we have worked with them throughout
the years.” –008, Other

“A favor de los requisitos de esta vacuna y de
todas las vacunas siempre vamos a encontrar
el sector de los profesionales de ciencia, de la
salud, de la medicina, educadores en salud, y
por supuesto guiados por el departamento de
salud local.” –005

“In support of this vaccine requirement, and
all the vaccines we will always the sector of
the science professionals, of health, medicine,
health educators, and of course always being
guided by the DOH.”—005,

Government: The government category consists of employees of the DOH, such as the
DOH vaccination program, that were mentioned as key actors of the adoption process. From the
stakeholder’s perspective, the DOH’s vaccination program position was always on par with the
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current scientific guidelines. The DOH had included the HPV vaccine as a recommended vaccine
for adolescents following the ACIP guidelines since the HPV vaccine was approved.
“Es como te dije los oficiales del
departamento de salud actuales de este
gobierno han sido sumamente clave para que
esto se dé, porque no todos
son provacuna” –009

“It is like I said the current Department of
Health officers [officials] of this
administration had been a key [factor] for
this to be [achieved] because not everyone is
pro-vaccine.” –009, Non-profit

“Sí, como te digo, ha habido el programa de
vacunación del departamento de salud,
definitivamente ha estado bien a la
vanguardia de esto […]”—018

“Yes, as I said, the vaccination program of
the DOH, they have been at the forefront of
this for sure […]” –018, Non-profit

Stakeholders also noted the key role of the current Sub-Secretary of Health. The SubSecretary of Health was described by the stakeholders as a strong supporter of the requirement
and the HPV vaccine. The following quote by a member of a medical professional organization
describes the role of the Sub-Secretary of Health as helping in the process;
“entonces eso ayudó que la doctora fuera
subsecretaria, de convencer al secretario de
que era importante que esta vacuna fuera
requisito.”—003

“hence it helped the sub-secretary was a
physician, of convincing the secretary that it
was important for the vaccine to become a
requirement.” –003, Professional
Organization

It is important to note that the Sub-Secretary of Health was also part of VOCES at some
point, as noted by this member of a non-profit organization;
“La subsecretaria de salud, [nombre] es
inclusive parte de la junta de directores de
VOCES de la coalición de vacunación, ella es
pediatra y también es una persona que está
muy envuelta y muy al tanto de esta
problemática.”—009

“The sub-secretary of health [name] actually
she is part of the board of directors of
VOCES the vaccine coalition, she is a
pediatrician y she is very involved and up-todate in this problem.” –009, Non-profit
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Private sector: The private sector included organizations such as hospitals, pharmacies,
physicians from private practice, a private group of gynecologists, and Merck which is the HPV
vaccine manufacturer. Overall, this sector collaborated by providing information, funding for
research, promotion related to the HPV vaccine, and support indicating their agreement to the
HPV vaccine school-entry requirement. For instance, stakeholders stated about the private sector
including Merck and physicians in the private practice;
“Obviamente Merk que son los que lo hacen,
ellos han dado mucha ayuda financiera para
campañas publicitarias, foros y ese tipo de
cosas, ellos han ayudado mucho
económicamente.”—009

“Obviously Merck who are the ones that
make it, they have provided a lot of financial
help for promotional campaigns, forums, and
that type of things, they have helped a lot
economically.” –009, Non-profit

“Muchos pediatras, profesionales de la salud
están a favor de este requisito, médicos,
ginecólogos. Muchos médicos están a favor
de este requisito.”—020

“A lot of pediatricians, health professionals
are in favor of the requirement, physicians,
gynecologists. A lot of physicians are in favor
of this requirement.” –020, Non-profit

Another active role undertaken by the stakeholders was to take part in public policy
advocacy. Members of nonprofit organizations such as VOCES, professional medical
associations, and the academia talked about their support for not only the HPV vaccine as a
public health prevention mechanism, but also for policy changes that were needed to increase
education and access to the HPV vaccine. The following quotes illustrate this advocacy role;
“El departamento [university] en pleno
hemos sido unos grandes advocates del uso
de la vacuna para prevención, desde el
primer día.” –017

“The department [university] in general,
since the first day we have been big advocates
of use of the vaccine for prevention.” –017,
Researcher

“Desde entonces ha habido una lucha y un
trabajo que se ha realizado, ya no solo por
vacunación en el departamento de salud sino
por diferentes sectores de la comunidad
médica y de la comunidad en general, las
sociedades que agrupan los pediatras, la

“Since then there has been a struggle and
work that has been undertaken, no longer just
by vaccination [program] in the department
of health but by different sectors of the
healthcare community and the community in
general, the societies that group
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Sociedad Americana del Cáncer, Centro
Compresivo del Cáncer de la Universidad de
Puerto Rico, por mencionarte algunos.” –
014

pediatricians, the American Cancer Society,
the University of Puerto Rico’s
Comprehensive Cancer Center, just to
mention some.” –014, Researcher

Lastly, stakeholders noted that with the pass of the years the narrative surrounding the
HPV vaccine changed. When the HPV vaccine came out the narrative used was related to a
vaccine-preventable STI. The current narrative is about the opportunity to prevent cancer,
specifically, cervical cancer. A participant noted;
“El tema de VPH es un tema que ha venido a
través de muchos años trabajándose con la
prensa, yo creo que en este año es que vamos
a ver más cobertura en los medios a raíz de
eso, porque el tema de VPH y de cáncer
cervical y de los canceres asociados al virus
se ha venido trabajando por mucho tiempo y
ha ido evolucionando. Al principio se veía
como una infección de transmisión sexual y
tenía unas connotaciones fuertes” –008

“The HPV topic has been a topic that has
been worked on with the press throughout
many years, I think that this year we will see
more media coverage because the topic of
HPV and cervical cancer and the virusrelated cancers has been worked on for a
long time and it has been evolving. At the
beginning, it was seen as a sexually
transmitted infection and had strong
connotations.”—008, Other

Aftermath of hurricane Maria
Participants were asked if they thought that the passing of hurricane Maria could affect
the implementation of the HPV vaccine school-entry requirement that was announced to start on
August 2018. All stakeholders agreed that hurricane Maria affected the vaccine availability and
the operation of the vaccination clinics and private medical offices. However, most stakeholders
did not anticipate any major barriers to HPV vaccine availability. They noted that, for the most
part, public clinics were going to be open and were going to have enough vaccinations, and that
private providers should be prepared.
“Los proveedores de vacunas, todavía no
están al 100% que estaban pero, estamos
cerca, estamos como a un 90%. O sea que en
cuanto a accesibilidad de vacunas no debe
ser el problema”. –010

“The vaccine providers are not 100% yet, but
we are close, we are about 90%. So, in terms
of vaccine accessibility, that should not be the
problem.”—010, Government
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“María trastocó pero, lo que es el programa
de vacunación y el sistema de vacunación, ha
vuelto a la normalidad en un gran porciento,
no 100% pero un gran porciento”. –015

“Maria affected but, the vaccination program
and the vaccination system, has returned to
normal by a large percentage, not 100%, but
a large percentage.”—015, Government

A few stakeholders seemed unsure about the current situation of the
healthcare/vaccination system but sounded optimistic about the implementation process. For
example, a Researcher said;
“yo pensaría que ya a estas alturas esto se ha
restablecido. Pero sinceramente cómo esa
infraestructura se afectó y cómo está
corriendo en estos momentos, tampoco tengo
esa información, discúlpame”. –014

“I would think that by now this has been
restored. But sincerely how that
infrastructure was affected and how is it
running right now, I do not have that
information either, excuse me.”—014,
Researcher

Phase 2: Content analysis of newspaper articles
Reliability
An inter-coder Kappa score of 0.80 was achieved with the second coder after
independently coding a random sample of 10 % of the articles. An intra-coder Kappa score of
0.95 was achieved after the researcher coded a randomly selected sample of 10% of the articles a
second time.
Overall sample description.
After removing the repeated news articles, there was a total of 286 news articles that
included the key terms (Figure 2). As stated in the methods, these key terms included “HPV” and
“HPV vaccine” (in Spanish). Most articles were published in 2016 (Table 6). Figure 3 shows the
average number of articles per month because data for 2018 only covers the first seven months
of the year.
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Figure 3. Average number of articles per month
For this study, primary focus means the main message the article was providing. Each
article could have more than one message, but the main one was captured during data
abstraction. To make this decision the researcher was guided by the title and the first paragraph
of the article. A list of the overall sample of articles, based on their primary focus, can be found
in Table 7. The most common primary focus category included educational articles with
information about the HPV and the HPV vaccine (23.8%), followed by the advertainment
category (16.8%). This category included adds promoting the HPV vaccine (e.g., by VOCES and
others by Merck), announcement of health fairs providing the HPV vaccine, and adds about
professional and health conferences. The third most common focus was articles providing
general information about vaccines (11.2%), such as types available, their benefits and
appropriate ages for inoculation. Articles focusing mainly on providing information about
cervical cancer and the importance of cervical cancer screening compromised about 11% of the
sample. The HPV vaccine school-entry requirement was the primary focus of discussion in a
total of 19 articles (6.6%). Other areas of focus included general health information (5.9%),
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cancer information or information on other types of HPV-related cancers such as oropharyngeal,
penile and anal (4.2%).
The distribution of the categories of primary focus was also evaluated by the year of
publication. Most of the articles about HPV and the HPV vaccine, advertisement, cervical cancer
and cervical cancer screening, as well as those providing information about cancer in general
were published in 2016. Most of the news articles with the HPV vaccine school-entry
requirement as their primary focus were published in 2017 (Table 8). Figure 4 shows the average
number of articles per month of each of the top eight focus categories by year because data for
2018 only covers the first seven months of the year.
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Figure 4. Average number of articles per month by the top eight primary focus categories
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Further investigation of the news articles that mentioned the HPV vaccine school-entry
requirement in PR.
To further investigate the sample, all the articles that mentioned the HPV vaccine school
entry requirement were evaluated. Of the 286 news articles, 34 articles (12.2%) mentioned the
HPV vaccine school-entry requirement. Note that ‘mentioned’ is broader than the primary focus
category. The highest number of publications that mentioned the HPV vaccine school-entry
requirement in PR occurred in 2017, and during the first seven months of 2018. The distribution
of those articles by year and newspaper source is presented in Table 9. Furthermore, when
explored by the month of publication, most of the news articles that mentioned the HPV vaccine
school-entry requirement were published during June (n = 13) and July (n = 8).
From the 34 articles, 20 (58.8%) presented arguments in favor of the HPV vaccine
school-entry requirement, five articles (14.7%) presented arguments against, and five articles
(14.7%) showed both sides of the arguments. Four (11.8%) of the articles only mentioned the
HPV vaccine school-entry requirement (n = 2) or were the DOH’s HPV vaccine school-entry
requirement announcement (n = 2). These four articles were grouped in an ‘other’ category.
Table 9 shows the distribution of these categories based on the argument presented in the article
by year of publication. Three out of the five articles citing arguments against the HPV vaccine
school-entry requirement were published in 2017. A similar pattern was observed in the articles
about been in favor of the requirement, where most of the articles were published in 2017
(Figure 5). Lastly, an area to note is that no articles with the HPV vaccine school-entry
requirement as the primary focus or mentioning it were published during 2016. This finding
should be considered within the limitations of the content analysis phase that are discussed in the
next chapter.
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Arguments against the HPV vaccine school-entry requirement articles.
During Phase 1 of this study, only one person who identified as been against the HPV
vaccine school-entry requirement was interviewed. Thus, in this section, a further analysis of the
articles that presented arguments against the requirement is presented.
The people who were cited providing arguments against the HPV vaccine school-entry
requirement in the articles reviewed included: a concerned mother, a couple of pediatricians, a
policymaker member of the legislature, members of a feminist non-profit organization, a
university professor, a member of an autism organization, and a representative of a religious
group.
The arguments listed in the articles included concerns related to the side effects of the
HPV vaccine (40%), the sexual nature of the transmission of the virus (40%), and that it should
be the parents’ right to choose to vaccinate their children (40%). Other areas such as the HPV
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clears by itself (20%) and that the is no consensus regarding the HPV vaccine (20%), were
mentioned less frequently. Below are some quotes that represent these types of arguments.
For instance, a member from an autism organization mentioned the sexual nature of the
transmission of the virus as one of the concerns;
“¿Qué necesidad tiene un niño o niña en
“What is the reason for a boy or a girl in
edad escolar que no se ha iniciado
school-age that has not initiated sexual
sexualmente de ser protegido contra una
activity, to be protected against a disease that
enfermedad que se adquiere por contacto
is acquired by sexual contact? […]” “This is
sexual? […] “Esta no es una enfermedad que not a disease that a boy sneezing will transmit
el nene va a estornudar y se le va a pegar a
it to the other one”, indicated [name], who
otro”, indicó [nombre], quien dijo que otra
said that another concern are the deaths, that
preocupación son las muertes que, en algunos in some countries, have been attributed to this
países, se le han atribuido a esta vacuna.
vaccine. Among these, she mentioned Japan.”
Entre estos, mencionó a Japón.” –246
– 246, endi.com, 2018

In an article published in 2017, a member of a feminist non-profit organization noted that
parents should decide, after reviewing the information, if they want to vaccinate their children.
“Las vacunas contra el VPH son una
herramienta de prevención del cáncer
cervical. Sin embargo, la vacuna no debe ser
obligatoria" "Cada familia, luego de haber
sido debidamente informada sobre ventajas y
riesgos de la vacuna, debe decidir libremente
cuáles de estas estrategias desean asumir
para su salud y la de su familia" –243

“The vaccines against HPV are a tool for
cervical cancer prevention. However, the
vaccine should not be mandated.” “each
family, after being rightly informed about the
advantages and risks of the vaccine, should
freely decide which of the strategies they
would like to use to protect their health and
their family’s health” –243, endi.com, 2017

In 2018 a policymaker was cited in one news article saying;
“(si se aprueba la medida [Proyecto
1303]), no aplicaría (el requisito escolar de
la vacuna contra el VPH) para entrar en
vigor en agosto”, dijo [name of
policymaker]” –203

“(if the Bill is passed [Bill 1303]), it would
not be required (the HPV vaccine schoolentry requirement) to start on August”, said
[name of policymaker]”—203, El Nuevo Dia,
2018
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The feminist group was emphatic that sex education and access to screening services
should be provided by the Government, a factor that was also a concern for the interviewee
against the HPV vaccine school-entry requirement. For example, in the article, the member of
the feminist group was cited as discussing that;

“[…] es responsabilidad del Estado
garantizar acceso a información completa y
objetiva sobre los beneficios, riesgos, y
limitaciones de cada una de las alternativas
de prevención disponibles.” –243

“[…] it is the Government responsibility to
guarantee access to complete and objective
information about the benefits, risks, and
limitations of every preventive option
available.” –243, endi.com, 2017

Some of these reasons or concerns were also mentioned by the participant who selfidentified as being against the HPV vaccine school-entry requirement. For instance, this quote
describes the concern related to the lack of education regarding the HPV vaccine, despite it been
mandated.
“Primero porque no viene acompañado de
una adecuada educación realmente, la
vacuna está siendo mandatoria, el pediatra lo
está también fomentando, pero voy a ponerlo
a nivel de escuela, en escuela te obligan
hacerlo.”

“First of all, it does not come with adequate
education, really, the vaccine is being
required, the pediatrician is also encouraging
it, it's going to be at the school level, at the
school you are required to do.”

This participant also noted during the interview that this lack of education would later
have effects on the girl’s future sexual decision making. This is illustrated in the following quote;
“La niña es la que tiene que decidir que
quiere, porque es la vida de ella y va a ser el
futuro de su vida sexual, pero como no
educan, cómo van a tomar una decisión
responsable si no los educo, no pueden,
nunca la tomaran, nunca.”

“The girl is the one who should decide what
she wants, because it is her life, and it’s going
to be the future of her sexual life, but since
there is no education, how are they going to
make a responsible decision if I don’t educate
them, they can’t, they will never make it,
never.”
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Lastly, an argument that was present in the news articles and was echoed by the
participant who identified as being against the HPV vaccine school-entry requirement, was the
belief that the HPV vaccine was a sort of business or marketing strategy to make money based
on fear. In a news article published in 2018 a university professor noted;
“Esto se ha convertido en algo que no es, y se
vende la vacuna bajo el factor del miedo,”
señaló.” –246

“This has become something that it’s not, and
the vaccine it's being sold under the fear
factor”, indicated.” –246, endi.com, 2018

The participant against the HPV vaccine school-entry requirement said during the
interview;
“Dinero, millones que cuando dicen dar,
desde apoyar campañas políticas, desde
favores políticos, pero sobre todo y más que
todo, dinero que igual pueden estar
distribuyendo a nivel de gobierno y estoy
hablando a nivel ya de Estados Unidos,
porque acuérdate que por nuestra situación
política, lo que pasa allá repercute acá y
algún acuerdo que se haya dado que a partir
de ahí se hace mandatorio y quizás es la
colaboración que existen entre todas las
agencias porque es mandato como quien dice
presidencial o gubernamental,
independientemente de.”

“Money, millions they say will give, from
support to political campaigns, from political
favors, but above all and beyond all, money
that they may be distributed to the
government, and I am speaking at the United
States level, because remember our political
situation, what happens there affects us here,
and any agreement making it mandatory, and
maybe is a collaboration that exists between
all agencies because its mandatory, like they
say presidential or governmental,
regardless.”

Data triangulation
There are some areas of similarity between the results of these two phases. The top area
of primary focus identified in the content analysis during the years before the adoption of the
HPV vaccine school-entry requirement (i.e., 2015, 2016, and 2017), included educational and
informative articles related to HPV and the HPV vaccine (Table 8). This type of information
could be important in terms of better understanding the process of education and awareness that
took place in PR and that stakeholders mentioned during the interviews. The second primary
focus, advertisement, including HPV vaccine ads from Merck and VOCES, also seems to
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support the findings from the interviews in which the stakeholders mentioned how the private
sector, which included Merck, provided education and support towards the vaccine and the
requirement.
It is interesting to note that the number of articles mentioning HPV as an STI or with
other STIs as the primary focus, declined from four in 2015 to zero in the first seven months of
2018 (Table 8). This would seem to align with what the stakeholders said about framing the HPV
vaccine and the HPV vaccine school-entry requirement as cancer prevention. Also, the number
of articles with cervical cancer as their primary focus increased in 2016 and 2017, which also
seem to support this idea.
One important finding of the interviews was the identification of the 2017 announcement
of the HPV vaccine school-entry requirement as the starting point or opening of the window of
opportunity. Findings from the content analysis show that the greatest number of publications
with the HPV vaccine school-entry requirement as the primary focus occurred in 2017 (Table 8),
followed by the year when the official announcement of the requirement was published and
noted by the stakeholders. This trend is similar when looking at the articles that mentioned the
HPV vaccine school-entry requirement (Table 9); most were published in 2017 and 2018.
During the interviews, stakeholders explained how the current immunization law
facilitated the process of adoption of the requirement. Per the current immunization law, the
DOH must publish every year the list of required vaccinations for school at least three months
before classes start. In PR classes start in August, the increase in number of articles that
mentioned the HPV vaccine school-entry requirement occurred during the months of June and
July, soon after the DOH announcements were published (Table 5).
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Another area of overlap between the findings of the two phases relates to the Report and
the case of Rhaiza, both mentioned by the stakeholders as important events that occurred in 2015
in the overall process of adoption of the HPV vaccine school-entry requirement. The two news
articles published in 2015 in favor of the requirement were about the presentation of the Report
during which tribute was paid to Rhaiza, and in which a variety of stakeholders, including
Rhaiza’s widower, advocated for making the HPV vaccine required for school entrance. It is
also important to note that articles with Rhaiza as the primary focus were scarce (n = 2, Table 8).
However, there were articles in the advertisement category that did mention Rhaiza and or used
pictures of her to promote the HPV vaccine.
From the stakeholders’ viewpoint, the composition of the anti-vaccination groups varied.
Some of the groups mentioned by the stakeholders, as well as the arguments against the HPV
vaccine and the requirement, were also found in the articles. In both datasets a feminist nonprofit organization, an autism organization, and a representative of a religious group were
present. Also, the arguments against the HPV vaccine school-entry requirement that the
stakeholders listed were also listed in the articles. The similar arguments included the concerns
about the HPV vaccine safety and side effects, the religious concerns related to the sexual nature
of the transmission of the virus, and that it should be the parents’ right to choose to vaccinate
their children. However, an argument that was only present in the articles was the concern the
member from a feminist group and the participant who identified as being against the HPV
vaccine school-entry requirement mentioned regarding the lack of human sexuality education in
PR.
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Summary
This chapter presented the findings for both phases of the study. It included the themes
based on the interview data, framed using the theoretical framework. Quotes were provided to
show examples of the conversations that took place during the interviews and in support of the
results. Additionally, this chapter presented the findings from the content analysis with a focus
on the arguments against the HPV vaccine school-entry requirement. The chapter ended with the
triangulation of the results from the interviews ant the content analysis. The following chapter
includes a discussion of the overarching findings of the study interweaving the results of the two
phases in the context of the theory and the literature.
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Chapter 6: Discussion
Introduction
Despite cancer-preventive properties of HPV vaccination and the effectiveness of prior
vaccine mandates, HPV vaccine school-entry requirements have not been widely adopted in the
US. There remains a public health need to understand the low adoption rates of the HPV vaccine
school-entry requirement. Thus, the purpose of this study was to understand the macro-level
factors that influenced the adoption of the HPV vaccine school-entry requirement in PR during
the summer of 2018. To accomplish this purpose a macro-level theory, the MSA was used to
guide the three research questions of this study. The following section includes a discussion of
the findings in the context of the theory and the literature, a recognition of the limitations and
strengths of this study, a description of the implications for research, policy, and practice, and
areas for future research.
Intersection of Problems, Policy, and Politics
The MSA posits that when policy entrepreneurs purposely intervene with different
tactics, the problems, policy, and politics streams will converge to create a window of
opportunity that results in a policy output (Kingdon, 1995; Zahariadis, 2007, 2014). Briefly, the
problems stream represents the issues that need to be solved. The policy stream includes the
soups of ideas that compete for the policymaker’s attention. The politics stream refers to the
political factors and pressure groups that influence adoption (Kingdon, 1995; Zahariadis, 2007,
2014). In the case of PR, findings from this study indicate that this window of opportunity
opened during the summer of 2017; ultimately, the final output was produced in the summer of
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2018 when the DOH, via the Secretary of Health, officially announced the requirement of the
HPV vaccine for school entrance. To be able to understand how this intersection occurred, each
of the streams will be discussed (Figure 6).

Figure 6. Application of MSA to study findings
Stakeholders agreed that specific health factors, or indicators, as the MSA labels them,
contributed to the process of adoption of the HPV vaccine school-entry requirement. As
indicated, PR is among the US states/territories with the highest rate of estimated HPVassociated cancer (including anal, cervical, oropharyngeal, and rectal cancers), with a rate of
13.10 cases per 100,000 people who develop cancer. Moreover, PR has the highest rate of HPVassociated cervical cancer in the nation with rates of 11.70 cases per 100,000 women (Viens et
al., 2016). The stakeholders in this study were concerned about the high incidence of HPV and
HPV-related cancers, in particular, cervical cancer and the increasing rates of oropharyngeal
cancer. These high rates of HPV and related cancers were among the main problems that
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stakeholders thought needed to be resolved by the HPV vaccine school-entry requirement. This
finding is similar to the case of Virginia’s HPV vaccine school-entry requirement, where
concerns regarding cervical cancer were noted as a health issue by the proposed legislation that
passed in 2009 (Abiola et al., 2013). Additionally, stakeholders described the relatively high
uptake HPV vaccination rates in PR as a facilitator; however, the low completion rates were an
indicator that was considered for the adoption process of the requirement.
In addition to the health indicators, there were two focusing events that contributed to the
initiation of the adoption process of the HPV vaccine school entry requirement in PR: 1) Rhaiza
López Plumey died of cervical cancer [January 2015] and 2) the VOCES HPV Advisory Panel
Report (Report) was published [May 2015]. The video posted on social media, and later the
announcement of Rhaiza’s death, contributed to bringing awareness among the Puerto Rican
population about the cervical cancer issue. The Report was meaningful because it included the
epidemiological and cost-effectiveness data based on studies conducted in PR. Having available
the local epidemiological data about the incidence of HPV and HPV-related cancers, and HPV
vaccine uptake rates, as well as data on cost-effectiveness, facilitated the process of adoption.
The results from the interviews show that stakeholders were guided by this Report, published
after the passing of Rhaiza, and that included objectives recommending education efforts and the
HPV vaccine school-entry requirement.
Before the window of opportunity opened, policy entrepreneurs worked on other areas
and issues that needed to be addressed to clear the way for the adoption of the HPV vaccine
school-entry requirement. The results of this study narrate the background of efforts undertaken
to address these areas. For instance, policies to make it mandatory for health insurance
companies to cover the HPV vaccine were supported by the policy entrepreneurs and created at
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the Legislature level. These policies allocated money and resources to pay for the HPV vaccine,
making it available for the population in the private sector.
Another facilitator of adoption process was the education campaigns that took place in
PR years before the adoption of the requirement and during the year between the DOH
announcement in 2017 and the official requirement in 2018. This process of education created
awareness of HPV, HPV-associated cancers, and the HPV vaccine. Findings indicate that, from
the stakeholders’ perspectives, this education process was essential to reduce the likelihood of
resistance from the anti-vaccination groups. The educational efforts also focused on the adoption
of the HPV vaccine requirement as a form of cancer prevention, rather than prevention of an STI.
This finding is similar to previous research in which the idea of preventing cancer is the primary
driver of the decision to adopt such a policy (Abiola et al., 2013; Colgrove et al., 2010).
Additionally, based on the content analysis data, most of the articles mentioning the HPV
vaccine school-entry requirement were published during the years of 2017 and 2018. Thus, the
process of adoption did get media attention, in particular during the months of June and July,
which are close to the dates of the DOH announcements. A previous content analysis of print
news from three states (i.e., Texas, Virginia, and DC), also found increased media attention in
response to governments’ discussions about HPV vaccine mandates (Casciotti et al., 2014).
In response to the DOH’s announcement of 2017, both the anti- and pro-vaccination
groups presented policies to members of the Legislature. These other policy options were in the
soup of ideas competing for the policymaker’s attention (Kingdon, 1995; Zahariadis, 2014). The
policies that the stakeholders discussed included, HR Bill 537, Bill 1303, and Bill 1579.
Policymakers gave attention to HR Bill 537 in 2017, and an investigation on the safety and
efficacy of the HPV vaccine was conducted through public hearings in 2018 (Table 4). This
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investigation resulted in a positive overview of the HPV vaccine, published in June 2018, after
the Secretary of Health had already announced the official HPV vaccine school-entry
requirement. Due to the positive results regarding the safety and efficacy of the HPV vaccine
published in the Bill 537 resolution, the legislators let the HPV vaccine school-entry requirement
continue its course. Despite that, at some point, policymakers were asking the secretary of health
to retract it. It is important to note that, during the summer of 2018, HR Bill 1576, petitioned by
members of the anti-vaccination groups, was presented but not discussed in plenary; neither was
Bill 1303, petitioned by the pro-vaccination group. Thus, the adoption of the HPV vaccine
school-entry requirement occurred despite the concurrent proposition of other policies.
An important finding from this study is that stakeholders thought that PR’s current
immunization law made it technically feasible to adopt the HPV vaccine school-entry
requirement. This regulatory approach may have facilitated the HPV vaccine school-entry
requirement adoption because convincing the members of the legislature, whose decisions are
highly influenced by the voters, can be difficult. Instead, policy entrepreneurs talked to and
shared scientific evidence with the current Secretary of Health. This approach is similar to the
case of the state of Rhode Island, where the Department of Health also established the
requirement via its rulemaking powers (Barraza et al., 2016; Washburn et al., 2016). On the other
hand, both Virginia’s and DC’ mandates were created through the legislature (Barraza et al.,
2016).
Another way in which the HPV vaccine school-entry requirement was described as
technically feasible by the stakeholders was because it only includes the 11 to 12 years old
cohort of children. This was important for the stakeholders because it meant that the government
and public health system would only spend money on the cost of two doses, which is the number
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of shots required for the targeted cohort. This is an in alignment with the current HPV vaccine
ACIP recommendations (Centers for Disease and Control Prevention, 2016b).
Related to the technical feasibility aspects of the HPV vaccine school-entry requirement,
findings support that there were considerations regarding the value of this policy approach.
Mainly, participants noted concerns about the public health and economic implications of the
HPV vaccine school-entry requirement. These were essential values captured by the HPV
vaccine school-entry requirement, which included the protection and the overall wellness of the
island population by preventing the physical, emotional, and economic implications of HPVrelated cancers in the long term.
From a political perspective, the stakeholders frequently mentioned the anti-vaccination
sector as active members of the society exercising pressure on the policymakers. These pressure
groups varied in composition and posed a direct resistance to the adoption of the HPV vaccine
school-entry requirement in PR. In an attempt to weaken the reach of the HPV vaccine schoolentry requirement, one of the anti-vaccination groups petitioned Bill 1576. The purpose of this
bill was to amend PR’s immunization law to include an opt-out option based on personal beliefs.
However, during the summer of 2018, the bill was not discussed. In other scenarios, such as in
the case of Virginia, the passing of an HPV mandate encountered less resistance. Here, a quick
passing of a bi-partisan bill did not provide enough time for an anti-bill campaign to form and be
a barrier for the passing (Abiola et al., 2013). Members for the RI’s DOH also noted minimal
opposition to the addition of the HPV vaccine to the school entrance requirements in 2014
(Washburn et al., 2016). However, there have been actions taken through the legislature to limit
RI’s DOH powers relating to its authority to establish vaccine requirements, particularly to
requirements related to diseases not contagious in the school setting (Barraza et al., 2016).
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Additionally, the political turn-over in key government positions seems to have
facilitated the HPV vaccine school-entry requirement adoption process in PR. With a change in
political party in the government of PR for 2017, new individuals were named to occupy
positions in the governor’s cabinet, including the secretary of health. Results from the interviews
indicate the policy entrepreneurs perceived the secretary of health as someone supportive of
vaccinations and open to making the reduction of cervical cancer one of his priorities. This
political turn-over in government positions was also considered a concern. Changes in
administrations due to changes in political parties could mean that whoever is named to occupy
the position of secretary of health may decide to remove HPV from the list of required
vaccinations. This is a limitation of how the HPV vaccine school-entry requirement was created
in PR, through an announcement of the secretary of health and not via the legislature.
Policy Entrepreneurs
The work needed for the problems, politics, and policies to intersect was conducted
through collaborations efforts among different sectors composed of the policy entrepreneurs.
Similar to the findings from Abiola et al. (2013), policy entrepreneurs were instrumental in the
adoption process of the HPV vaccine school-entry requirement in PR. As the MSA describes
(Kingdon, 1995; Zahariadis, 2014), and noted in the findings from this study, the role policy
entrepreneurs played, and their participation in the adoption process indicates how they made the
three streams intersect/converge. For instance, policy entrepreneurs worked in changing
narrative related to the HPV vaccine; thus, creating awareness in the population. This change in
narrative was a result of the education and campaigns and efforts discussed by the stakeholders.
They were all giving the same message to the community, as noted before, that the HPV vaccine
school-entry requirement is about cancer prevention.
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In the case of the Virginia mandate, Senator Janet Howell and Delegate Hamilton were
the policy entrepreneurs who achieved consensus in the legislature and support from stakeholder
organizations (Abiola et al., 2013). In contrast, policy entrepreneurs in PR were from a variety of
sectors of the population. For example, VOCES, PR’s pro-vaccinations coalition, played an
important role unifying all the sectors to advocate for the HPV vaccine school-entry requirement
with the scientific evidence needed to convince the secretary of health. Also, other sectors, some
of which are part of VOCES, had additional roles based on each of their expertise and area of
interest. In the case of DC’s mandate, the ACS provided a statement in support of the legislation
(Barraza et al., 2016).
Comparison of PR’s HPV vaccine school-entry requirement to Virginia,
Washington DC and Rhode Island’s HPV vaccine school-entry requirements.
Barraza et al. (2016) identified some areas of similarities and differences between the
Virginia, Washington DC, and Rhode Island’s HPV vaccine school-entry requirements. These
areas include when the requirement was adopted, mode or process of adoption, who the
requirement applies to and the timing of the HPV vaccine doses, and the opt-out mechanisms
available to the population. In this section, these areas will be compared to the PR’s HPV
vaccine school-entry requirement.
Back in 2009, when the state of Virginia adopted its HPV vaccine school-entry
requirement, it was done through the legislature (Barraza et al., 2016; Colgrove et al., 2010;
Virginia Department of Health, 2014). This approach is similar to the Washington DC
requirement, which was enacted in 2009 via the legislature (Barraza et al., 2016; Government of
the District of Columbia Department of Health, 2015). In contrast, RI’s 2015 and PR’s 2018

117

requirements were adopted using the DOH regulatory and administrative powers (Barraza et al.,
2016; Washburn et al., 2016).
The present HPV vaccine school-entry requirements vary with respect to who should get
the vaccine and the timing of the HPV vaccine doses. Washington DC, RI and PR’s
requirements, all currently indicate that girls and boys should get the HPV vaccine for school
entrance (Barraza et al., 2016; Government of the District of Columbia Department of Health,
2015; "Ley de Inmunizacion," 1983; State of Rhode Island Department of Health, 2015). In the
state of Virginia, the requirement only applies to girls. Virginia requires three doses to be
completed before entering the sixth grade (Barraza et al., 2016; Virginia Department of Health,
2014). In Washington DC, three doses are needed upon starting sixth grade at 11 years old. The
state of RI took a different approach and requires the first dose of the HPV vaccine before
starting seventh grade and finishing the series before starting ninth grade (Barraza et al., 2016).
In PR, the DOH requests the HPV vaccine for all 11 and 12 years old.
Lastly, in terms of opt-out options, there is a range of variation. Virginia has the most
lenient process of exception. Basically, by just reviewing some educational materials and signing
a documented waiver, parents can get the exception approved, without the need to provide any
documentation at the school (Barraza et al., 2016; Virginia Department of Health, 2014). In the
case of the Washington DC requirement, the three exceptions allowed are the religious, the
medical and the philosophical (Government of the District of Columbia Department of Health,
2015). Both RI and PR only allow for medical and religious exceptions (Barraza et al., 2016;
Puerto Rico Department of Health, 2013; State of Rhode Island Department of Health, 2015).
Arguments in favor of and against the HPV vaccine school-entry requirement in PR
Arguments influencing support for HPV vaccine mandates have been framed under the
umbrella of women’s health and children’s welfare (Colgrove, 2006). Vamos et al. (2008)
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summarized the arguments literature in favor of a school vaccine mandates describing them as
those about the appropriate age for vaccination, those related the cost-effectiveness of requiring
the HPV vaccine, those highlighting the need for the prevention and reduction of cervical cancer,
and the parent’s participation in the health decisions concerning their children. In PR, the
framing strategy used was to describe the HPV vaccine school-entry requirement as a tool for
cancer prevention. Notably, based on the need to reduce the high rates of cervical cancer among
Puerto Rican women. Additionally, the cost-effectiveness and the alignment with the ages of
inoculation, 11 and 12 years old, were important for the policy entrepreneurs, as was the public
health impact on the wellness of the population due to the reduction of HPV-related cancers.
Studies among physicians have reported similar reasons in support of the HPV school-entry
requirement such as its effectiveness in increasing immunization and its public health impact on
immunization (Kahn et al., 2007; Tissot et al., 2007; Vercruysse et al., 2016).
Conversely, arguments against the need for HPV vaccine school-entry requirements are
based on lack of transmission of the virus through casual contact, intrusion into parental
autonomy, public distrust due to pharmaceutical lobbying during the policy development
process, and the potential economic burden on the government, and health care system including
the health departments and private physicians’ offices (Gostin & DeAngelis, 2007; Javitt et al.,
2008; Mello et al., 2012). Some of these reasons were echoed in the findings from this study as
described by the stakeholders and in the news articles reviewed.
Arguments against the HPV vaccine school-entry requirement seem to be intrinsically
related to the HPV vaccine and the virus. For instance, concerns related to the side effects and
safety of the HPV vaccine were mentioned by the stakeholders and present in the articles, as
reasons to be against the HPV vaccine school-entry requirement. This reason has also been
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discussed among parents in previous research who thought that the vaccine was new and had
concerns about its safety and side effects and were more likely to be against the HPV vaccine
school-entry requirement (Carlos et al., 2011; Horn et al., 2010; Perkins et al., 2010; Robitz et
al., 2011; Smith et al., 2011).
Another argument mentioned by the stakeholders, and that also was presented in the
reviewed articles, was the mode of transmission of the virus and its association with sexual
activity. Previous studies among parents discussed the way of HPV transmission as a reason to
be against the HPV vaccine school-entry requirement, while other studies have reported the lack
of casual transmission (Perkins et al., 2013; Vercruysse et al., 2016), or emphasized the sexual
transmission of the virus (Pitts & Tufts, 2013) as arguments against the HPV vaccine schoolentry requirement. Similarly, Casciotti et al. (2014) found that in the print media that
encouragement of sexual activity was an argument against the HPV vaccine school-entry
requirement. Moreover, Vercruysse et al. (2016) found that parents discussed that adolescents
were not sexually active; thus, there was no need for the requirement. A similar reason was
presented in the news articles by one of the anti-vaccination groups.
Finally, parental rights to decide what is best for their children was another argument
discussed during the interviews and published in the Puerto Rican news articles. Previous
research with parents has also reported the parents’ choice or decision to vaccinate their children
(Perkins et al., 2013; Pitts & Tufts, 2013; Smith et al., 2011; St John et al., 2010; Vercruysse et
al., 2016) as an argument against the HPV vaccine school-entry requirement. The government
imposition of the HPV vaccine to parental autonomy was the most common theme that was
reported by Casciotti et al. (2014) in print news media from Texas, Virginia, and DC between
2005 and 2009.
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Strengths and Limitations
As with any research study, some strengths and limitations should be noted. There are
different types of biases that could have affected this study. For instance, researcher bias could
be considered a limitation to this study. Based on my education and life experiences, I am a
supporter of HPV vaccination and school-entry requirements. Therefore, I took steps to maintain
a neutral position while conducting the interviews, and while analyzing both the qualitative and
quantitative data. To address this issue, I was aware of and documented my biases, which are
presented in the Reflexivity section of this dissertation. Recall bias from the participants may also
be impacting the findings, more so in the narratives related to the work done before the summer
of 2018, when data were collected.
Overall, purposive sampling limits the generalizability of the results. Additionally, there
are problematic aspects of conducting interviews with stakeholders such as participant
recruitment and participation. In terms of recruitment, the strategies that worked best in this
study to access participants in favor of the HPV vaccine school-entry requirement were key
informant introduction and snowballing. Nonetheless these strategies, the researcher had only
one person who identified as been against the HPV vaccine school-entry requirement. Not
having a key informant who could introduce the researcher to the community of stakeholders that
were against the HPV vaccine school-entry requirement may have hindered the recruitment
process.
This posits limitations to the findings of this study, which are mostly informed by the
participants who identified as been in favor of the requirement. To address this limitation, the
content analysis was conducted and emphasis was given to explore the argument against the
HPV vaccine school-entry requirement.
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It is important to note that this study lacks an in-depth exploration of the HPV vaccine
school-entry requirement adoption process from the perspective of the stakeholders who were
opposed to the mandate. Some participants from this study mentioned that the anti-vaccination
groups mainly communicate and obtain their information via social media. Future research could
look at the anti-vaccination groups utilizing social media as a means for recruitment or engaging
with this type of stakeholder.
Regarding participation, the type of participant chosen for this study tends to have limited
time to engage in activities not related to their primary duties, such as research studies. This
limitation was addressed by using two different strategies to conduct the interviews, in-person or
via phone. Providing the participant these options enabled them to choose the most convenient
method for them. Thus, facilitating their participation.
Moreover, there could be issues related to saturation. Saturation is an iterative process in
which the researcher is the one who notes if saturation has been achieved (Hennink et al., 2011)
and has become the ‘gold standard by which purposive sample sizes are determined in health
science research” (Guest et al., 2006, p. 60). The researcher noted saturation in the themes.
However, saturation may not have been achieved for some sub-codes or sub-themes (e.g.,
misinformation available in the social media). Not achieving data saturation in these themes
hinders their validity (Fusch & Ness, 2015); thus; careful consideration of these themes should
be noted.
In terms of the content analysis, a limitation was that the search process for each
newspaper’s database differed. These search engines are created for everyday use and leisure
reading. They are not designed with rigorous algorithms needed for research (Lacy, Watson,
Riffe, & Lovejoy, 2015). Thus, there may be a possibility that not all the news articles that were
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published were captured in the searches executed. To address this limitation, the researcher used
two newspaper search engines and online databases. The missing of the last five months of the
2018 year is another limitation related to the content analysis. Additionally, the articles were
sampled purposively (a non-probabilistic sample), and the data are not truly dichotomous, thus;
inferential analysis is not recommended (Guest et al., 2012a).
Besides these methodological limitations, there were also theoretical limitations. MSA
assumes that each of the streams runs independent from each other and only converge at short
times called the windows of opportunity (Kingdon, 1995; Zahariadis, 2007). Nonetheless, in the
case of the HPV vaccine school-entry requirement adoption process in PR, it was difficult to
evaluate the streams in isolation. From the data, it seems that the streams are always in contact
with one another. They were influenced by the policy entrepreneurs who were in constant
interaction with the streams at many points in time (Figure 6). Additionally, time was an
important factor in the findings of this study. MSA posits that the window of opportunity is short
in duration (Kingdon, 1995; Zahariadis, 2007). However, based on the findings of this study, the
window of opportunity opened when the Secretary of Health made the announcement during the
summer of 2017 and stayed opened for about a year until the official announcement was
published in the summer of 2018. Moreover, the previous work conducted by the policy
entrepreneurs dated years before the window of opportunity opened. This is noted by the blue
arrows in Figure 6.
Also, this theory is ‘adoption biased.’ This means that not only it favors evaluation of the
creation of policies, but it also falls short in looking at the implantation phase. This limitation
about lacking a focus on the implementation of policies, was also discussed by Blackman (2005)
her literature review of tobacco control policy development in California. To somewhat address
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this limitation, the researcher asked about the potential effects that the hurricane Maria could
posit to the implementation of the requirement. To this question, participants noted that for the
most part it, the vaccine was supposed to be available. Nonetheless, the use of theory can also be
a strength, since it did serve to guide the research questions, analyze, and summarize the data.
Several other strengths exist in this study. The data collection process of this study was
opportune. This study took place amid the HPV vaccine school-entry requirement adoption
process in PR and helps with reducing the chances of recall bias. Also, the addition of the
content analysis served to gather more data on the reasons expressed against the HPV vaccine
school-entry requirement. It was used to triangulate the data from the interviews that primarily
had the perspective of people in favor of the HPV vaccine school-entry requirement.
Research, Practice, and Policy Implications
This study has the potential to contribute to research because it adds to the existing
literature trying to understand the controversies surrounding the HPV vaccine school-entry
requirements. Additionally, it helps to inform the application of a macro-level theory to data
from a current policy issue. Similar interviews with stakeholder from other states, and even from
other Spanish-speaking countries, can be conducted to explore additional contextual issues
surrounding the potential creation of HPV vaccine-related policies. Furthermore, this study’s
methodology could be applied to the exploration of the creation of other immunization or health
policies. Thus, contributing to the development of health policy research.
Further research is still needed regarding the HPV vaccine school-entry requirement. For
example, there is a need to study the HPV school entry requirement adoption process in PR from
different perspectives, such as the perspective of parents with adolescent children, or staff from
the school system. This can contribute to seeing the whole picture of the HPV vaccine schoolentry requirement adoption process. Also, for a comprehensive content analysis of the newspaper
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articles published in PR regarding the HPV vaccine school-entry requirement, future research
should include the last five months of the 2018 year. Another area of interest would be to explore
the misinformation regarding the HPV vaccine available in social media from PR. Lastly, future
research should also look at the implementation process of the HPV vaccine school-entry
requirement occurring in PR, taking into consideration HPV vaccination outcomes for evaluation
of the policy.
Moreover, this study also has several practice implications. The study identified the
relevant factors that facilitated the adoption process of an HPV vaccine school-entry
requirement. Thus, messages could be created to raise awareness and support among parents and
other key stakeholders towards this type of population-based strategy. Public health practitioners
should also consider the importance multisector collaborations, that work cohesively towards the
same goal and with the same message. Additionally, for the messaging and ultimately the
adoption of these policies to be facilitated. Thus, having local epidemiological data seems to be
meaningful for the decision makers, as well as, been purposeful in aligning the messages with
the values of the policymakers. The timing of educational programs and interventions should
also be considered, as it can potentially facilitate the process of adoption of similar policies.
Also, the people in power and key administrative staff should also be considered and influenced
to facilitate the adoption process. Public health practitioners and advocates of immunization
policies can use this information to develop action plans for their states.
Finally, this research could impact public health policy in several ways. This study of
PR’s HPV vaccine school-entry requirement provides an overview of an adoption process that
recently took place and could inform other states and public health practitioners interested in
making the HPV vaccine mandatory. This study also provides insight into the policies that may
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need to be in place prior to the adoption of an HPV vaccine school-entry requirement. For
instance, in the case of PR, a policy that made the month of January the cervical cancer
prevention month, was used to create awareness among the population. As the participants of this
study asserted, creating awareness of the issue before the HPV vaccine school-entry requirement
was adopted may have contributed to the facilitation of the process. Additionally, the process
that occurred in PR, in which the requirement was adopted via the DOH can also serve as an
example to other states in which going through the Legislature may seem a difficult policy
creation process. Lastly, findings from this study can inform other HPV vaccine policy initiatives
to improve HPV vaccination rates across the US and target the prevention of HPV-related
cancers.
Summary
The purpose of this study was to understand the macro-level factors that influenced the
adoption of the HPV vaccine school-entry requirement in PR during the summer of 2018. MSA
was useful to identify factors and understand the process that took place in PR for the HPV
vaccine school-entry requirement to be created. Policy entrepreneurs actively guided the
intersection of local problems, politics, and policies to educate the population and prevent cancer
in PR. This timely look at the facilitators and barriers of the HPV vaccine school-entry provides
practical information about the process of adopting a cancer prevention policy-based strategy.
Findings from this study can inform other states and public health practitioners interested in
adopting HPV vaccine policy initiatives to improve HPV vaccination rates across the US and
target the prevention of HPV-related cancers.
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Tables and Figures
Table 1: Information regarding available HPV vaccines
Type

Name

Manufacturer

FDA
approval

Year
recommended
for routine
vaccination

HPV strains covered by each vaccine
6

2vHPV

Cervarix®

GlaxoSmithKline

4vHPV

Gardasil®

Merck and Co, Inc.

9valent

Gardasil-9®

Merck and Co, Inc.

2009 F

2009 F

2006 F

2006 F

2009 M

2011 M

2014 B

2015 B

11

16

18

X

X

X

X

X

X

X

X

X

X

31

33

45

52

58

X

X

X

X

X

Note: M = males, F = females, B = both sexes (Markowitz et al., 2014, Petrosky et al., 2015)
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Table 2: Studies about stakeholders’ reasons and factors associated with HPV vaccine school-entry requirement in the US: Studies’
characteristics (N=25)
Authors, year

Type of Stakeholder

Location

Study Design*

Methodology

Date data
collected
2005

Sample size

Theory

31

For data analysis –
Framework analysis

Tissot et al.
(2007)

Pediatricians

Three-state
region: Ohio,
Indiana,
Kentucky

QL

semistructured
interviews

Kahn et al.
(2009)

Primary care
physicians

Texas

QT

web survey

2008

1,122

Model informed by
Theory of Planned
Behavior, the
Awareness-to-adherence
model and diffusion
model

Millen et al.
(2009)

Emergency
department patients

Boston,
Massachusetts

QT

researcher
administered
survey

2007

387

None mentioned

Sanderson et al.
(2009)

HPV+ and HPVLatina mothers

Texas

QT

2007-08

405

Colgrove et al.
(2010)†

Multiple: mostly
policymakers,
industry, medical
prof. orgs.,
advocacy groups

6 states:
California,
Indiana, New
Hampshire,
New York,
Texas,
Virginia, and at
National level

QL

researcher
administered
survey
Key
informant
interviews
(face to face
and phone)

2008-09

73

Mentioned in discussion
– HBM (findings align
with constructs)
None mentioned
(potentially the same as
Abiola et al. 2013, since
same
database/participants)
Data analysis: thematic
content analysis

Ferris, Horn,
and Waller
(2010)††

Parents/guardians
of children 9-17
years old

Atlanta,
Georgia and
North Augusta,
South Carolina

QT

selfadministered
survey

2008

325

None mentioned
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Table 2: (continued)
Authors, year
Kahan 2010

Type of Stakeholder
National sample of
American adults

Location

Study Design*

Methodology

National panel
sample

Exp.
3 conditions
(1.no
argument,
2.unattributed
arguments,
3.culturally
identifiable
advocated)

Online
experiments

(did not specified if
had to be parents)

Date data
collected
April and August
of 2007

Sample size

Theory

1,538
(n1=254,
n2=252,
n3=1,032)

Cultural
Cognition/cultural
theory of risk
For data collection:
previously validated
scales, and new ones

Rebecca B.
Perkins, PierreJoseph,
Marquez, Iloka,
and Clark
(2010)

Parents of girls 11 to
18 (included ethnic
minorities)

Boston,
Massachusetts

QL/qt- with
demographic
data

Interviews,
Likert scale

2007-08

73

Data analysis: informed
by grounded theory and
content analysis

St John et al.
(2010) †††

News media and
parents/guardians of
girls 9-13

Virginia

M

Thematic
analysis of
Virginia
newspapers

Stories from Jan.
2006-08.

29

Journalistic framing

2008
8 focus
groups with
parents
Yeganeh,
Curtis, and Kuo
(2010)

Parents/guardians
(all females) of girls
ages 11-17 (mostly
Latino)

Los Angeles,
California

QT

Researcher
administered
survey

33

2008

95

None mentioned
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Table 2: (continued)
Authors, year

Type of Stakeholder

Study Design*

Methodology

Carlos 2011
(Study looks at
intent to
follow/comply
with HPV
vaccination
laws)

Mothers/caretakers
(25-55 years old) of
females 9 to 17
engaging in breast &
cervical cancer
screening

Chicago,
Illinois (urban
site – mostly
black)

QT

mail-based
selfadministered
survey

Parents (mostly
Hisp. Or AA) of 11
to 18 years old girls
from communities
with high-risk for
cervical cancer

Los Angeles,
California

QT

Telephone
survey

J. S. Smith et
al. (2011)

Parents/guardians of
girls 10 to 18 years
old

Southeastern
North Carolina

QT

Sara E. Abiola,
James
Colgrove, and
Michelle M.
Mello
(2013)†**

Multiple: mostly
policymakers,
industry, medical
prof. orgs.,
advocacy groups

6 states:
California,
Indiana, New
Hampshire,
New York,
Texas,
Virginia, and at
National level

QL

R. B. Perkins et
al. (2013)

Low income and
minority
parents/guardians of
boys 11 to 17 years
old

Boston,
Massachusetts

QL/qt with
demographic
data

Protocol
published in
2010
Robitz et al.
(2011)

Location

Date data
collected
3/4 years after
HPV vaccine
approval
Dec. 1, 2007 –
Nov. 30, 2008
(retrospectively
identified)

Sample size

Theory

937

Data collection:
previously used scales
based on the Health
Belief Model

2007-08

484

None mentioned

Telephone
survey

2007

866

Survey based on
constructs of HBM

Newspaper
articles and
archival
materials.
Key
informant
interviews
(face to face
and phone).
Interviews

2006-08

-

Multiple Streams Model
(Theory)
Data analysis: thematic
content analysis

2008-09

73

2010-2011*
“prior to
universal
recommendation
for boys”
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Southeastern,
Michigan
(suburban site –
mostly white)

Health Belief Model
(perceived severity,
perceived susceptibility,
perceived benefits, and
perceived barriers)
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Table 2: (continued)
Authors, year

Type of Stakeholder

Pitts and Tufts
(2013) †††

Parents/guardians 4th
to 7th grade (9 to 13)
girls
Undergraduate
students 18 to 29

Study Design*

Methodology

Virginia

QL

8 Focus
Groups

Northeastern,
US

Exp.

Web-based

Not reported:
estimated to be
2012 (p. 34),
asked about girls
only law

559
Gain =292,
loss =267

Pierre Joseph,
Belizaire, et al.
(2014)

Minority men 18 to
22 years old

Boston,
Massachusetts

QL

In-person
surveys with
open-ended
questions

2010-11

89

Health Belief Model –
questions
Data analysis: grounded
theory and content
analysis

Pierre Joseph,
Clark, et al.
(2014)

Minority women 18
to 22 years old

Boston,
Massachusetts

M

In-person
survey, semistructure
interview,
medical
record review

2007-09

132

Health Belief Model –
qualitative questions
Data analysis: grounded
theory and content
analysis

M. L. Smith et
al. (2014)

18 to 22 college
students

Texas

QT

Online survey

Not reported
(probably same
as Wilson, 2016)

1,322

None mentioned

Califano et al.
(2016)
(ask about HPV
vaccine schoolentry for all
aged 11 to 12
years old)

Physicians
(pediatricians and
family physicians)

National panel
sample

QT

Online survey

2014

775

None mentioned

Nan et al.,
(2014)

Location

(asked about
HPV vaccine
mandate for
girls only)

Date data
collected
2008

Sample size
33

Theory
For data analysis:
thematic analytic
procedures
Cultural theory of Risk
(cultural worldviews)
and message framing
theory (gained framed vs
loss framed)
some constructs of the
Health Belief Model
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Table 2: (continued)
Authors, year

Type of Stakeholder

Location

Study Design*

Methodology

Calo et al.,
(2016)
(asked about
HPV vaccine
school-entry for
all 11 to 12
year olds)

Parents of 11 to 17year-old children

Vercruysse et
al. (2016)
(asked about
HPV vaccine
school-entry for
children to go
to high and
middle school)
Wilson and
Smith (2016)

Date data
collected
Nov. 2014 to Jan.
2015

Sample size

National panel
sample

QT

Web-based
survey

Parents of 11 to 17year old girls and
health care providers

Boston,
Massachusetts

QL/qt – chisquares

Semistructured
interviews

2012-13

129(parents)
34(providers)

College female
students

2 large Texas
universities

QT

Internetdelivered
questionnaire

Feb. 2011 to
March 2011

1,105

1,501

Theory
None mentioned – look
at the literature to look
for predictors, scale for
psychologic reactance,
items from the Carolina
HPV immunization
attitudes and beliefs
scale, item for vaccine
importance
Health Belief Model and
Transtheoretical model –
for the questions

None mentioned – for
data collection they used
previously validated
items.

Note: * QL = qualitative, QT = quantitative, M = mixed methods, Exp. = experimantal. † = same dataset/participants, †† = same dataset/participants, ††† =
same dataset/participants. ** This study is mostly about the policy formation process, but some opinions about school-entry requirements are discussed,
thus, was included.
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Table 3: Studies about stakeholders’ reasons and factors associated with an HPV vaccine school-entry requirement in the US: Main
findings (N=25)
Author, year

Type of stakeholder

Support

Against

Tissot et al. (2007)

Pediatricians

Maximize public health impact on immunization

HPV not casually transmitted, concerned about
long-term safety and efficacy of vaccines

Kahn et al. (2009)

Primary care
physicians

Effective strategy for vaccine uptake, access,
policy guided by PH impact of vaccination,
parents can opt-out (religious, philosophical and
other)

Patients not covered by Medicaid or VFC may
not be able to get vaccine, public poor
understanding of HPV and the vaccine, not
enough data on long-term efficacy, parents’
autonomy, clinicians experience with vaccine is
limited, HPV not casually transmitted, risky
sexual behaviors

Millen et al. (2009)

Emergency
department patients

Higher support among those who knew that HPV
was STD

Support was not higher among those who have
heard of HPV or that knew it causes cervical
cancer

Sanderson et al. (2009)

HPV+ and HPVLatina mothers
Multiple: mostly
policymakers,
industry, medical prof.
orgs., advocacy groups

Majority HPV+ and HPV- in favor of Texas law,
HPV+ more than twice likely
Cervical cancer severity, efficacy of the vaccine,
mandate promote uptake equity (less motivated or
knowledgeable parents)

Parents/guardians
of children 9-17 years
old

Characteristic of parents – low SES, history of
HPV-related disease, understand children
susceptibility, interested in the HPV vaccine,
know HPV vaccine reduces risk cervical cancer.
Parents more likely to comply – children ages 12
to 14, knew vaccine reduces risks of genital warts
and cervical cancer

Colgrove et al. (2010)†

Ferris et al. (2010)††

8 factors: 5 – based on the characteristics of the
vaccine (newness of the vaccine, sexually
transmitted nature of HPV, HPV not
transmittable in classroom, discomfort with
involvement of the vaccine manufacturer, price)
3 – based on the vaccine policymaking process
(government coercion, anti-vaccine activism,
policymaking process)
In a scenario that HPV vaccine was required most
allowed to vaccinate their children, those who
don’t – autonomy
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Table 3: (continued)
Author, year

Type of stakeholder

Support

Horn et al. (2010)††

Parents/guardians
of children 9-17 years
old

Most supported mandatory vaccine programs but
only 43% if HPV vaccine included

Infringement on their rights, vaccine not well
studied, vaccine has many side effects

“when subjects see the argument, they are
disposed to reject being made by the advocate
whose values they share, and the argument they
are predisposed to accept being made by the
advocate whose values they repudiate,
polarization shrinks to the point of disappearing.”
(P. 509)
“The results of the experiment suggest that
disagreements about the risks and benefits of
HPV vaccination are shaped by cultural values,
which exert their influence through the biased
assimilation of information and through
attributions of information-source credibility.” (p.
512)

No argument condition:
Hierarchy correlated positively with risk
(participants perceived > risk as
they became more hierarchical and < risk as they
became more egalitarian)
unattributed arguments condition:
“subjects exposed to arguments became more
concerned about risk as their worldviews became
more individualistic and less concerned as their
worldviews became more communitarian.” (p.
508)

Kahan 2010

Against

Rebecca B. Perkins et al.
(2010)

Parents of girls 11 to
18 (included ethnic
minorities)

62% of parents in favor but varied by ethnicity
only 11% of Caucasians endorsed it, immigrants
more likely to support. Reasons: to prevent
cervical cancer, protect from sexually active
adolescents, PH intervention good for all

Personal choice, transmission not through social
contact, new vaccine with side effects

St John et al. (2010)†††

News media and
parents/guardians of
girls 9-13

This study is about an existing mandate. News:
legislation aspects, opt-out amendment by the
governor, support from the legislature, based on
discourse from experts (lacked parents
discussion), supporters – prevent
Focus groups: positive about the HPV vaccine

Yeganeh et al. (2010)

Parents/guardians (all
females) of girls ages
11-17 (mostly Latino)

64% agree with the mandate, 89% would get
daughter vaccinated. More likely to support if
thought vaccines were safe, had pap test in the
last year, already vaccinated daughter, Latino.

News: concerns about marketing and lobbying of
vaccine, recent approval by the FDA, not long on
the market, critics – bill too quick
Focus groups: skeptical of the motivations,
concerns pharma lobbying, opt-out as a ploy to
get to agree, lack of information, HPV
vaccination should be a personal choice
20% disagree, 15% unsure.
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Table 3: (continued)
Author, year

Type of stakeholder

Support

Against

Carlos 2011

Mothers/caretakers
(25-55 years old) of
females 9 to 17
engaging in breast &
cervical cancer
screening

Low intent 22.2%, undecided (14.3%), and high
intent 63.5%.*
When looking only at mothers of 11 to 12 years
old – 29.3% low intent, 12% undecided, 58.7%
high intent
Univariate analyses – individual knowledge and
attitudes, vaccination benefits, belief daughter
medical provider recommends, daughter is
sexually active or soon will be higher odds to
intent to comply with the mandate
Multivariate model – high vaccine benefits
*scale had 11 items, collapse into 3 groups

Univariate analyses – demographics not
associated
Univariate analyses – safety concerns, daughter
too young, and religious and moral beliefs had
lower odds of intention to comply.
Multivariate model – high safety concerns,
daughter too young for vaccination,

Robitz et al. (2011)

Parents (mostly
Hispanic or African
American) of 11 to 18
years old girls from
communities with
high-risk for cervical
cancer

59% thought the law was a good idea, mostly
were Hispanics responding in Spanish, daughter’s
HPV-vaccinated or intent to vaccine, belief the
HPV vaccine works well.
Agreement increased to 92% when including
participants who think the law is ok if parents can
opt-out.

African American less likely to support, belief
vaccine not work well, daughters not vaccinated
or no intent, HPV vaccine is too new

J. S. Smith et al. (2011)

Parents/guardians of
girls 10 to 18 years old

47% agree to HPV-school entry laws, agreement
increased to 84% when opt-out mentioned
Predictors to support – daughters had initiated or
intent to get the HPV vaccine, belief HPV
vaccine effective against cervical cancer,
beneficial if given at young age, regret if
daughters not vaccinated and got HPV, belief that
all children should get it.

Less likely to support predictors – concerns HPV
vaccine safety, causing health lasting problems,
daughter might initiate sex, belief HPV vaccine
pushed by drug companies, new vaccine, decision
is for parents alone

Sara E. Abiola et al. (2013)
†**

Multiple: mostly
policymakers,
industry, medical prof.
orgs., advocacy groups

Effective policy entrepreneurship – policy (any)
would likely succeed

Factors against compulsory measures: HPV is
sexually transmitted (not spread through social
contact, girls would perceive can engage in sex,
make parents have sexual intimacy conversations
when not ready or willing) concerns of the new
vaccine’s safety and efficacy, vaccine
manufacturer too involved in the policy process
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Table 3: (continued)
Author, year
R. B. Perkins et al. (2013)

Type of stakeholder

Support

Against

Low income and
minority
parents/guardians of
boys 11 to 17 years
old

Prevention and protection, protect child, public
health, perceived severity of HPV.

Personal choice, lack of information, not
transmissible by casual contact, depends on age
of the child

Pitts and Tufts (2013)†††

Parents/guardians 4th
to 7th grade (9 to 13)
girls

This study is about an existing mandate. Positive
about the opt-out option

Parental rights and decision, HPV sexually
transmitted, not enough research on the vaccine,
not known long term efficacy of the vaccine, lack
knowledge about the mandate, need for education

Nan et al., (2014)
(asked about HPV vaccine
mandate for girls only)

Undergraduate
students 18 to 29
(ask about the mandate
for girls on only)

Having the HPV vaccine predicted more
perceived benefit and less risk
Individualism-communitarianism – no prediction
of benefits or risk.
Pre-exposure attitudes, having the HPC vaccine
strong predictor of support
Support – loss-framed message support among
the hierarchical, egalitarians supported policies
with a gain-framed message

Female students perceived the mandate less
beneficial and riskier than males
Blacks perceived greater risk
Stronger hierarchical worldview predicted less
benefit and perceived more risk of the HPV
vaccine mandate
Females, Hierarchical worldview showed less
support

Pierre Joseph, Belizaire, et
al. (2014)

Minority men 18 to 22
years old

Latino (72%) and Haitian (58%) more promandate, next Caucasian (57%) and African
American (55%)
Important for public health, benefit victims of
sexual abuse

Might promote promiscuity, beliefs “Christian
scientists”
There might be some ethnic differences in
supporting/against the HPV vaccine.

Pierre Joseph, Clark, et al.
(2014)

Minority women 18 to
22 years old

Mostly supported because adolescents are
engaging in sexual activity and parents don’t
know, public health concerns

Personal choice, left to parents, students are not
having sex in school

M. L. Smith et al. (2014)

18 to 22 college
students

57.8% supported HPV vaccination mandates for
both genders. 48.9% supported mandates for ages
18 to 26, 48.4% for ages 12 to 17, and 15.1% for
ages 9 to 11.
Mostly non-white, and engage in sex, friends had
HPV vaccine

42% did not support HPV vaccination mandates
for boys or girls

All participants (supporters and not) thought
requirements should be for males and females.
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Table 3: (continued)
Author, year

Type of stakeholder

Support

Against

Califano et al. (2016)
(ask about HPV vaccine
school-entry for all aged
11 to 12 years old)

Physicians
(pediatricians and
family physicians)

47% agree to HPV vaccine for school entrance,
18% with opt-out provisions only,
74% with or without opt-out
Predictors: in practice longer than 20 years,
giving quality HPV recommendation, HPV is as
important as Tdap and meningococcal

Only 12% did not agree under any circumstances

Calo et al., (2016)
(ask about HPV vaccine
school-entry for all aged
11 to 12 years old)

Parents of 11 to 17year-old children

21% parents agree that laws are a good idea
When opt-out options were included agreement
increased - 57%
Factors (without opt-out) in multivariate model:
Hispanic parents, HPV vaccine was as or more
important than other vaccines, HPV vaccine
effective in prevention cervical cancer, it would
be hard to find a clinic or provider where they
could afford it
Factors (with opt-out) in multivariate model:
believed HPV prevents cervical cancer and HPV
vaccine was as or more important than other
vaccines.

54% disagree

Vercruysse et al. (2016)
(asked about HPV vaccine
school-entry for children to
go to high and middle
school)

Parents of 11 to 17year-old girls and
health care providers

Parents: overall prevention or protection of their
child’s health, support of other vaccines, the
benefits overweighed risks, and the protection
adolescents from STIs
Providers: a third favored this mandate option,
mentioned the common good and improving
vaccination rates
This study also addressed parents and providers
attitudes - school-based programs.

Disagreement 21%
Factors (without opt-out) in multivariate model:
believed HPV vaccine was pushed by drug
companies to make money, resided in the
Midwest states compared to Northeast states
Factors (with opt-out) in multivariate model: no
other variable associated.

Parents: limitation to parents’ autonomy, lack of
transmission through casual contact, a new
vaccine, and adolescents not been sexually active
Providers: worried that implementation could be
challenging and costly, society not ready and lack
transmission through casual contact
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Table 3: (continued)
Author, year
Wilson and Smith (2016)

Type of stakeholder

Support

Against

College female
students

13% supported HPV vaccine mandates for 9 to
11, 47.5% for aged 11-17
Reasons: (agree/strongly agree)
61% protect the public from disease, 51% to
59.5% believe mandates violate personal
lower societal health-care costs, 70% to promote
freedom, 47.0% believe mandates violate parental
women’s health concerns, and 19.5% to make
rights.
casual sex safer.
25% reported government is untrustworthy,
Participants characteristics associated – those
safety concerns and 51.2% because of costs
who completed the HPV vaccine
Participants supported mandates for both agegroups: sexually active, had Pap test, and had
more friends who reported receiving the HPV
series
Participants who supported mandates for 12–17
years old were single & engaged in sexual
activity
Beliefs associated mandates 9 to 11 years – HPV
prevented by using condom, and getting a vaccine
Mandate for 12 to 17-year-old - HPV is
preventable by getting a vaccine aged 9–11
significant larger proportion of participants
small proportion is against vaccination mandates
completed the HPV vaccination supports for all
reasons
Note: † = same dataset/participants, †† = same dataset/participants. ** This study is mostly about the policy formation process, but some opinions about schoolentry requirements are discussed.
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Table 4: Additional exemplary quotes by theme
Theme
Problems

Sub-theme
Indicators

Quote Spanish
“Las estadísticas dicen que, "Ocho de cada 10 personas
van a verse afectadas en el virus", y yo acabo de tener
un infográfico, que dice que, "Una de cada 54 personas
va a padecer con cáncer cervical asociado al VPH en
Puerto Rico". […] Nosotros somos más altos en HVP
que en Estados Unidos, tenemos más cáncer, por
ejemplo, 4.6 es la incidencia de cáncer cervical en
Estados Unidos, en Puerto Rico creo es un 11.”—002

Quote English
“Statistics say that, “Eight out of ten people will be
affected by the virus”, and I just had an infographic that
said, “One out of 54 people in Puerto Rico will suffer from
HPV related cervical cancer.” [...] We are higher on HPV
than in the United States, we have more cancer, for
example, 4.6 is the cervical cancer incidence in the United
States, in Puerto Rico, I believe it is 11.”—2, Non-profit

Focusing events

“yo te diría que un trabajo de muchos años; claro, en
VOCES, desde que se constituyó ha tenido un rol bien
importante la coalición porque ellos conformaron un
grupo de paneles de expertos y desarrollaron el informe
que habla específicamente sobre el informe en relación
al Virus de Papiloma Humano con este comité, este
panel asesor.” –008

“A work of many years I would say; clearly, in VOCES,
since its founding, the coalition has had a very important
role because they formed a group of experts and
developed the report that specifically talks about the
report in relation to the Human Papillomavirus with this
committee, this advising panel.” –008, Other

“Ahora mismo, hoy te puedo decir que hemos sido
reconocidos recientemente, Puerto Rico obtuvo un
premio en los Estados Unidos porque es uno de los
países donde tiene una alta incidencia de vacunación.
Así que yo creo que eso es positivo, pero tenemos que
aspirar a un poquito más.” – 021

“Right now, today I can say that we have been recently
recognized, Puerto Rico obtained an award because it is
one of the countries in which there is a high vaccination
rate. So, I believe that is positive, but we need to aspire to
a bit more.” –021, Government

“El proyecto de ley de la cámara 1303 apoya todos los
esfuerzos que está haciendo el secretario de salud, no
habla específicamente de la vacuna VPH, habla de
todas las vacunas y de cómo mejorar el acceso a todas
las vacunas, por ejemplo, con un reporte de la
administración de cada vacuna para tener un sistema
epidemiológico completo que nos va a permitir hacer
proyecciones de qué regiones de las isla están más
protegidas, tienen una inmunidad más completa, en caso
de brote estamos mejor preparados para entrar a
proteger, esos sectores que estén más vulnerables.” –
005

“The HR bill 1303 supports all the efforts that the
secretary of health is doing it does not specifically talks of
the HPV vaccine, it talks about all vaccines and how can
access be improved for all vaccines, for example, with a
report of each vaccine administered so that we have a
complete epidemiological system that will allow us to
create projections of which island regions are protected
more, have a more complete immunity, in case of an
outbreak we are better prepared to go in [and] protect the
most vulnerable sectors.” –005, Other

Feedback

Policy

Soup of ideas
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Table 4: (continued)
Theme
Policy

Sub-theme
Technical
Feasibility

Quote Spanish
“En Puerto Rico hay una peculiaridad bien importante y
es que quien decide las vacunas y las dosis que se van a
requerir para admisión escolares, es el secretario de
Salud. “En otros estados es la legislatura. Aquí es un
proceso que se ha determinado desde 1974, desde
nuestro primer mandato legislativo en vacunación, que
es una jurisdicción exclusiva de quien tiene la expertise
en materia de salud científica.” –005

Quote English
“In Puerto Rico there is a very important distinctiveness
and that is that the one who decides the vaccines and the
dosages that will be required for school entrance, is the
secretary of health. In other states it is the legislature.
Here it is a process that has been determined since 1974,
since our first legislative immunization law, which is an
exclusive jurisdiction of who has the expertise on the field
of scientific health.” –005, Other

“Así que dentro de los primeros 10 cánceres, vamos a
poner tanto en hombres como en mujeres, cánceres
asociados a VPH son las primeras razones de muerte.
Por ende, esto es un asunto de salud pública que hay
que atender.” —002

“So in the first 10 cancers, including in men as in women,
HPV-related cancers are the first [number one] causes of
death. Hence, this is a public health matter that needs to
be addressed.”—002, Non-profit

Level of
integration

“Hubo un consenso, uniforme de todos los
participantes, de que en Puerto Rico se debía promover
el uso de la vacuna y que, eventualmente, si queríamos
bajar nuestras tasas de incidencia del virus, debíamos
promocionar también que fuese uno de los requisitos de
admisión escolar, ¿por qué? Porque durante las edades
que es más efectiva crear la inmunidad en el cuerpo
contra ese virus es las edades de adolescencia.” –005

“Hubo un consenso, uniforme de todos los participantes,
de que en Puerto Rico se debía promover el uso de la
vacuna y que, eventualmente, si queríamos bajar nuestras
tasas de incidencia del virus, debíamos promocionar
también que fuese uno de los requisitos de admisión
escolar. Why? Because it is the most effective during the
ages of adolescence to create immunity in the body
against that virus.” –005, Other

Pressure-groups
campaigns

“Muchos padres han hecho este comentario, pero no les
gusta que se sientan obligados, que es obligatorio, que
es mandado, por eso es que se usa la palabra requisito,
no mandatorio.” –010

“Many parents have made this comment, but they do not
like feeling forced, that it is mandatory, that it is
mandated, that is why the word requirement is used, not
mandatory.” –010, Government

Value
acceptability

Politics

140

Table 4: (continued)
Theme
Politics

Sub-theme
Administrative or
legislative
turnover

Quote Spanish
“No solamente en las esferas de salud, sino también las
esferas legislativas o en las esferas organizacionales,
gubernamentales, en este caso el Departamento de
Salud, para que ahora se tome la decisión de cuán
importante es incluir la vacuna del virus del papiloma
humano como una vacuna requisito, considerarlo y
ahora de acuerdo al secretario de Salud que salió la
carta hace poco del schedule de vacuna para este nuevo
donde, se incluye. Entiendo que todos estos esfuerzos
han ayudado a que otras esferas, como son estas, hayan
tomado el interés genuino y se hayan dado la tarea a
conocer un poco más, al punto de ahora tengamos un
secretario que sí está apoyando lo que es el requisito en
la vacuna.” –018

Quote English
“Not only in the health sectors, but also in the legislative
sectors or in the organizational sectors, governmental, in
this case the Department of Health in order to make the
decision now of how important it is to include the human
papillomavirus vaccine as a required vaccine, consider it
and now in accordance to the Secretary of Health a
vaccine schedule announcement was recently released for
this new, where it is included. I understand that all of
these efforts have helped other sectors, like these ones,
take a genuine interest and take the task of getting to know
a bit more, to the extent that now we have a secretary that
is supporting the vaccine requirement.” –018, Non-profit

“[…] este año pasado nos sentamos con el secretario de
Salud y con el Programa de Vacunación y demostramos
que se habían cubierto todas las áreas que habíamos
establecido, y que ya estábamos listos para dar el paso.
No solamente estábamos listos para dar el paso, sino
que era un momento importante […]” –002

“[…] this past year we sat with the Secretary of Health
and with the Vaccination Program, and we demonstrated
that we had covered all the areas that we had established,
and that we were ready to take the step. Not only were we
ready for taking the step, but it was [also] an important
moment.” –002, Non-profit

Non-profit
organizations

“El Departamento de Salud, VOCES, que es la coalición
de vacunación, el Centro Compresivo del Cáncer, las
asociaciones que tienen que ver con cáncer cervical y
eso, la Coalición de Cáncer de Puerto Rico, ese tipo de
organizaciones o grupos. –011”

“The Department of Health, VOCES, which is the
vaccination coalition, the Comprehensive Cancer Center,
the cervical cancer related associations and that, the
Cancer Coalition of Puerto Rico, that type of
organizations or groups.” –011, Government

Academia

“Lo que ha pasado en Puerto Rico es que esto se ha
seguido investigando y en la medida que tú tienes más
investigación, más información; y me refiero, por
ejemplo, a los estudios que ha hecho el Centro
Comprensivo de Cáncer.”
“Obviamente tiene el endoso del presidente del Colegio
de Médicos que es la asociación privada del sector
privado más importante de salud en Puerto Rico, más el
endoso de todas las organizaciones pediátricas.”—004

“What has happened in Puerto Rico is that there has been
ongoing research and as you have more research, more
information; and I am referring to, for example, the
studies conducted by the Comprehensive Cancer Center.”

Policy window

Policy
Entrepreneurs

Medical
professional
organizations

“Obviously, it has the endorsement from the president of
the College of Physicians, which is the most important
private health association in Puerto Rico, plus the
endorsement of all the pediatrics organizations.”—004,
Researcher
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Table 4: (continued)
Theme
Policy
Entrepreneurs

Sub-theme
Government

Private sector

Quote Spanish
“Colaboramos mucho también con el programa de
vacunación del Departamento de Salud. Yo creo que
todas esas conversaciones han llegado también al
secretario, y por eso es que se hace esta
recomendación.” –014
“Sí, el sector privado también, no cabe duda de que
hemos tenido un apoyo increíble de todos los
sectores.”—005

Quote English
“We also collaborated a lot with the Department of
Health’s vaccination program. I think all of those
conversations have also reached the secretary, and for
that it is why this recommendation is being made.” –014,
Researcher
“Yes, the private sector too, there is no doubt that we have
had an incredible support from all the sectors.” –005,
Other
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Table 5: Timeline of policies and strategies leading to the HPV vaccine school-entry requirement
in PR
Date
July 23rd,
1974

Policy, Strategy or Event
Act 235: Compulsory Immunization
of students

Description
First immunization law in PR*

Sept. 25th,
1983
Jan. 20th,
2010

Act 25: Immunization Law

Current immunization law*

Act 9: Insurance coverage

Private health insurance companies must cover the HPV
vaccine for girls ages 11 to 18*

Sept. 15th,
2012

Act 255: Amendment to Act 9 of
2010

To include 11 to 18 boys to the HPV vaccine health
insurance coverage*

January
2015
May 2015

Rhaiza López Plumey

Passing and Interview video posted on social media

VOCES HPV Advisory Panel
Report

Sponsored by VOCES*

June 19th,
2015

Act 91

To declare the first week of August “The week of HPV
awareness and prevention.”

June 12th,
2017

DOH announcement

The HPV vaccine was going to be required for schoolentry for the 2018-2019 academic year*

Summer
2017
June 20th,
2017

Education and promotion
campaigns
Act 36: Make the month of January
the “Cervical Cancer Prevention
Month.”

By non-profit organizations, such as VOCES and the DOH

Aug. 30th,
2017

HR Bill 537: Investigation

To order the Health committee of the HR to investigate the
efficacy and safety of the HPV vaccine. Approved on Sept.
15th, 2017

Nov. 1st,
2017

HR Bill 1303: New immunization
law

To create a new immunization law for minors and students.
Petitioned by VOCES

Feb. 8th,
2018

HR Bill 1303 and
HR Resolution 537 - investigation

Public hearings

May 2nd,
2018
June 11th,
2018

HR Bill 1576

Petitioned by an anti-vaccination group

HR Resolution 537 – investigation
published

Concludes that the DOH’s determination to include the
HPV vaccine to the school required vaccine schedule
aligns with the medical community position.

May 30th,
2018

DOH announcement

HPV vaccine school-entry requirement*

Jan. 27 “Cancer Prevention Day” TEAL day

Notes: HR – House of Representatives, DOH – Dept. of Health, specific dates were obtained from the HR bills or announcements, * policies or
strategies known by the researcher before data collection
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Table 6: Number of news articles published by year
Year
2015
2016
2017
2018*
Total

Frequency
65
92
82
47
286

Percent
22.7
32.2
28.7
16.4
100.0

*Note: until July 31st, 2018

Table 7: Overall distribution of newspaper articles by primary focus
Primary Focus
Educational/informative about HPV & HPV vaccine
Advertisement
Vaccines in general
Cervical cancer/screening
HPV vaccine school-entry
Health in general
Cancer in general
Other HPV-related cancers
Scientific/Research advancements
About STIs including HIV
School-entry/Other policies
DOH/government announcement
Reforma/Obamacare/insurance
Contraceptives
Other Focus
Rhaiza López Plumey
Total

Frequency
68
48
32
31
19
17
17
12
9
8
8
7
3
3
2
2
286

Percent
23.8
16.8
11.2
10.8
6.6
5.9
5.9
4.2
3.1
2.8
2.8
2.4
1.0
1.0
0.7
0.7
100

144

Table 8: Articles published for each primary focus category by year
Focus
Educational/informative about HPV & HPV
vaccine
Advertisement
Vaccines in general
Cervical cancer/screening
HPV vaccine school-entry
Health in general
Cancer in general
Other HPV-related cancers
Scientific/Research advancements
About STIs including HIV
School-entry/Other policies
DOH/government announcement
Salud/Obamacare/insurance
Contraceptives
Other Focus
Rhaiza
Total

2015

2016

2017

2018*

Total

14
4
12
4
1
5
5
3
4
4
2
2
2
3
0
0
65

25
22
7
15
0
5
7
3
3
1
1
2
0
0
0
1
92

18
13
6
9
13
5
3
6
0
3
2
1
1
0
1
1
82

11
9
7
3
5
2
2
0
2
0
3
2
0
0
1
0
47

68
48
32
31
19
17
17
12
9
8
8
7
3
3
2
2
286

*Note: until July 31st, 2018

Table 9: Number of articles that mentioned the HPV vaccine school-entry requirement published
by year and newspaper source
Year
Source
El Nuevo Dia
Endi.com
Vocero
vocero.com
Total

2015

2016

2017

2018*

Total

1
1
0
0
2

0
0
0
0
0

9
2
2
3
16

10
1
2
3
16

20
4
4
6
34

*Note: until July 31st, 2018
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Table 10: Type of argument included in the articles that mentioned the HPV vaccine schoolentry requirement by year of publication
Year
Type of argument
Against
In favor of
Both arguments
Other
Total

2015
0

2017
3

2018*
2

Total
5

2

10

8

20

0

1

4

5

0

2

2

4

2

16

16

34

st

*Note: until July 31 , 2018
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